<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) - Ngwenya, O - 2024 | Cochrane Library</title> <meta content="Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) - Ngwenya, O - 2024 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012693.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) - Ngwenya, O - 2024 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012693.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012693.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI)" name="citation_title"/> <meta content="Olina Ngwenya" name="citation_author"/> <meta content="University of Manchester" name="citation_author_institution"/> <meta content="Sarah F Lensen" name="citation_author"/> <meta content="University of Melbourne" name="citation_author_institution"/> <meta content="Andy Vail" name="citation_author"/> <meta content="University of Manchester" name="citation_author_institution"/> <meta content="Ben Willem J Mol" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Frank J Broekmans" name="citation_author"/> <meta content="Jack Wilkinson" name="citation_author"/> <meta content="University of Manchester" name="citation_author_institution"/> <meta content="jack.wilkinson@manchester.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD012693.pub3" name="citation_doi"/> <meta content="2024" name="citation_date"/> <meta content="2024/01/04" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012693.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012693.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012693.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Fertilization in Vitro [methods]; Follicle Stimulating Hormone [pharmacology]; Follicle Stimulating Hormone, Human; Gonadotropins; Live Birth [epidemiology]; *Ovarian Hyperstimulation Syndrome [chemically induced, epidemiology]; *Ovarian Reserve; Ovulation Induction [methods]; Pregnancy Rate; Sperm Injections, Intracytoplasmic [methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012693.pub3&amp;doi=10.1002/14651858.CD012693.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012693\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012693\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012693.pub3",title:"Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI)",firstPublishedDate:"Jan 4, 2024 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecology and Fertility Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012693.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012693.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012693.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012693.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012693.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012693.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012693.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012693.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012693.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012693.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1613 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012693.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-sec-0220"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-sec-0203"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/appendices#CD012693-sec-0225"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/supinfo/CD012693-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/supinfo/CD012693-dataPackage.zip?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#CD012693-cr-0004">Olina Ngwenya</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#CD012693-cr-0005">Sarah F Lensen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#CD012693-cr-0006">Andy Vail</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#CD012693-cr-0007">Ben Willem J Mol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#CD012693-cr-0008">Frank J Broekmans</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information#CD012693-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Jack Wilkinson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information/en#CD012693-sec-0240">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 04 January 2024 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012693.pub3">https://doi.org/10.1002/14651858.CD012693.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012693-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012693-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012693-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012693-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012693-abs-0010">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012693-abs-0001" lang="en"> <section id="CD012693-sec-0001"> <h3 class="title" id="CD012693-sec-0001">Background</h3> <p>During a stimulated cycle of in vitro fertilisation or intracytoplasmic sperm injection (IVF/ICSI), women receive daily doses of gonadotropin follicle‐stimulating hormone (FSH) to induce multifollicular development in the ovaries. A normal response to stimulation (e.g. retrieval of 5 to 15 oocytes) is considered desirable. Generally, the number of eggs retrieved is associated with the dose of FSH. Both hyper‐response and poor response are associated with an increased chance of cycle cancellation. In hyper‐response, this is due to increased risk of ovarian hyperstimulation syndrome (OHSS), while poor response cycles are cancelled because the quantity and quality of oocytes is expected to be low. Clinicians often individualise the FSH dose using patient characteristics predictive of ovarian response. Traditionally, this meant women's age, but increasingly, clinicians use various ovarian reserve tests (ORTs). These include basal FSH (bFSH), antral follicle count (AFC), and anti‐Müllerian hormone (AMH). It is unclear whether individualising FSH dose improves clinical outcomes. This review updates the 2018 version. </p> </section> <section id="CD012693-sec-0002"> <h3 class="title" id="CD012693-sec-0002">Objectives</h3> <p>To assess the effects of individualised gonadotropin dose selection using markers of ovarian reserve in women undergoing IVF/ICSI. </p> </section> <section id="CD012693-sec-0003"> <h3 class="title" id="CD012693-sec-0003">Search methods</h3> <p>We searched the Cochrane Gynaecology and Fertility Group Specialised Register of controlled trials, CENTRAL, MEDLINE, Embase, and two trial registers in February 2023. </p> </section> <section id="CD012693-sec-0004"> <h3 class="title" id="CD012693-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that compared (a) different doses of FSH in women with a defined ORT profile (i.e. predicted low, normal, or high responders based on AMH, AFC, and/or bFSH) or (b) an individualised dosing strategy (based on at least one ORT measure) versus uniform dosing or a different individualised dosing algorithm. </p> </section> <section id="CD012693-sec-0005"> <h3 class="title" id="CD012693-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodological procedures. Primary outcomes were live birth/ongoing pregnancy and severe OHSS. </p> </section> <section id="CD012693-sec-0006"> <h3 class="title" id="CD012693-sec-0006">Main results</h3> <p>We included 26 studies, involving 8520 women (6 new studies added to 20 studies included in the previous version). We treated RCTs with multiple comparisons as separate trials for the purpose of this review. Meta‐analysis was limited due to clinical heterogeneity. Evidence certainty ranged from very low to low, with the main limitations being imprecision and risk of bias associated with lack of blinding. </p> <p><b>Direct dose comparisons according to predicted response in women</b> </p> <p>Due to differences in dose comparisons, caution is required when interpreting the RCTs in predicted low responders. All evidence was low or very low certainty. Effect estimates were very imprecise, and increased FSH dosing may or may not have an impact on rates of live birth/ongoing pregnancy, OHSS, and clinical pregnancy. </p> <p>Similarly, in predicted normal responders (10 studies, 4 comparisons), higher doses may or may not impact the probability of live birth/ongoing pregnancy (e.g. 200 versus 100 international units (IU): odds ratio (OR) 0.88, 95% confidence interval (CI) 0.57 to 1.36; I<sup>2</sup> = 0%; 2 studies, 522 women) or clinical pregnancy. Results were imprecise, and a small benefit or harm remains possible. There were too few events for the OHSS outcome to enable inferences. </p> <p>In predicted high responders, lower doses may or may not affect live birth/ongoing pregnancy (OR 0.98, 95% CI 0.66 to 1.46; 1 study, 521 women), severe OHSS, and clinical pregnancy. It is also unclear whether lower doses reduce moderate or severe OHSS (Peto OR 2.31, 95% CI 0.80 to 6.67; 1 study, 521 participants). </p> <p><b>ORT‐algorithm studies</b> </p> <p>Eight trials compared an ORT‐based algorithm to a non‐ORT control group. It is unclear whether live birth/ongoing pregnancy and clinical pregnancy are increased using an ORT‐based algorithm (live birth/ongoing pregnancy: OR 1.12, 95% CI 0.98 to 1.29; I<sup>2</sup> = 30%; 7 studies, 4400 women; clinical pregnancy: OR 1.04, 95% CI 0.91 to 1.18; I<sup>2</sup> = 18%; 7 studies, 4400 women; low‐certainty evidence). However, ORT algorithms may reduce moderate or severe OHSS (Peto OR 0.60, 95% CI 0.42 to 0.84; I<sup>2</sup> = 0%; 7 studies, 4400 women; low‐certainty evidence). There was insufficient evidence to determine whether the groups differed in rates of severe OHSS (Peto OR 0.74, 95% CI 0.42 to 1.28; I<sup>2</sup> = 0%; 5 studies, 2724 women; low‐certainty evidence). Our findings suggest that if the chance of live birth with a standard starting dose is 25%, the chance with ORT‐based dosing would be between 25% and 31%. If the chance of moderate or severe OHSS with a standard starting dose is 5%, the chance with ORT‐based dosing would be between 2% and 5%. These results should be treated cautiously due to heterogeneity in the algorithms: some algorithms appear to be more effective than others. </p> </section> <section id="CD012693-sec-0007"> <h3 class="title" id="CD012693-sec-0007">Authors' conclusions</h3> <p>We did not find that tailoring the FSH dose in any particular ORT population (low, normal, high ORT) affected live birth/ongoing pregnancy rates, but we could not rule out differences, due to sample size limitations. Low‐certainty evidence suggests that it is unclear if ORT‐based individualisation leads to an increase in live birth/ongoing pregnancy rates compared to a policy of giving all women 150 IU. The confidence interval is consistent with an increase of up to around six percentage points with ORT‐based dosing (e.g. from 25% to 31%) or a very small decrease (&lt; 1%). A difference of this magnitude could be important to many women. It is unclear if this is driven by improved outcomes in a particular subgroup. Further, ORT algorithms reduced the incidence of OHSS compared to standard dosing of 150 IU. However, the size of the effect is also unclear. The included studies were heterogeneous in design, which limited the interpretation of pooled estimates. It is likely that different ORT algorithms differ in their effectiveness. </p> <p>Current evidence does not provide a clear justification for adjusting the dose of 150 IU in poor or normal responders, especially as increased dose is associated with greater total FSH dose and cost. It is unclear whether a decreased dose in predicted high responders reduces OHSS, although this would appear to be the most likely explanation for the results. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012693-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012693-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012693-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012693-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012693-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012693-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012693-abs-0006">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012693-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012693-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012693-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012693-abs-0002" lang="en"> <h3>How effective are individualised doses of hormones for women trying to become pregnant through in vitro fertilisation (IVF)? </h3> <p><b>Key messages</b> </p> <p>We did not find clear evidence to support or reject the use of ovarian reserve tests (ORTs) to select the stimulation dose, for either live birth or ovarian hyperstimulation syndrome (OHSS). </p> <p>Future studies could evaluate the impact of using ORTs to select the stimulation dose, over several treatment attempts. </p> <p><b>What is individualised stimulation in IVF treatment?</b> </p> <p>In vitro fertilisation (IVF) is a type of assisted reproductive technology where eggs are combined with sperm outside a woman’s body. During a typical IVF cycle, doctors give women hormones that encourage a group of eggs to mature. This is referred to as ovarian stimulation. </p> <p>In planning an IVF cycle, the dose of ovarian stimulation medicines is based on certain characteristics of each woman, such as age. New tests have been developed that may better predict a woman's response to stimulation, called ovarian reserve tests (ORTs). They measure the number of eggs available in the ovaries. It is unclear whether tailoring doses of stimulation medicines based on individual ORTs can help increase the chance of getting pregnant and having a baby, or whether the tests help to improve the safety of the IVF cycle, such as reducing the chances of the serious condition OHSS. </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to establish if ovarian hormone stimulation tailored to individual women based on certain characteristics was better than standard doses for: </p> <p>‐ helping women have a live birth;</p> <p>‐ avoiding OHSS;</p> <p>‐ helping women achieve a pregnancy.</p> <p><b>What did we do?</b> </p> <p>We searched for studies that compared individualised ovarian stimulation dosing to standard dosing or to another type of individualised dosing. We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 26 studies involving 8520 women. We grouped these into two comparisons:</p> <p>‐ direct dose comparison studies recruited women predicted to respond to IVF stimulation either poorly, normally, or excessively, based on their ovarian reserve test. Women were then randomly assigned to different doses of ovarian‐stimulating hormones to see whether the different doses would affect IVF outcomes. </p> <p>‐ ORT‐based dose selection studies divided women into those whose stimulation dose was based on the women's ORT and those receiving a standard dose or one based on another characteristic. </p> <p><b>Main results for direct dose comparison studies</b> </p> <p>For women predicted to respond poorly or normally to stimulation based on their ovarian reserve test, it was unclear whether increasing the dose of stimulation medication influenced the chance of getting pregnant, having a baby, or the chance of OHSS. However, the included studies were small and compared different doses of medication. For women predicted to respond poorly, if the chance of having a live birth after taking 150 international units (IU) of hormone is 16%, the chance with 300 or 450 IU would be between 13% to 26%. For women predicted to have a normal response, if the chance of live birth or ongoing pregnancy with 150 IU is 29%, the chance with 200/225 IU would be between 22% to 36%. </p> <p>For women predicted to have an excessive response to stimulation, reducing the stimulation dose may or may not affect the chance of having a baby. If the chance of live birth with 100 IU is 25%, the chance with 150 IU would be between 18% to 33%. Reducing the dose may reduce the rate of OHSS. If the chance of moderate or severe OHSS with a lower dose is 1.6%, the chance with a higher dose would be between 1.3% and 9.6%, but this is also unclear. </p> <p><b>Main results for ORT‐based dose selection studies</b> </p> <p>There was no notable reduction in ongoing pregnancy or live birth when using ORTs to select a dose, but it is unclear whether there is a benefit. Different methods of using ORT to select the dose might be more or less effective compared to others. If the chance of an ongoing pregnancy or live birth with a standard starting dose were 25%, the chance with dosing based on an ORT would be between 25% and 31%. Individualised dosing did appear to reduce the chance of having OHSS when compared to giving all women the same dose of stimulation medication, but we have little confidence in this evidence. If the chance of moderate or severe OHSS with a standard starting dose were 5%, the chance with dosing based on an ovarian reserve test would be between 2% and 5%. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We assessed the certainty of the evidence as very low to low, due to limitations in study design (researchers and participants often knew which treatment was assigned) and statistical imprecision, as the studies included too few women to provide clear results for the most important outcomes, such as having a baby. </p> <p><b>How up to date is this evidence?</b> </p> <p>This review updates our previous review. The evidence is current to February 2023.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012693-sec-0220" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012693-sec-0220"></div> <h3 class="title" id="CD012693-sec-0221">Implications for practice</h3> <section id="CD012693-sec-0221"> <p>We did not find that tailoring the follicle‐stimulating hormone (FSH) dose in any particular ovarian reserve test (ORT) population (low, normal, high ORT) influenced rates of live birth/ongoing pregnancy, but we could not rule out differences, due to sample size limitations. In predicted high responders, lower doses of FSH seemed to reduce the overall incidence of moderate and severe ovarian hyperstimulation syndrome (OHSS). Low‐certainty evidence suggests that ORT‐based individualisation does not generally decrease live birth/ongoing pregnancy rates compared to a policy of giving all women 150 international units (IU), but effectiveness is likely to vary for different algorithms. Further, ORT algorithms reduced the incidence of OHSS compared to standard dosing of 150 IU, probably by facilitating dose reductions in women with a predicted high response. However, the size of the effect is unclear. The included studies were heterogeneous in design, which limited the interpretation of pooled estimates, and many of the included studies had a high risk of bias. </p> <p>Current evidence does not provide a clear justification for adjusting the standard starting dose of 150 IU in the case of poor or normal responders, especially as increased dose is generally associated with greater total FSH dose and therefore greater cost. However, a decreased dose in predicted high responders may reduce OHSS. Results of trials of an ORT‐based dosing algorithm using follitropin delta were somewhat variable in relation to effects on live birth. </p> <p>The knowledge of individual ORT measures may be helpful for clinicians in identifying a woman's anticipated response, as the data suggest that a lower dose is beneficial in high responders for reducing the risk of OHSS, with no observed impact on the probability of clinical pregnancy or live birth. An individual ORT measure may also be helpful for counselling patients about their predicted response, in terms of the probability of cycle cancellation for poor or hyper‐response, and the probability of achieving live birth. Evidence suggests that women with low anti‐Müllerian hormone/antral follicular count (AMH/AFC) values are less likely to achieve pregnancy from in vitro fertilisation (IVF) than women with normal or high AMH/AFC. This may be useful information for patients planning to embark on an IVF cycle, especially if the treatment is at their own expense; they may wish to factor in the probability of success, which can be better predicted with knowledge of their own ORT. However, currently there is limited evidence to suggest that any dose adjustment based on this ORT is beneficial to the chance of conceiving, and increased dosing in predicted low or normal responders increases the cost of treatment. Preliminary analysis describing follow‐up of anticipated high responders in <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a> suggests that a reduced dose may be associated with a reduction in births of second children from one cycle, but this was not included as an outcome in the present review. </p> </section> <h3 class="title" id="CD012693-sec-0222">Implications for research</h3> <section id="CD012693-sec-0222"> <p>Analysis of IVF data from randomised trials is complicated by the multistage nature of the treatment. We found multiple instances where trialists had reported or analysed their outcomes in ways that undermined the validity of the result. A common error was to report outcomes in subgroups of participants for whom treatment had not failed outright in the earlier stages. An illustrative example relates to the outcome measure 'number of oocytes'. This is a key mechanistic parameter in relation to this intervention, since the aim of tailoring ovarian stimulation to the individual is to reduce variation in the number of eggs obtained (i.e. to reduce poor or excessive egg yields). This is intended to safely maximise the chances of live birth. However, it was usual to report this outcome only in women who had a successful egg collection. If egg collection does not occur, however, it is usually because the IVF cycle has been cancelled for futility, and sometimes for hyper‐response. Consequently, this approach will more often select out poor responders, exaggerating the expected egg yield. The exaggeration will be greater the higher the number of cancelled cycles, so there is scope for this approach to greatly overstate the benefits of treatment in women with low ovarian reserve. Further, if an individualised dosing strategy leads to a greater reduction in cycle cancellations in one group compared to the other, this would not be reflected in an outcome that only includes women reaching oocyte retrieval, and the subsequent result would be misleading. We recalculated the mean oocyte numbers in all women randomised by considering women with cancelled cycles to have zero eggs, and making an ad hoc inflation to the reported standard deviation. However, future researchers should be aware of the risks of selection bias to the internal validity of their trials. </p> <p>Researchers should also be aware of the improvements in live birth rate that can realistically be detected in trials without rather large sample sizes. Even the larger studies included in the review were not powered to detect anything other than quite large treatment effects (in the region of improvements in birth rates of 10 percentage points or higher). If studies are only powered to detect clear game‐changers, then meaningfully better treatments will go overlooked. This is likely to represent an impediment to incremental progress. Unfortunately, this is the nature of randomised trials with binary primary outcomes, such as live birth, the most important outcome. Because studies were so heterogeneous, we were unable to convincingly overcome the limitation of study sizes for most comparisons. Although we did pool similar studies in a post hoc manner in order to increase sample size, the resulting estimates were still rather imprecise. </p> <p>The review provides relatively little direct information on the safety of the included interventions, although benefits in reducing moderate or severe OHSS were observed. We note that, while it is universally recognised as unacceptable, there is little agreement on how to define severe OHSS. We would suggest that this should be made a priority in subfertility research. Further, there was heterogeneity in the reporting of review outcomes, such as the definitions of poor, normal, or hyper‐response. For example, one study defined a normal response as the retrieval of five to 12 oocytes (<a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>), while another defined it as eight to 12 oocytes (<a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>). </p> <p>Our risk of bias assessments have highlighted some recurrent design limitations in trials in this field. We would urge researchers to implement blinding in trials of dose individualisation, since there are many opportunities for clinician expectations to influence treatment decisions, such as cycle cancellation, and outcomes, such as number of oocytes retrieved. We note that, as long as the initial dose allocation is concealed from the care team, it is not necessary to prohibit monitoring of the stimulation phase or even dose adjustment. It is legitimate – and not a source of bias – to make changes on the basis of response to treatment if blinding to treatment allocation is in place. </p> <p>Finally, a recent multilevel modelling study attempted to quantify the extent to which variation in ovarian response could be anticipated and controlled for on the basis of current knowledge (<a href="./references#CD012693-bbs2-0113" title="RustamovO , WilkinsonJ , La MarcaA , FitzgeraldC , RobertsSA . How much variation in oocyte yield after controlled ovarian stimulation can be explained? A multilevel modelling study. Human Reproduction Open2017;2017(3):1-10.">Rustamov 2017</a>). Even after taking into account many patient and treatment factors, including ORT and FSH dose, the authors found that an individual woman's response to stimulation was highly variable across multiple IVF cycles. This difficulty in predicting women's responses to treatment on the basis of their characteristics presents an obstacle to individualised IVF. The same study also identified substantial variation in oocyte yield according to the surgeon performing the oocyte pickup. This suggests greater standardisation of some aspects of treatment as a possible alternative (or complement) to ORT‐based individualisation, for the purpose of reducing variation in response. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012693-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012693-sec-0008"></div> <div class="table" id="CD012693-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">ORT‐based algorithm compared to standard starting dose of FSH for women undergoing IVF/ICSI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ORT‐based algorithm compared to standard starting dose of FSH for women undergoing IVF/ICSI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : women undergoing IVF/ICSI<br/><b>Setting</b> : hospital or fertility clinic<br/><b>Intervention</b> : ORT‐based algorithm<br/><b>Comparison</b>: standard starting dose FSH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Evidence summary</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 150 IU FSH</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ORT‐based algorithm</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000 (250 to 310)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000 (270 to 330)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.12<br/>(0.98 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4400<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a suggestion, but not clear evidence, of an overall increase in live birth rate. However, this estimate is difficult to interpret due to differences in interventions, which may differ in their effectiveness. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OHSS</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>13 per 1000 (6 to 17)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(4 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/>(0.42 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2724<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Although the effect estimate remains imprecise, the pooled evidence suggests that ORT‐based algorithms reduce the incidence of moderate or severe OHSS by an unspecified amount. Effects on severe OHSS are unclear. There were zero events in one study. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>5 per 1000 (2 to 5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(8 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.6<br/>(0.42 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4400<br/>(7 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000 (290 to 350)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000<br/>(300 to 360) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.04<br/>(0.91 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4400<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although the effect estimate remains imprecise, the pooled evidence suggests it is unlikely that ORT‐based algorithms impacted on rates of clinical pregnancy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FSH</b> : follicle‐stimulating hormone; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IVF</b> : in vitro fertilisation; <b>OHSS</b> : ovarian hyperstimulation syndrome; <b>OR</b> : odds ratio; <b>ORT</b> : ovarian reserve test; <b>RCT</b>: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias, associated mainly with performance bias due to lack of blinding and/or selective reporting.<br/><sup>b</sup>Downgraded one level for serious imprecision associated with a small number of events.<br/><sup>c</sup>Downgraded one level for indirectness arising from the choice of control group. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012693-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anticipated low responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anticipated low responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : women undergoing IVF/ICSI who are anticipated to have a low response to stimulation based on one or more ORT measure<br/><b>Setting</b> : hospital or fertility clinic<br/><b>Intervention</b> : higher dose of FSH<br/><b>Comparison</b>: lower dose of FSH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Evidence summary</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher dose</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome: live birth or ongoing pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300/450 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (130 to 260)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000 (140 to 280)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.20 (0.78 to 1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>538<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>It was difficult to determine whether the different doses impacted on rates of live birth or ongoing pregnancy; therefore, there is no evidence to suggest increased dosing in low responders is beneficial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400/450 IU vs 300 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (40 to 380)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000 (30 to 320)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.77 (0.19 to 3.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 IU vs 450 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000 (80 to 230)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(100 to 290) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.33<br/>(0.71 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome: ovarian hyperstimulation syndrome (OHSS)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300/450 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>It was not possible to determine whether the different doses impacted on rates of OHSS, as the event rates were too low (there were no incidents of severe OHSS in any of the studies). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/>(2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>400/450 IU vs 300 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>600 IU vs 450 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356<br/>(1 study) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome: clinical pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300/450 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000 (170 to 320)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>227 per 1000(140 to 260)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.85<br/>(0.57 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>538<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of clinical pregnancy. Therefore, there is no evidence to suggest increased dosing in low responders is beneficial, and it may even be detrimental compared to a dose of 150 IU. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400/450 IU vs 300 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000 (40 to 280)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000 (30 to 250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.84<br/>(0.26 to 2.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 IU vs 450 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (110 to 270)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/>(111 to 274) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.14<br/>(0.66 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FSH</b> : follicle‐stimulating hormone; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IU</b> : international units; <b>IVF</b> : in vitro fertilisation; <b>OHSS</b> : ovarian hyperstimulation syndrome; <b>OR</b> : odds ratio; <b>ORT</b> : ovarian reserve test; <b>RCT</b>: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated mainly with performance bias due to lack of blinding and/or selective reporting.<br/><sup>b</sup>Downgraded one level for serious imprecision associated with a small number of events.<br/><sup>c</sup>Downgraded two levels for very serious imprecision associated with a very small number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012693-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anticipated normal responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anticipated normal responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure<br/><b>Setting</b> : hospital or fertility clinic<br/><b>Intervention</b> : higher dose of FSH<br/><b>Comparison</b>: lower dose of FSH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Evidence summary</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher dose</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> : <b>live birth or ongoing pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000 (130 to 260)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000 (120 to 250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.88<br/>(0.57 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of live birth or ongoing pregnancy. Therefore, there is no evidence to suggest increased dosing in normal responders is beneficial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225/200 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000 (220 to 360)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000 (220 to 360)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.98<br/>(0.70 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>686<br/>(2 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 IU vs 225 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000 (170 to 470)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/>(120 to 360) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.65<br/>(0.32 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000 (70 to 590)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000 (60 to 530)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.19 to 3.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> : <b>ovarian hyperstimulation syndrome (OHSS)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>5 per 1000</p> <p>(0 to 34)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.14 (0.00 to 6.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>It was impossible to determine whether the dose differences impacted on rates of OHSS.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>31 per 1000</p> <p>(7 to 60)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> <p>(4 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.62 (0.21 to 1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522<br/>(2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225/200 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>12 per 1000</p> <p>(6 to 29)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000 (6 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/>(0.20 to 5.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>740<br/>(4 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>27 per 1000 (14 to 73)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> <p>(60 to 260)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.21<br/>(0.51 to 2.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>740<br/>(4 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300 IU vs 225 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>15 per 1000</p> <p>(0 to 100)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.14 (0.00 to 6.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135 (1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>44 per 1000</p> <p>(5 to 155)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000 (3 to 110)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.67<br/>(0.11 to 3.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/>(1 study) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> : <b>clinical pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000 (110 to 270)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000 (100 to 250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.86 (0.50 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of clinical pregnancy. Therefore, there is no evidence to suggest increased dosing in normal responders is beneficial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225/200 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000 (250 to 350)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000 (250 to 350)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/>(0.79 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1446<br/>(6 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 IU vs 225 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>440 per 1000 (270 to 590)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>420 per 1000 (250 to 570)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.91<br/>(0.46 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FSH</b> : follicle‐stimulating hormone; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IU</b> : international units; <b>IVF</b> : in vitro fertilisation; <b>OHSS</b> : ovarian hyperstimulation syndrome; <b>OR</b> : odds ratio; <b>ORT</b> : ovarian reserve test; <b>RCT</b>: randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated mainly with performance bias due to lack of blinding and/or selective reporting and/or selection bias due to unclear methods of randomisation.<br/><sup>b</sup>Downgraded one level for serious imprecision associated with a small number of events.<br/><sup>c</sup>Downgraded two levels for very serious imprecision associated with a very small number of events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012693-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anticipated high responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anticipated high responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : women undergoing IVF/ICSI who are anticipated to have a hyper‐response to stimulation based on at least one ORT measure<br/><b>Setting</b> : hospital or fertility clinic<br/><b>Intervention</b> : higher dose of FSH<br/><b>Comparison</b>: lower dose of FSH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Evidence summary</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher dose</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> : <b>live birth or ongoing pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000 (180 to 330)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>251 per 1000<br/>(184 to 333) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.98<br/>(0.66 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of live birth or ongoing pregnancy. Therefore, there is no evidence to suggest increased dosing in high responders is beneficial. </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> : <b>ovarian hyperstimulation syndrome (OHSS)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>16 per 1000</p> <p>(3 to 60)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(3 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.72<br/>(0.16 to 3.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It was not possible to definitively say whether dose differences impacted on rates of OHSS, but there could be a reduction with lower doses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>16 per 1000</p> <p>(13 to 96)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(13 to 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 2.31<br/>(0.80 to 6.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (1 RCT)</p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> : <b>clinical pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000 (230 to 390)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000<br/>(228 to 386) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.14<br/>(0.78 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of clinical pregnancy. Therefore, there is no evidence to suggest increased dosing in high responders is beneficial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FSH</b> : follicle‐stimulating hormone; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IU</b> : international units; <b>IVF</b> : in vitro fertilisation; <b>OHSS</b> : ovarian hyperstimulation syndrome; <b>OR</b> : odds ratio; <b>ORT</b> : ovarian reserve test; <b>RCT</b>: randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated mainly with performance bias due to lack of blinding and/or selective reporting.<br/><sup>b</sup>Downgraded one level for serious imprecision associated with a small number of events.<br/><sup>c</sup>Downgraded two levels for very serious imprecision associated with a very small number of events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012693-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012693-sec-0009"></div> <section id="CD012693-sec-0010"> <h3 class="title" id="CD012693-sec-0010">Description of the condition</h3> <p>As many as 15% of couples experience difficulties getting pregnant and are defined as being subfertile (<a href="./references#CD012693-bbs2-0120" title="ThomaME , McLainAC , LouisJF , KingRB , TrumbleAC , SundaramR . Prevalence of infertility in the United States as estimated by the current duration approach and a traditional constructed approach. Fertility and Sterility2013;99(5):1324-31.">Thoma 2013</a>). Treatments are available to help these couples conceive, such as intrauterine insemination, ovulation induction, in vitro fertilisation (IVF), and intracytoplasmic sperm injection (ICSI). IVF, with or without ICSI (referred to as IVF/ICSI when used together), is the leading treatment for most causes of infertility; however, the success rate remains modest at approximately 15% to 20% per cycle started and 30% per cumulative cycle (including fresh and all frozen embryo transfers) (<a href="./references#CD012693-bbs2-0082" title="DyerS , ChambersGM , De MouzonJ , NygrenKG , Zegers-HochschildF , MansourR , et al. International committee for monitoring assisted reproductive technologies world report: Assisted reproductive technology 2008, 2009 and 2010. Human Reproduction2016;31(7):1588-1690.">Dyer 2016</a>; <a href="./references#CD012693-bbs2-0086" title="GunbyJ , BissonnetteF , LibrachC , CowanL . Assisted reproductive technologies (ART) in Canada: 2006 results from the Canadian ART Register. Fertility and Sterility2010;93:2189-201.">Gunby 2010</a>; <a href="./references#CD012693-bbs2-0123" title="ToftagerM , BogstadJ , LosslK , PraetoriusL , ZedelerA , BryndorfT , et al. Cumulative live birthrates after one ART cycle including all subsequent frozen-thaw cycles in 1050 women: secondary outcome of an RCT comparing GnRH-antagonist and GnRH-agonist protocols. Human Reproduction2017;32(3):556-67.">Toftager 2017</a>). </p> <p>During an IVF/ICSI cycle, daily doses of the gonadotropin follicle‐stimulating hormone (FSH) are used to induce multifollicular development in the ovaries. Generally, the number of eggs retrieved depends on the dose of FSH; however, individual women's responses vary (<a href="./references#CD012693-bbs2-0069" title="AndersenAN , DevroeyP , ArceJC . Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Human Reproduction2006;21(12):3217-27.">Andersen 2006</a>; <a href="./references#CD012693-bbs2-0118" title="SunkaraSK , RittenbergV , Raine-FenningN , BhattacharyaS , ZamoraJ , CoomarasamyA . Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Human Reproduction2011;26(7):1768-74.">Sunkara 2011</a>). A low or poor ovarian response has been classified as the retrieval of three or fewer oocytes (<a href="./references#CD012693-bbs2-0084" title="FerrarettiA , La MarcaA , FauserBCJM , TarlatzisB , NargundG , GianaroliL . ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction2011;26(7):1616-24.">Ferraretti 2011</a>), and it often results in cycle cancellation, poor outcomes, and consequent stress and disappointment to the couple. The prevalence of poor response increases with age: approximately 10% to 15% of women aged 35 to 40 experience a poor response (<a href="./references#CD012693-bbs2-0084" title="FerrarettiA , La MarcaA , FauserBCJM , TarlatzisB , NargundG , GianaroliL . ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Human Reproduction2011;26(7):1616-24.">Ferraretti 2011</a>). Conversely, a hyper‐response (or high response) is often defined as the retrieval of 15 to 20 or more oocytes and is associated with an exponential increase in the risk of ovarian hyperstimulation syndrome (OHSS) (<a href="./references#CD012693-bbs2-0116" title="StewardRG , LanL , ShahAA , YehJS , PriceTM , GoldfarbJM , et al. Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertility and Sterility2014;101(4):967-73.">Steward 2014</a>; <a href="./references#CD012693-bbs2-0131" title="YoussefM , MouradS . Volume expanders for the prevention of ovarian hyperstimulation syndrome. Cochrane Database of Systematic Reviews2016, Issue 11. Art. No: CD001302. [DOI: 10.1002/14651858.CD001302]">Youssef 2016</a>). The incidence of OHSS is difficult to determine as there is no strict consensus definition (<a href="./references#CD012693-bbs2-0071" title="Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility and Sterility2016;106:1634-47.">ASRM 2016</a>). Historically, mild and moderate forms of OHSS were reasonably common, occurring in approximately 0% to 30% and 3% to 6% of cycles, respectively (<a href="http://mail52a.webmail.libero.it/cp/ps/Main/Delvigne%202002" target="_blank">Delvigne 2002</a>). Severe OHSS is much less common but has the potential to cause thromboembolic phenomena, multiple organ failure, and even death (<a href="http://mail52a.webmail.libero.it/cp/ps/Main/Delvigne%202002" target="_blank">Delvigne 2002</a>). More recent estimates of the incidence of moderate OHSS range from 0.6% to 5% per IVF/ICSI cycle (<a href="./references#CD012693-bbs2-0071" title="Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertility and Sterility2016;106:1634-47.">ASRM 2016</a>; <a href="./references#CD012693-bbs2-0081" title="Calhaz-JorgeC , De GeyterC , KupkaMS , de Mouzon, ErbK , MocanuE , et al. Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE. Human Reproduction2016;31(8):1638-52.">Calhaz‐Jorge 2016</a>; <a href="./references#CD012693-bbs2-0096" title="KawwassJF , KissinDM , KulkarniAD , CreangaAA , SessionDR , CallaghanWM , et al. Safety of assisted reproductive technology in the United States, 2000-2011. JAMA2015;313(1):88.">Kawwass 2015</a>). Estimates of the rate of hospitalisation due to severe OHSS range from less than 0.01% to 0.3% of cycles (<a href="./references#CD012693-bbs2-0089" title="HarrisK , FitzgeraldO , PaulRC , MacaldowieA , LeeE , ChambersGM . Assisted reproductive technology in Australia and New Zealand 2014. Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales, 2016.">Harris 2016</a>; <a href="./references#CD012693-bbs2-0098" title="KupkaMS , FerrarettiAP , deMouzonJ , ErbK , D'HoogheT , CastillaJA , et al. European IVF-Monitoring Consortium, for the European Society of Human Reproduction and Embryology (ESHRE). Assisted reproductive technology in Europe, 2010: results generated from European registers by ESHRE. Human Reproduction2014;29(10):2099-113.">Kupka 2014</a>). This rate increases with the number of oocytes retrieved, reaching 4% with the retrieval of over 20 oocytes (<a href="./references#CD012693-bbs2-0089" title="HarrisK , FitzgeraldO , PaulRC , MacaldowieA , LeeE , ChambersGM . Assisted reproductive technology in Australia and New Zealand 2014. Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales, 2016.">Harris 2016</a>). </p> <p>The aim of most IVF cycles is to produce an embryo that leads to the live birth of a baby. Most specialists consider that obtaining a number of high‐quality oocytes is an important step in this process, and that the number of retrieved oocytes depends on many patient and treatment factors, two of which are the dose of FSH administered and the size of the pool of recruitable follicles. Up to certain limits, an increase in the FSH dose may increase the number of growing follicles and the resulting oocyte yields (<a href="./references#CD012693-bbs2-0079" title="BroerSL , vanDisseldorpJ , BroezeKA , DollemanM , OpmeerBC , BossuytP , et al, on behalf of the IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Human Reproduction Update2013;19(1):26-36.">Broer 2013b</a>). As a consequence, the use of a very low dose of FSH may increase the risk of poor response. Conversely, a very high dose of FSH may increase the risk of hyper‐response (in women with sufficient ovarian reserve). Although the retrieval of five to 15 eggs is correlated with the best chance of pregnancy and live birth (<a href="./references#CD012693-bbs2-0118" title="SunkaraSK , RittenbergV , Raine-FenningN , BhattacharyaS , ZamoraJ , CoomarasamyA . Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Human Reproduction2011;26(7):1768-74.">Sunkara 2011</a>), it does not (necessarily) follow that increasing the FSH dose in order to obtain more eggs – for example, in women with a previous or predicted poor response – will increase the probability of pregnancy for an individual woman. </p> </section> <section id="CD012693-sec-0011"> <h3 class="title" id="CD012693-sec-0011">Description of the intervention</h3> <p>Clinicians may use a test of a woman's ovarian reserve to select the starting FSH dose for ovarian stimulation (<a href="./references#CD012693-bbs2-0083" title="FauserBCJM . Patient-tailored ovarian stimulation for in vitro fertilization. Fertility and Sterility2017;108(4):585-91.">Fauser 2017</a>). This is done to reduce the variation in ovarian response. In general, this means administering higher doses to women with a low ovarian reserve test (ORT) result and lower doses to women with a high ORT result. Multifactorial dose‐selection algorithms have also been developed, combining one or more ORT results with other patient characteristics such as age (<a href="./references#CD012693-bbs2-0099" title="La MarcaA , PapeleoE , GrisendiV , ArgentoC , GiuliniS , VolpeA . Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles. BJOG2012;119(10):1171-9.">La Marca 2012</a>). </p> <p>Apart from female age, the oldest ovarian reserve test (ORT) is basal FSH (bFSH), measured in serum in the early follicular phase of a menstrual cycle. This was later supplemented by the antral follicular count (AFC) and, more recently, with anti‐Müllerian hormone (AMH). AFC is measured by ultrasound and is a count of the number of antral follicles measuring about 2 mm to 10 mm (according to standard criteria) that are available in both ovaries (<a href="./references#CD012693-bbs2-0076" title="BroekmansFJ , deZieglerD , HowlesCM , GougeonA , TrewG , OlivennesF . The antral follicle count: practical recommendations for better standardization. Fertility and Sterility2010;94(3):1044-51.">Broekmans 2010</a>). It indicates the number of gonadotropin‐sensitive follicles available for stimulation in an IVF cycle. AMH is a protein expressed and secreted by the granulosa cells of the ovary and reflects the size of antral and pre‐antral follicles (<a href="./references#CD012693-bbs2-0129" title="VisserJA , deJongFH , LavenJS , ThemmenAP . Anti-Müllerian hormone: a new marker for ovarian function. Reproduction2006;131(1):1-9.">Visser 2006</a>). AMH can be measured in serum and is a more direct and independent measure of the growing pre‐antral and antral follicular pool (<a href="./references#CD012693-bbs2-0114" title="SeiferDB , MacLaughlinDT , ChristianBP , FengB , SheldenRM . Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility and Sterility2002;77(3):468-71.">Seifer 2002</a>; <a href="./references#CD012693-bbs2-0127" title="Van RooijIA , BroekmansFJ , te VeldeER , FauserBC , BancsiLF , deJongFH , et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Human Reproduction2002;17(12):3065-71.">Van Rooij 2002</a>). </p> </section> <section id="CD012693-sec-0012"> <h3 class="title" id="CD012693-sec-0012">How the intervention might work</h3> <p>Ovarian reserve test‐based individualisation of the FSH dose requires two components. First, there must be an ORT that can predict a woman's response when given a particular dose of FSH. Second, there must be a dose‐response relationship between FSH and ovarian response, enabling manipulation of the response through adjustment of the dose administered. </p> <p>In relation to the first component (prediction of response), diagnostic test studies have reported that ORT can be used to predict ovarian response to stimulation, with AMH and AFC being superior to bFSH (<a href="./references#CD012693-bbs2-0075" title="BroekmansFJ , KweeJ , HendriksDJ , MolBW , LambalkCB . A systematic review of tests predicting ovarian reserve and IVF outcome. Human Reproduction Update2006;12:685-718.">Broekmans 2006</a>; <a href="./references#CD012693-bbs2-0078" title="BroerSL , DóllemanM , vanDisseldorpJ , BroezeKA , OpmeerBC , BossuytPM , et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertility and Sterility2013;100(2):420-9.">Broer 2013a</a>; <a href="./references#CD012693-bbs2-0079" title="BroerSL , vanDisseldorpJ , BroezeKA , DollemanM , OpmeerBC , BossuytP , et al, on behalf of the IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Human Reproduction Update2013;19(1):26-36.">Broer 2013b</a>; <a href="./references#CD012693-bbs2-0080" title="BroerSL , BroekmansFJM , LavenJSE , FauserBCJM . Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Human Reproduction Update2014;20(5):688-701.">Broer 2014</a>; <a href="./references#CD012693-bbs2-0100" title="La MarcaA , SunkaraSK . Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Human Reproduction Update2014;20(1):124-40.">La Marca 2014</a>). One meta‐analysis of individual patient data found that for predicting excessive response, AMH and AFC showed similarly high performance (areas under the receiver operator characteristic curves (AUC) of 0.81 and 0.79, respectively) (<a href="./references#CD012693-bbs2-0078" title="BroerSL , DóllemanM , vanDisseldorpJ , BroezeKA , OpmeerBC , BossuytPM , et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertility and Sterility2013;100(2):420-9.">Broer 2013a</a>). However, bFSH had lower predictive value (AUC of 0.66). Predictive performance was improved by combining AMH and AFC (AUC 0.85). A second meta‐analysis showed that AFC and AMH as single tests both had high predictive value for poor response (AUC 0.78 and 0.76, respectively), and that combining these two tests did not substantially improve prediction (AUC 0.80, P = 0.19) (<a href="./references#CD012693-bbs2-0079" title="BroerSL , vanDisseldorpJ , BroezeKA , DollemanM , OpmeerBC , BossuytP , et al, on behalf of the IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Human Reproduction Update2013;19(1):26-36.">Broer 2013b</a>). </p> <p>In relation to the second component (dose‐response relationship), one study indicated that increasing the dose of FSH increases oocyte yield in women with AMH between 5 pmol/L and 50 pmol/L (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>). For example, women who receive higher FSH doses will produce more follicles than those receiving lower FSH doses. However, the capacity to manipulate a woman's ovarian response may largely depend on her ovarian reserve. In particular, if a woman has relatively few antral follicles (and consequently is predicted to have a low ovarian response), then it may not be possible to compensate for this fact by increasing the FSH dose (<a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0107" title="LekamgeDN , LaneM , GilchristRB , TremellenKP . Increased gonadotrophin stimulation does not improve IVF outcomes in patients with predicted poor ovarian reserve. Journal of Assisted Reproduction and Genetics2008;25(11-12):515-21.">Lekamge 2008</a>). It is important to remember that the relationship between the stimulation response and probability of pregnancy is poorly understood, so the use of surrogate outcomes, such as number of eggs retrieved, does not necessarily reveal the effects on pregnancy and live birth (<a href="./references#CD012693-bbs2-0126" title="VailA , GardenerE . Common statistical errors in the design and analysis of subfertility trials. Human Reproduction2003;18:1000-4.">Vail 2003</a>). In fact, the above‐mentioned individual patient data analysis found that ORTs did not improve prediction of ongoing pregnancy following IVF more than age alone (<a href="./references#CD012693-bbs2-0079" title="BroerSL , vanDisseldorpJ , BroezeKA , DollemanM , OpmeerBC , BossuytP , et al, on behalf of the IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Human Reproduction Update2013;19(1):26-36.">Broer 2013b</a>). </p> </section> <section id="CD012693-sec-0013"> <h3 class="title" id="CD012693-sec-0013">Why it is important to do this review</h3> <p>In vitro fertilisation plus intracytoplasmic sperm injection is expensive and invasive, and it requires extensive clinical monitoring. Those desiring a pregnancy often have to make a substantial financial investment, including time away from work, and the process is associated with a high emotional burden. If tailoring the dose of FSH can increase the likelihood of an appropriate response, it has the potential to increase pregnancy and live birth while reducing cancelled cycles (for either poor or hyper‐response) and OHSS. Individualised FSH dosing also has the potential to be more cost‐effective. On the other hand, an individualised approach to FSH dosing may be associated with greater cost in terms of price of FSH medication (if increased dose is recommended), cost of ORT testing itself, and increased administrative burden and complexity in monitoring of IVF cycles. However, there is no up‐to‐date review of the relevant literature available to help clinicians and individuals seeking IVF/ICSI to weigh these considerations. This review update helps to fill this gap; it includes six new studies published since the previous version of the review (<a href="./references#CD012693-bbs2-0133" title="LensenSF , WilkinsonJ , LeijdekkersJA , La MarcaA , MolBW , MarjoribanksJ , et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012693. [DOI: 10.1002/14651858.CD012693.pub2] [PMID: 29388198]">Lensen 2018</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012693-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012693-sec-0014"></div> <p>To assess the effects of individualised gonadotropin dose selection using markers of ovarian reserve in women undergoing IVF/ICSI. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012693-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012693-sec-0015"></div> <section id="CD012693-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012693-sec-0017"> <h4 class="title">Types of studies</h4> <p>Published and unpublished randomised controlled trials (RCTs) were eligible for inclusion. We excluded non‐randomised and quasi‐randomised studies (e.g. studies with evidence of inadequate sequence generation, such as allocation by alternate days or patient numbers), as they are associated with a high risk of bias (<a href="./references#CD012693-bbs2-0094" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We did not use data from ongoing studies but will incorporate their results in future updates of the review. We did not identify any eligible cross‐over trials for this review update. In future updates, we will include any relevant cross‐over trials identified, and use only data from the trial's first period (i.e. first IVF/ICSI cycle) in our meta‐analysis. </p> <p>Several trial designs are appropriate to the broad goal of investigating aspects of individualised FSH (<a href="./references#CD012693-bbs2-0119" title="TajikP , ZwindermanAH , MolBW , BossuytPM . Trial designs for personalizing cancer care: a systematic review and classification. Clinical Cancer Research2013;19(17):4578-88.">Tajik 2013</a>). Broadly, the two types of design included in this review are: </p> <p> <ul id="CD012693-list-0001"> <li> <p><b>direct dose comparison studies</b>, randomising women within a given ORT range to one of several doses of FSH; and </p> </li> <li> <p><b>ORT‐algorithm studies</b>, randomising women either to dose selection according to their ORT value using an algorithm, or to dose selection without ORT or using an alternative algorithm. </p> </li> </ul> </p> <p>The first type of design (direct dose comparison studies) allocates women of a given ORT profile to one of two (or more) doses of FSH, in order to compare the responses of similar women under each of the doses. An example would be a trial of women with low AMH (predicted low responders) who are randomised to two different doses of FSH (e.g. 150 international units (IU) versus 300 IU). This type of design is useful for establishing whether there is a dose‐response relationship between FSH and outcome in subgroups of women, or for identifying the optimal FSH dose for women with a given set of predictive characteristics. This design is able to tell us whether certain groups of women would benefit from a particular FSH dose (<a href="./references#CD012693-bbs2-0119" title="TajikP , ZwindermanAH , MolBW , BossuytPM . Trial designs for personalizing cancer care: a systematic review and classification. Clinical Cancer Research2013;19(17):4578-88.">Tajik 2013</a>). We use the terms 'low responders' and 'high responders' to refer to the <i>predicted</i> response of women, and the terms 'poor response' and 'hyper‐response' to refer to the <i>observed</i> response of women to ovarian stimulation, usually measured by the number of oocytes retrieved. </p> <p>The second type of design (ORT‐algorithm studies) randomises women either to FSH dose selection determined by an algorithm including ORT, or to a standard FSH dose (i.e. for all women, regardless of their ORT). In this design, all women in the control arm receive the same dose of FSH, and women in the intervention arm receive different doses of FSH according to their individual characteristics, such as AMH level. A variant of this type of design randomises women to one of two (or more) individualised dose‐selection algorithms/policies, where the comparator algorithms may or may not include ORT. The purpose of designs of this type is to compare an ORT‐individualised dose‐selection algorithm to either a uniform dose or alternative dose‐selection policy. </p> <p>We included studies of both design types in separate comparisons in this review. Sometimes, trials were not explicitly presented as falling into one of the above types of design, but nonetheless it was possible to interpret and analyse them in such a way that they were equivalent. In these cases, the trials were eligible for this review. </p> </section> <section id="CD012693-sec-0018"> <h4 class="title">Types of participants</h4> <section id="CD012693-sec-0019"> <h5 class="title">Direct dose comparison studies</h5> <p>For these studies to be eligible, the study population had to be women undergoing IVF/ICSI, categorised as either predicted low, normal, or high responders based on at least one ORT (AMH, bFSH, or AFC) (or providing data that enabled categorisation by review authors). Studies including unselected populations were not eligible unless we could obtain data from eligible subgroups within the studies. </p> </section> <section id="CD012693-sec-0020"> <h5 class="title">ORT‐algorithm studies</h5> <p>Studies of this type had to include a (possibly unselected) population of women undergoing IVF/ICSI. </p> <p>Studies in women who did not plan to undergo embryo transfer – for example, women planning oocyte donation or fertility preservation, or who were receiving donated oocytes – were excluded. We excluded studies including only women with polycystic ovarian syndrome (PCOS), which represents a distinct clinical entity and likely warrants unique individualised dosing algorithms. We included studies that enrolled women with and without PCOS, and we attempted to obtain data only for women without PCOS. There were no exclusion criteria related to age, cause of infertility, or previous IVF/ICSI exposure. </p> </section> </section> <section id="CD012693-sec-0021"> <h4 class="title">Types of interventions</h4> <section id="CD012693-sec-0022"> <h5 class="title">Included interventions</h5> <p>Studies comparing ovarian stimulation doses with each other (direct dose comparison studies) or comparing ORT‐based FSH dose individualisation versus an alternative dosing policy (ORT‐algorithm studies) were eligible for inclusion. Eligible individualised policies included those where the dose was selected, at least in part, using the woman's ORT measure (e.g. AMH, AFC, bFSH). We also included policies of dose selection on the basis of combinations of characteristics, provided one or more ORTs were amongst the considered factors. Studies comparing doses of human menopausal gonadotropin (HMG), which contains both FSH and luteinising hormone, were also eligible. </p> <p>Additionally, we included ORT‐algorithm studies comparing different preparations and brands, provided that the dose‐selection algorithm varied between study arms. This reflects the more pragmatic nature of the questions being answered by these designs. Studies that allowed dose adjustment following a certain number of days of administration of the randomised dose were eligible, as long as that adjustment was permitted in both study arms. This was subject to sensitivity analysis. </p> </section> <section id="CD012693-sec-0023"> <h5 class="title">Excluded interventions</h5> <p>For direct dose comparison studies, we excluded studies comparing different preparations, brands, or routes of administration, since treatment effects in these studies might not be attributable to differences in dose. </p> <p>We excluded studies:</p> <p> <ul id="CD012693-list-0002"> <li> <p>comparing HMG to pure FSH preparations;</p> </li> <li> <p>using medications other than gonadotropins, such as clomiphene citrate or letrozole;</p> </li> <li> <p>comparing doses of corifollitropin alfa;</p> </li> <li> <p>comparing step‐up/step‐down protocols, or protocols amending the FSH dose in only one arm after commencing stimulation; for example, coasting or withholding FSH for a number of days; and </p> </li> <li> <p>comparing different stimulation regimens (for example, gonadotropin‐releasing hormone (GnRH) agonist versus GnRH antagonist). </p> </li> </ul> </p> </section> </section> <section id="CD012693-sec-0024"> <h4 class="title">Types of outcome measures</h4> <section id="CD012693-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012693-list-0003"> <li> <p>Live birth or ongoing pregnancy. We defined ongoing pregnancy as evidence of a gestational sac with foetal heart motion at or after twelve weeks' gestation, confirmed with ultrasound (<a href="./references#CD012693-bbs2-0088" title="Harbin Consensus Workshop Group. Improving the Reporting of Clinical Trials of Infertility Treatments (IMPRINT): modifying the CONSORT statement. Human Reproduction2014;29(10):2075-82.">Harbin Consensus Workshop Group 2014</a>). We only used ongoing pregnancy data when live birth data were not available. In the event that studies included multiple cycles for an individual woman, we also reported cumulative live births. If studies reported the live birth outcome of the fresh transfer and the first frozen transfer for women with freeze‐all cycles, we also reported this outcome separately. We counted multiple live births (e.g. twins or triplets) as one live birth event. </p> </li> <li> <p>Severe ovarian hyperstimulation syndrome (OHSS) (as defined by study authors).</p> </li> </ul> </p> </section> <section id="CD012693-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012693-list-0004"> <li> <p>Clinical pregnancy, defined as evidence of an intrauterine gestational sac on ultrasound or other definitive signs of pregnancy, including ectopic pregnancy. </p> </li> <li> <p>Time to clinical pregnancy.</p> </li> <li> <p>Moderate or severe OHSS (as defined by study authors).</p> </li> <li> <p>Multiple pregnancy in randomised women.</p> </li> <li> <p>Multiple pregnancy in women with clinical pregnancy, noting that this does not reflect a randomised comparison. </p> </li> <li> <p>Number of oocytes retrieved per woman randomised.</p> </li> <li> <p>Poor response to stimulation (as defined and prespecified by trial authors).</p> </li> <li> <p>Normal response to stimulation (as defined and prespecified by trial authors).</p> </li> <li> <p>Hyper‐response to stimulation (as defined and prespecified by trial authors).</p> </li> <li> <p>Cycle cancellations for hyper‐response (including freeze‐all cycles).</p> </li> <li> <p>Cycle cancellations for poor response.</p> </li> <li> <p>Cycle cancellations for poor or hyper‐response.</p> </li> <li> <p>Women with at least one transferable embryo.</p> </li> <li> <p>Total dose of FSH.</p> </li> <li> <p>Duration of FSH administration.</p> </li> <li> <p>Cost per woman randomised.</p> </li> <li> <p>Cumulative live birth rate.</p> </li> </ul> </p> </section> </section> </section> <section id="CD012693-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched for all published and unpublished RCTs that met our inclusion criteria, without language or date restriction and in consultation with the Cochrane Gynaecology and Fertility Group (CGF) Information Specialist. </p> <section id="CD012693-sec-0028"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases, trial registers, and websites in November 2016 and on 27 July 2017. For the review update, we searched the websites from 1 July 2017 to 15 February 2023. </p> <p> <ul id="CD012693-list-0005"> <li> <p>Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of Controlled Trials, ProCite platform (searched 15 February 2023) (<a href="./appendices#CD012693-sec-0226">Appendix 1</a>). </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), Ovid platform (searched 15 February 2023, January Issue) (<a href="./appendices#CD012693-sec-0227">Appendix 2</a>). </p> </li> <li> <p>MEDLINE, Ovid platform (searched from 1946 to 15 February 2023) (<a href="./appendices#CD012693-sec-0228">Appendix 3</a>). </p> </li> <li> <p>Embase, Ovid platform (searched from 1980 to 15 February 2023) (<a href="./appendices#CD012693-sec-0229">Appendix 4</a>). </p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature), EBSCO platform (searched from 1982 to 27 July 2017) (<a href="./appendices#CD012693-sec-0230">Appendix 5</a>). CINAHL records are now included in the CENTRAL search output. </p> </li> </ul> </p> <p>We combined the MEDLINE search with the Cochrane highly sensitive search strategy for identifying randomised trials, described in chapter 4.4 of the <i>Cochrane Handbook of Systematic Reviews of Interventions</i> (<a href="./references#CD012693-bbs2-0106" title="LefebvreC , GlanvilleJ , BriscoeS , FeatherstoneR , LittlewoodA , MarshallC , et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.">Lefebvre 2022</a>). We combined the Embase and CINAHL searches with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (<a href="https://www.sign.ac.uk/what-we-do/methodology/search-filters/" target="_blank">https://www.sign.ac.uk/what-we-do/methodology/search-filters/</a>). </p> <p>We searched the following electronic sources of trials from their inception to 15 February 2023. </p> <p> <ul id="CD012693-list-0006"> <li> <p>Trial registers for ongoing and registered trials: <a href="http://clinicaltrials.gov/ct2/home" target="_blank">www.clinicaltrials.gov</a> (a service of the US National Institutes of Health) and <a href="http://www.who.int/trialsearch/Default.aspx" target="_blank">www.who.int/trialsearch/Default.aspx</a> (the World Health Organization International Trials Registry Platform search portal). </p> </li> <li> <p>DARE (Database of Abstracts of Reviews of Effects) on the Cochrane Library: <a href="http://onlinelibrary.wiley.com/o/cochrane/cochrane_cldare_articles_fs.html" target="_blank">onlinelibrary.wiley.com/o/cochrane/cochrane_cldare_articles_fs.html</a> (for reference lists from relevant non‐Cochrane reviews). </p> </li> <li> <p>Web of Knowledge: <a href="http://wokinfo.com/" target="_blank">wokinfo.com/</a> (another source of trials and conference abstracts). </p> </li> <li> <p>OpenGrey: <a href="http://www.opengrey.eu/" target="_blank">www.opengrey.eu/</a> for unpublished literature from Europe. </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information) database: <a href="http://regional.bvsalud.org/php/index.php?lang=en" target="_blank">regional.bvsalud.org/php/index.php?lang=en.</a> </p> </li> <li> <p>PubMed and Google Scholar (for recent trials not yet indexed in the major databases).</p> </li> </ul> </p> <p>We detail the search strategies used in the <a href="#CD012693-sec-0225">Appendices</a>. </p> </section> <section id="CD012693-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists of articles retrieved by the search and contacted experts in the field to obtain additional data. We also handsearched relevant journals and conference abstracts that were not covered in the CGF register, in liaison with the Information Specialist. </p> </section> </section> <section id="CD012693-sec-0030"> <h3 class="title" id="CD012693-sec-0030">Data collection and analysis</h3> <section id="CD012693-sec-0031"> <h4 class="title">Selection of studies</h4> <p>After an initial screen of titles and abstracts retrieved by the search, we retrieved the full texts of all potentially eligible studies. Two review authors independently examined these full‐text articles for compliance with the inclusion criteria and selected studies eligible for inclusion in the review. We corresponded with study investigators as required to clarify study eligibility. We resolved disagreements as to study eligibility by discussion or by involving a third review author. We documented the selection process with a PRISMA flow chart. </p> </section> <section id="CD012693-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from eligible studies using a data extraction form that we designed and pilot‐tested. We resolved any disagreements by discussion or by involving a third review author. Data extracted included study characteristics and outcome data. Where studies had multiple publications, we collated the multiple reports; the study rather than the report was the unit of interest in the review. Studies with multiple reports had a single study ID with multiple references. </p> <p>We corresponded with study investigators for further information on methods, results, or both, as required. </p> </section> <section id="CD012693-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the included studies for risk of bias using the Cochrane risk of bias assessment tool, which considers bias arising from: selection (random sequence generation and allocation concealment), performance (blinding of participants and personnel), detection (blinding of outcome assessors), attrition (incomplete outcome data), reporting (selective reporting), and other causes (<a href="./references#CD012693-bbs2-0094" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We resolved any disagreements by discussion or by involving a third review author. We described all judgements fully and presented the conclusions in the risk of bias table, which we incorporated into the interpretation of the review findings both qualitatively and formally, by means of sensitivity analyses. Where identified studies failed to report the primary outcome of live birth but did report interim outcomes such as pregnancy, we undertook informal assessment as to whether the interim values (e.g. pregnancy rates) were similar to those reported in studies that also reported live birth. </p> <p>We considered the following methods of random sequence generation adequate:</p> <p> <ul id="CD012693-list-0007"> <li> <p>referring to a random number table;</p> </li> <li> <p>using a computer random number generator;</p> </li> <li> <p>coin tossing;</p> </li> <li> <p>shuffling cards or envelopes;</p> </li> <li> <p>throwing dice;</p> </li> <li> <p>drawing of lots.</p> </li> </ul> </p> <p>We considered it insufficient to state that the study was 'randomised' and rated these studies at unclear risk of bias. </p> <p>We considered the following methods of allocation concealment adequate:</p> <p> <ul id="CD012693-list-0008"> <li> <p>central allocation (including telephone, Internet‐based, and pharmacy‐controlled randomisation);</p> </li> <li> <p>sequentially‐numbered, opaque, sealed envelopes (SNOSE).</p> </li> </ul> </p> <p>We considered blinding of participants and personnel to carry a low risk of bias if there was a description of adequate blinding measures; for example, administering doses that were identical in appearance. There was potential for performance bias, as some methods and outcomes were not strictly objective, such as cycle cancellation for poor or hyper‐response, number of eggs collected, embryo selection for embryo transfer, decision to freeze all embryos, etc. Additionally, in trials that allowed dose adjustment during stimulation, there was potential for performance bias, so we considered the risk to be high in these cases. </p> <p>We considered the domain 'Blinding of outcome assessors' to be relevant only for OHSS outcomes, and we rated it as low risk for other outcome variables. This is because diagnosis and classification of OHSS can be subjective. For OHSS outcomes, we rated the domain as being at low risk of bias if there was some description of adequate blinding measures. For example, if the text stated that diagnosis of OHSS was done by a clinician not involved in the trial, we rated the risk of bias as low for this domain. </p> <p>We considered studies with a loss to follow‐up of 15% or more as being at high risk of attrition bias. This cut‐off is arbitrary, but there is value in prespecifying a criterion in order to reduce post hoc decisions. </p> <p>We considered studies that had collected more outcome measures than were reported in the paper as being at high risk of reporting bias. It was often difficult to determine which outcomes they measured unless a study protocol was available. Therefore, in the absence of a protocol, we might have rated the risk of bias as unclear. However, if a study reported all expected outcomes, we assigned a low risk rating. </p> </section> <section id="CD012693-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data (e.g. live birth rates), we used the numbers of events in the control and intervention groups of each study to calculate Mantel‐Haenszel odds ratios (ORs). If event rates in a particular analysis were low, however, we preferred Peto's method (e.g. multiple pregnancy and OHSS). For continuous data (e.g. total dose of FSH), if all studies reported exactly the same outcomes, we calculated the mean difference (MD) between treatment groups. Had studies reported time‐to‐event data, we would have used hazard ratios (HRs) as the measure of treatment effect. </p> <p>We reversed the direction of effect of individual studies to ensure consistency across trials (for example, in direct dose comparison studies, consistently ordering the higher and lower doses). We presented 95% confidence intervals (CIs) for all outcomes. Where data to calculate ORs or MDs were not available, we utilised the data available to proceed with the most reasonable analysis available (e.g. test statistics, P values). We emphasised the magnitude, precision, and direction of effects rather than relying on arbitrary and uninformative standards of statistical significance. </p> </section> <section id="CD012693-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>We performed the primary analysis with the denominator of randomised women. We also included per pregnancy data for the outcome of multiple pregnancy, as this better reflects the proportion of pregnancies that were multiple, but readers should interpret these results with caution, as they do not represent a randomised comparison. For time to clinical pregnancy, we had anticipated that the unit of time in the analysis would have been the cycle; however, no study reported this outcome (two trials reported time to ongoing pregnancy only: <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). We narratively summarised any data that did not allow valid analyses. Where studies followed women over multiple treatment cycles, we included 'cumulative' birth events in the numerator as a separate outcome. </p> </section> <section id="CD012693-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>For all outcomes, we carried out analyses on an intention‐to‐treat basis as far as possible; that is, we attempted to analyse all participants in the group to which they were randomised, regardless of whether they received the allocated intervention. The denominator for each outcome was the number randomised, except for the outcome 'multiple pregnancy in women with clinical pregnancy'. For the primary outcome 'live birth', we assumed that those who dropped out of the study did not have a successful treatment outcome. When necessary, we contacted the authors of included studies to obtain missing data. </p> <p>Additional statistical analyses were required for an intention‐to‐treat analysis of the outcome 'number of oocytes'. It was common for studies to exclude cycles cancelled when reporting this outcome. This is akin to active censoring, which violates the randomisation in the study and biases the estimated treatment effect. In these cases, we recalculated the mean numbers of oocytes including all randomised participants by setting the values for participants with cancelled cycles to zero and including these women in the divisor. We also had to impute the corresponding standard deviations, which would be larger than those calculated using only uncensored patients. On the basis of simulations, we determined that adding half the difference between the reported and the new mean to the reported standard deviation produced a suitably adjusted estimate. This amounted to a small adjustment (less than one oocyte). These imputed standard deviations have the disadvantage of probably being wrong, but the advantage of being an improvement over the reported values. For one study (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>), individual patient data were available, allowing us to conduct multiple imputations for any cancelled cycles. Some studies reported the median rather than the mean number of oocytes. Because the distribution of numbers of oocytes is skewed, we imputed the mean by adding one to the median. This small adjustment was deemed to be appropriate on the basis of analyses conducted using the <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a> data. Finally, the skewed distribution meant that meta‐analysis based on an assumption of a normal distribution was not appropriate. Accordingly, we adopted a method for the meta‐analysis of skewed data (method 1 in <a href="./references#CD012693-bbs2-0093" title="HigginsJP , WhiteIR , Anzures-CaberaJ . Meta-analysis of skewed data: combining results reported on log-transformed or raw scales. Statistics in Medicine2008;27:6072-92.">Higgins 2008</a>). Briefly, this involves approximating the difference in log scale means and a corresponding standard error, based on the summary data available. These were synthesised using the generic inverse‐variance functionality in Review Manager (<a href="https://revman.cochrane.org/info" target="_blank">revman.cochrane.org/info</a>). For these reasons, the mean differences reported here differ slightly from those in the papers. </p> </section> <section id="CD012693-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta‐analysis to provide a clinically meaningful summary. We assessed statistical heterogeneity by the measure of the I<sup>2</sup>. We interpreted an I<sup>2</sup> measurement greater than 50% as indicating substantial heterogeneity (<a href="./references#CD012693-bbs2-0092" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>), although we acknowledge that this threshold is essentially arbitrary. </p> </section> <section id="CD012693-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert to the duplication of data. If there had been 10 or more studies in an analysis, we would have used a funnel plot to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more beneficial in smaller studies). </p> </section> <section id="CD012693-sec-0039"> <h4 class="title">Data synthesis</h4> <p>Although we had anticipated that the included studies would display considerable protocol heterogeneity, the data synthesis scheme we had proposed in the review protocol could not comfortably accommodate the variety of eligible direct dose comparison studies we identified in the search. Accordingly, we modified it, and the modified scheme we eventually used is described here (see also <a href="#CD012693-sec-0244">Differences between protocol and review</a>). We retained this scheme in the update. </p> <p>For direct dose comparison studies (women with a given ORT measurement randomised to one of several doses), we considered the following comparisons. </p> <p> <ul id="CD012693-list-0009"> <li> <p><b>Comparison 1</b>. All pairwise dose comparisons tested in women predicted to have a low response on the basis of one or more ORT. </p> </li> <li> <p><b>Comparison 2</b>. All pairwise dose comparisons tested in women predicted to have a normal response on the basis of one or more ORT. </p> </li> <li> <p><b>Comparison 3</b>. All pairwise dose comparisons tested in women predicted to have a high response on the basis of one or more ORT. </p> </li> </ul> </p> <p>We made a post hoc decision to pool studies within each predicted response category (low, normal, high) if they shared the same comparator dose (e.g. to pool a trial comparing 200 IU versus 150 IU with another trial comparing 300 IU versus 150 IU). We made this decision in the final stages of the review after observing that most of the included studies compared different dose sets. This pooling, to the extent that it is interpretable, answered a broader question of the data: compared to a dose of 150 IU, does a higher dose offer any benefit in women with predicted low‐response? Readers should consider these pooled comparisons as summaries of the studies, rather than as unified estimates of underlying treatment effects. </p> <p>We used the cut‐offs described below to guide the categorisation of women; these cut‐offs are based on categorisations used previously (e.g. <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). </p> <p> <ul id="CD012693-list-0010"> <li> <p>AMH &lt; 7 pmol/L, AFC &lt; 7, bFSH &gt; 10 IU/L categorised as predicted low responders.</p> </li> <li> <p>AMH 7 pmol/L to 21 pmol/L, AFC 7 to 15 categorised as predicted normal responders (bFSH is not considered to be a reliable predictor for normal response). </p> </li> <li> <p>AMH &gt; 21 pmol/L, AFC &gt; 15 categorised as predicted high responders (bFSH is not considered to be a reliable predictor for hyper‐response). </p> </li> </ul> </p> <p>We considered the ORT values of the cohorts in each study as a potential source of heterogeneity but determined that it would not be feasible to stratify the trials further on the basis of type of ORT. </p> <p>In the review protocol, we noted that it was not possible to anticipate the combinations of study arms that would be compared in ORT‐algorithm studies. Accordingly, we modified the basic scheme we had proposed in the protocol to accommodate the eligible trials we found in the search (see <a href="#CD012693-sec-0244">Differences between protocol and review</a>) and presented the modified scheme we used here. </p> <p>For ORT‐algorithm studies (women randomised to either have a dose selected according to their ORT value using an algorithm, or to a uniform dose/dose selected using an alternative algorithm), we considered the following comparisons. </p> <p> <ul id="CD012693-list-0011"> <li> <p><b>Comparison 4</b>. ORT‐based dose selection algorithm for ovarian stimulation versus dose selection without ORT (including uniform dosing policies). </p> </li> <li> <p><b>Comparison 5</b>. ORT‐based dose selection algorithm for ovarian stimulation versus alternative ORT‐based dose selection algorithm. </p> </li> </ul> </p> <p>Within comparison 4, we stratified the trials according to the comparator arm and did not consider it to be meaningful to pool across strata. Specifically, we deemed it appropriate to pool studies comparing ORT‐based algorithms to a uniform dose if that dose was the same in the different studies. We did not pool studies with non‐ORT dose selection algorithms as comparator interventions with the studies with uniform dose control groups, however. We would stress that pooled estimates derived from comparison 4 should be considered as summaries of the effects estimated in the included studies, rather than an estimate of a distinct underlying treatment effect. </p> <p>The trials included in comparison 5 each made a unique comparison between ORT‐based algorithms, and we did not consider it appropriate to pool these studies. </p> <p>Any increase in the odds of a particular outcome under a higher dose (for direct dose comparison studies) or under an ORT‐based algorithm (ORT‐algorithm studies), regardless of whether it was beneficial (e.g. live birth) or detrimental (e.g. adverse effects), was displayed graphically in the meta‐analyses to the right of the centre line. Any decrease in the odds of an outcome was displayed to the left. For comparison 5, comparing ORT‐based algorithms against one another, the decision of which algorithm to treat as the comparator and which to treat as the 'experimental' treatment was essentially arbitrary. </p> <p>When trials reported outcomes for total dose of FSH and duration of FSH as medians, we treated these as means. This approach assumed a symmetrical outcome distribution, which is unlikely to have occurred in reality. </p> <p>In line with a new Cochrane Gynaecology and Fertility policy, we restricted the primary analysis for the primary outcomes to studies without a high risk of bias for sequence generation and allocation concealment. </p> </section> <section id="CD012693-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We intended to conduct subgroup analyses where at least one trial fitted within each subgroup, data were available, and substantial heterogeneity existed, to determine the separate evidence within the following subgroups for primary outcomes only. </p> <p> <ul id="CD012693-list-0012"> <li> <p>Predicted response category (e.g. high responders, normal responders, low responders). The stratification of women into predicted response categories was already a feature of our analysis plan for direct dose comparison studies. However, we intended to consider the evidence, where available, for subgroups determined by predicted response category in ORT‐algorithm studies. </p> </li> <li> <p>Age (less than 35 years, 35 to 40 years, more than 40 years)</p> </li> <li> <p>IVF protocol type (e.g. long GnRH agonist, short GnRH agonist (or 'Flare'), antagonist)</p> </li> </ul> </p> <p>Where we detected substantial heterogeneity, we explored possible explanations in sensitivity analyses. We incorporated statistical heterogeneity into our interpretation of results, paying particular attention to any variation in the direction of effect. </p> </section> <section id="CD012693-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses for the primary outcomes to determine whether the conclusions were robust to arbitrary decisions made regarding the eligibility and analysis. These analyses included consideration of whether the review conclusions would have differed if: </p> <p> <ul id="CD012693-list-0013"> <li> <p>eligibility had not been restricted to studies without a high risk of bias for sequence generation and allocation concealment; </p> </li> <li> <p>we had adopted a random‐effects model.</p> </li> </ul> </p> <p>We did not perform the first sensitivity analysis, as all included studies were at low or unclear risk of bias in the first two domains. When we adopted a random‐effect model for analysis, we did not reach a different conclusion for any comparison. </p> </section> <section id="CD012693-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared summary of findings tables using GRADEpro software and Cochrane methods (<a href="./references#CD012693-bbs2-0085" title="GRADEpro GDT. Version accessed 1 June 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2014. Available at gradepro.org.">GRADEpro GDT 2014</a>; <a href="./references#CD012693-bbs2-0094" title="HigginsJP , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). These tables evaluate the overall certainty of the body of evidence for the main review outcomes (live birth or ongoing pregnancy, OHSS, clinical pregnancy) in each of the main comparisons of the review, using GRADE criteria. There was one comparison for each patient subgroup in the direct dose comparison studies (predicted low responders, normal responders, high responders) and a further comparison for use of ORT‐based algorithms versus dosing without ORT. GRADE criteria relate to study limitations (i.e. risk of bias), inconsistency of effect, imprecision, indirectness and publication bias. Two review authors independently made judgements on evidence certainty (high, moderate, low, or very low), resolving disagreements by discussion. We justified, documented, and incorporated these judgements into the reporting of results for each outcome. </p> <p>We extracted study data, formatted our comparisons in data tables, and prepared summary of findings tables before writing the results and conclusions of the review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012693-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012693-sec-0043"></div> <section id="CD012693-sec-0044"> <h3 class="title">Description of studies</h3> <section id="CD012693-sec-0045"> <h4 class="title">Results of the search</h4> <p>For this update, new searches yielded 1926 unique articles (<a href="#CD012693-fig-0001">Figure 1</a>). We excluded 1888 records based on screening the title and abstract, and we retrieved the full texts (which included articles and trial registrations) of 38 records for more detailed assessment. Of these, we identified 15 studies (15 records) that were not eligible for inclusion in the review, mainly because they used an ineligible intervention. We listed five studies (five records) as 'awaiting classification', and we identified two ongoing studies (two records)(<a href="./references#CD012693-bbs2-0065" title="NCT05103228. Cumulative pregnancy rate with lower and higher gonadotropin dose during IVF among poor responders. clinicaltrials.gov/ct2/show/NCT05103228 (first received 2 November 2021). ">NCT05103228</a>; <a href="./references#CD012693-bbs2-0064" title="NCT03914651. CLBR per initial cycle with different starting dose in aged patients with poor ovarian reservation: 300IU versus 150IU. clinicaltrials.gov/ct2/show/NCT03914651 (first received 16 April 2019). ">NCT03914651</a>). </p> <div class="figure" id="CD012693-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012693-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>Of the remaining 16 full‐text records obtained for detailed assessment, we identified nine articles corresponding to six new eligible studies, and seven articles for previously included studies. Adding these six new studies to the 20 included in the first version of this review, we now have a total of 26 included studies in this review update. This total includes four studies that we essentially treat as multiple trials for the purposes of this review (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>, <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>). Most studies were published as full‐text articles. However, one study was available as an abstract only, and we obtained the individual participant data from the trialists to enable further data analysis (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). </p> </section> <section id="CD012693-sec-0046"> <h4 class="title">Included studies</h4> <section id="CD012693-sec-0047"> <h5 class="title">Study design and setting</h5> <p>We included 26 parallel‐group randomised controlled trials in the review. Twenty‐two studies had two arms (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>; <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>), three studies had four arms (<a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), and one had five arms (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>). Three studies had trial arms that were not relevant and which we excluded from this review (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>). </p> <p>Most studies took place in European countries, including Denmark (<a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>), Ireland (<a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>), Italy (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>), the Netherlands (<a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), the UK (<a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>), and Sweden (<a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>). Three studies were conducted across multiple European countries (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>). Two studies each took place in Canada (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>) and Japan (<a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>), and there was one study each from Brazil (<a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>), Turkey (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>), China (<a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>), Australia (<a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>), and Vietnam (<a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>), along with two in multiple Asian countries (<a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>). Twelve studies took place in a single centre (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>; <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>), and fourteen were multicentre (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). </p> <p>Two of the direct dose comparison studies were conducted in tandem as part of a wider cohort study (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). We essentially treated the four‐armed <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a> study as two separate trials for the purpose of this review: a comparison of 450 IU to 150 IU, and a comparison of 225 IU to 150 IU. Further, these trials are all merged to produce one ORT‐algorithm study (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). </p> </section> <section id="CD012693-sec-0048"> <h5 class="title">Participants and interventions</h5> <p>All studies but <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a> had inclusion criteria based on age. Thirteen studies used a long agonist protocol; however, 10 used an antagonist protocol (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>), one used a microdose flare protocol (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>), and two did not require the use of any specific stimulation protocol (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). Ten studies permitted dose adjustment in at least one arm during the stimulation phase (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>; <a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>), while six studies did not permit adjustment for any reason (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>); in one study it was unclear (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). Two studies permitted dose adjustment only between IVF cycles (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), which is only relevant for the outcome of cumulative live birth rate reported in this study (over 18 months). </p> <section id="CD012693-sec-0049"> <h6 class="title">Direct dose comparison studies</h6> <p>All 21 direct dose comparison studies (including three studies that are used twice in different comparisons/subgroups) focused on a population defined as either predicted low, normal, or high responders based on at least one ORT measure (AMH, AFC or bFSH), or reported on at least one of these measures demographically (as per the review protocol). Six studies involved predicted low responders (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>); twelve studies, predicted normal responders (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>); and three studies, predicted high responders (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). Of the ORTs, nine used AMH to define their population or reported AMH as a demographic (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), 10 used or reported AFC (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), and all but five used or reported bFSH (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). There was significant variation in the thresholds and application of ORTs as eligibility criteria. For example, some trials required participants to satisfy all ORT criteria to be eligible (e.g. <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a> required participants to have bFSH of less than 12 IU/L and AFC 8 to 21), and other trials permitted participants to satisfy at least one of a number of criteria (e.g. <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a> required participants to meet at least two of the three following criteria: age over 40 years, previous poor response, abnormal ORT measure). Note that we included <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a> in both the predicted low responders and predicted normal responders' analyses, and that we included <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> in both the predicted normal and predicted high responders' analyses. </p> <p>The six studies in predicted <b>low responders</b> employed five separate dose comparisons, and we pooled these as follows. </p> <p> <ul id="CD012693-list-0014"> <li> <p>300/450 IU versus 150 IU: included two studies comparing 300 IU versus 150 IU (<a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>), and one comparing 450 IU versus 150 IU (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). </p> </li> <li> <p>400/450 IU versus 300 IU: included one study comparing 400 IU versus 300 IU (<a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>), and one study comparing 450 IU versus 300 IU (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>). </p> </li> <li> <p>600 IU versus 450 IU (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>). </p> </li> </ul> </p> <p>There were four separate pooled comparisons amongst the 12 studies in predicted <b>normalresponders</b>. </p> <p> <ul id="CD012693-list-0015"> <li> <p>200 versus 100 IU (<a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>). </p> </li> <li> <p>225/200 IU versus 150 IU (<a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>). </p> </li> <li> <p>300 versus 225 IU (<a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>). </p> </li> <li> <p>300 versus 150 IU (<a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>). </p> </li> </ul> </p> <p>A five‐arm dosing study used a novel FSH (FE 999049), expressed in µg rather than IU, which is not directly translatable to IU (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>). Therefore, we were unable to pool the data from this trial with the other studies and instead present the five dosing arms in separate forest plots for each outcome in incremental comparisons (i.e. 5.2 µg versus 6.9 µg; 6.9 µg versus 8.6 µg; 8.6 µg versus 10.3 µg; 10.3 µg versus 12.1 µg). Similarly, in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, the three dosing arms were presented in incremental comparisons (i.e. 6 µg versus 9 µg; 9 µg versus 12 µg). </p> <p>The study with five arms and the study with three arms also had strata of women included in the comparison for predicted <b>highresponders</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>), along with a third study (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). In total, the 21 direct dose comparison studies included 1004 low responders, 2262 normal responders, and 719 high responders. </p> </section> <section id="CD012693-sec-0050"> <h6 class="title">ORT‐algorithm studies</h6> <p>There were eight ORT‐algorithm studies included, which generally recruited women with a broader ORT spectrum. We merged the data from two of the direct dose comparison studies conducted in tandem as part of a wider cohort study, <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a> and <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>, and included them as one ORT‐algorithm study (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). All eight studies used or reported AFC; all but two also used or reported AMH (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>), and all but two also used bFSH (<a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). </p> <p>Eight studies compared an ORT‐based algorithm to a method that did not use any ORT, either a standard starting dose of 150 IU (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>), or an algorithm not using ORT (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). In this latter study, the dose selection in the non‐ORT arm was based solely on age (women aged 35 years or less received 150 IU, those older than 35 years received 225 IU). Three studies compared two different ORT‐based algorithms with each other. One study compared an AMH‐based algorithm to an AFC‐based algorithm (<a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>); one study compared an AFC‐based algorithm to an algorithm using both AFC and AMH (<a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>); and one study compared an algorithm based on a number of markers (age, bFSH, oestradiol, and polycystic ovaries' status) to an algorithm based on AMH and AFC in addition to the other markers (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). In total, the eleven ORT‐algorithm studies included 5462 participants, 4594 of whom contributed to a comparison between an ORT‐algorithm and a non‐ORT method of dose selection, and 778 to a comparison of two different ORT‐based algorithms. </p> </section> </section> </section> <section id="CD012693-sec-0051"> <h4 class="title">Excluded studies</h4> <p>The first version of this review excluded 14 studies (<a href="./references#CD012693-bbs2-0133" title="LensenSF , WilkinsonJ , LeijdekkersJA , La MarcaA , MolBW , MarjoribanksJ , et al. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI). Cochrane Database of Systematic Reviews2018, Issue 2. Art. No: CD012693. [DOI: 10.1002/14651858.CD012693.pub2] [PMID: 29388198]">Lensen 2018</a>). We excluded a further 15 studies after full‐text screening for this update, giving a total of 29 excluded studies. The reasons for exclusion are as follows: </p> <p> <ul id="CD012693-list-0016"> <li> <p>ineligible intervention: 12 studies (<a href="./references#CD012693-bbs2-0027" title="AleyammaTK , SinghalH , PremkumarPS , AcharyaM , KamathMS , GeorgeK . Local endometrial injury in women with failed IVF undergoing a repeat cycle: A randomized controlled trial. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2017;214:109-114. ">Aleyamma 2017</a>; <a href="./references#CD012693-bbs2-0031" title="CTRI/2012/11/003139. Compare clinical outcome in conventional ART protocol and novel AMH tailored protocol in ART a prospective randomised controlled trial [To determine whether clinical outcome is better when treatment is decided on basis of age and follicular stimulating hormone as guide to treatment or Antimullerian hormone values in in vitro fertilisation patients]. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=4633 (first registered 22 November 2012). ">CTRI/2012/11/003139</a>; <a href="./references#CD012693-bbs2-0033" title="DrakakisP , LoutradisD , KallianidisK , MilingosS , Dionyssiou AsteriouA , MichalasS . The clinical efficacy of recombinant FSH (r-FSH) as compared to highly purified urinary gonadotrophin (hMG-FD) and the use of a low starting dose of r-FSH in IVF or ICSI. A randomized prospective study. Italian Journal of Gynaecology &amp; Obstetrics2002;14(3):64-8. ">Drakakis 2002</a>; <a href="./references#CD012693-bbs2-0035" title="GhaffariF , JahangiriN , MadaniT , KhodabakhshiS , ChehraziM . Randomized controlled trial of gonadotropin- releasing hormone agonist microdose flare- up versus flare- up among poor responders undergoing intracytoplasmic sperm injection. International Journal of Gynecology and Obstetrics2020;148(1):59-64. ">Ghaffari 2018</a>; <a href="./references#CD012693-bbs2-0044" title="NCT03809221. The effectiveness and safety of the prolonged down-regulation protocol for controlled ovarian hyperstimulation [The Effectiveness and Safety of the Early Follicular Phase Prolonged Down-regulation Protocol for Controlled Ovarian Hyperstimulation: a Randomized, Paralleled, Controlled, Multicenter Trial]. ClinicalTrials.gov (first posted 18 January 2019). ">NCT03809221</a>; <a href="./references#CD012693-bbs2-0038" title="LawrenzB , Melado L , DigmaS , SibalJ , CoughlanaC , AndersenCY , et al. Reintroducing serum FSH measurement during ovarian stimulation for ART. Reproductive BioMedicine Online2022;44(3):548-56. ">Lawrenz 2022</a>; <a href="./references#CD012693-bbs2-0039" title="Lobato‐PascualA , RakiM , GreggainsG , FedorcsakP . Gonadotropin endocytosis as a biomarker of optimal FSH dosage-a randomised clinical trial. Human Reproduction2017;32(Suppl 1):i106-7. ">Lobato‐Pascual 2017</a>; <a href="./references#CD012693-bbs2-0041" title="NCT01926210. Comparison of ovarian mild stimulation and controlled ovarian stimulation in poor ovarian responders (POR). clinicaltrials.gov/study/NCT01926210 (first registered 21 August 2013). ">NCT01926210</a>; <a href="./references#CD012693-bbs2-0042" title="NCT02635607. Effectiveness and safety study of fixed versus flexible of gonadotropin-releasing hormone antagonist protocol (GnRH) [A RCT study to evaluate the safety and efficacy of the fixed day-5 antagonist protocol versus the flexible antagonist protocol for the controlled ovarian stimulation in Chinese women with predicted high ovarian response]. clinicaltrials.gov/study/NCT02635607 (first posted 21 December 2015). ">NCT02635607</a>; <a href="./references#CD012693-bbs2-0052" title="ThomasS , AcharyaM , MuthukumarK , ChandyA , KamathMS , AleyammaTK , et al. Effectiveness of anti-mullerian hormone-tailored protocol compared to conventional protocol in women undergoing in vitro fertilization: a randomized controlled trial. Journal of Human Reproductive Sciences2018;11(1):24-8. ">Thomas 2018</a>; <a href="./references#CD012693-bbs2-0040" title="NCT00225433. Luteal phase FSH in the IVF poor responder [Luteal Phase Recombinant FSH vs. Follicular Phase Recombinant FSH for IVF Stimulation in the Poor Responder]. clinicaltrials.gov/study/NCT00225433 (first registered 21 September 2005). ">NCT00225433</a>; <a href="./references#CD012693-bbs2-0055" title="YoussefMA , vanWelyM , Al-InanyH , MadaniT , JahangiriN , KhodabakhshiS , et al. A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial. Human Reproduction2017;32(1):112-8. ">Youssef 2016</a>); </p> </li> <li> <p>did not measure or report at least one of AMH, bFSH, or AFC: 13 studies (<a href="./references#CD012693-bbs2-0029" title="CamierB . A multicentre, prospective, randomised study to compare low dose protocol versus conventional administration of Rh-FSH (GONAL-F) in normo-responders undergoing ART. Congress of Controversies in Obstestrics, Gynaecology and Infertility1999;1:7. ">Camier 1999</a>; <a href="./references#CD012693-bbs2-0030" title="CavagnaM , DzikA , FreitasGC , SoaresJB , DonadioN , CavagnaF , et al. A prospective and randomized trial comparing 225IU and 300 IU follitropin-alpha; in a fixed-dose regimen for controlled ovarian stimulation. Jornal Brasileiro de Reproducao Assistida2009;24(2):66-70. ">Cavagna 2009</a>; <a href="./references#CD012693-bbs2-0032" title='De JongD , MacklonNS , FauserBC . A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertility and Sterility2000;73(5):1051-4. '>DeJong 2000</a>; <a href="./references#CD012693-bbs2-0034" title="FlukerMR , CopelandJE , YuzpeAA . A prospective randomized clinical trial of four fixed starting doses of recombinant FSH in women undergoing ovarian stimulation for IVF. Human Reproduction2000;15:26. ">Fluker 2000</a>; <a href="./references#CD012693-bbs2-0037" title="Latin-American Puregon IVF Study Group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle-stimulating hormone in women undergoing in vitro fertilization. Fertility and Sterility2001;76(5):950-6. ">Latin‐American Puregon IVF Study Group 2001</a>; <a href="./references#CD012693-bbs2-0043" title="NCT02915900. Optimising FSH dosage during in vitro fertilization (IVF) [Method for determining optimal FSH dosage during in vitro fertilization (IVF)]. clinicaltrials.gov/ct2/show/NCT02915900 (first received 27 September 2016). ">NCT02915900</a>; <a href="./references#CD012693-bbs2-0045" title="OutHJ , LindenbergS , MikkelsenAL , Eldar-GevaT , HealyDL , LeaderA , et al. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. Human Reproduction1999;14(3):622-7. ">Out 1999</a>; <a href="./references#CD012693-bbs2-0046" title="OutHJ , BraatDD , LintsenBM , GurganT , BukulmezO , GökmenO , et al. Increasing the daily dose of recombinant follicle stimulating hormone (Puregon) does not compensate for the age-related decline in retrievable oocytes after ovarian stimulation. 2000 Human Reproduction;15(1):29-35. ">Out 2000</a>; <a href="./references#CD012693-bbs2-0047" title="OutHJ , DavidI , Ron-ElR , FriedlerS , ShalevE , GeslevichJ , et al. A randomized, double-blind clinical trial using fixed daily doses of 100 IU or 200 IU of recombinant FSH in ICSI cycles. Human Reproduction2001;16(6):1104-9. ">Out 2001</a>; <a href="./references#CD012693-bbs2-0048" title="PruksananondaK , SuwajanakornS , SereepapongW , VirutamasenP . Comparison of two different fixed doses of follitropin-β in controlled ovarian hyperstimulation: a prospective randomized, double blind clinical trial. Journal of the Medical Association of Thailand2004;87(10):1151-5. ">Pruksananonda 2004</a>; <a href="./references#CD012693-bbs2-0050" title="SimbergN , RovaK , GudmundssonJ , Lundkvist Ö, LundqvistM , BekuretsionM , et al. A randomized study comparing Puregon 100 IU or 150 IU as starting dose in IVF treatment. Human Reproduction2000;Abstract book 1:125. ">Simberg 2000</a>; <a href="./references#CD012693-bbs2-0053" title="TsagareishviliG , KhonelidzeN , LazarevA . Results of application of high daily doses of recombinant follicle stimulating hormone in different age groups of women in IVF program. In: Georgian Medical News. Vol. 6. 2005:11. ">Tsagareishvili 2005​</a>; <a href="./references#CD012693-bbs2-0054" title="WiklandM , BerghC , BorgK , HillensjöT , HowlesCM , KnutssonA , et al. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Human Reproduction2001;16(8):1676-81. ">Wikland 2001</a>); </p> </li> <li> <p>ineligible study design: two studies (we discovered that <a href="./references#CD012693-bbs2-0028" title="BerkkanogluM , OzgurK . What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?Fertility and Sterility2010;94(2):662-5. ">Berkkanoglu 2010</a> was quasi‐randomised following correspondence with authors (<a href="./references#CD012693-bbs2-0073" title="BerkkanogluM . Query on trial: 600 vs 450 vs 300 IU FSH. Fertility and sterility 2010. Email to: Lensen S 4 May 2017.">Berkkanoglu 2017 [pers comm]</a>); in <a href="./references#CD012693-bbs2-0049" title="RasmussenBB , MannaertsB , KleinBM , HelmgaardL , ArceJC , et al, ESTHER-1 trial group. Low immunogenicity potential of follitropin delta, a recombinant FSH preparation produced from a human cell line: results from phase 3 trials (ESTHER-1 and ESTHER-2). In: Abstracts of the 32nd Annual Meeting of the European Society of Human Reproduction and Embryology. 2016. ">Rasmussen 2016</a>, the women underwent repeated cycles of ovarian stimulation); </p> </li> <li> <p>ineligible patient population: one study (<a href="./references#CD012693-bbs2-0051" title="Tandler-SchneiderA , GriesingerG , TörökA , KovacsP , SydowP , EbertP , et al. Fully human glycooptimized recombinant FSH: a randomized, assessor-blind, multi-center, multi-national phase II trial to investigate the efficacy and safety of FSH-GEX in women undergoing ART. Human Reproduction2014;29(Suppl 1):i1-i389. ">Tandler‐Schneider 2014</a>); </p> </li> <li> <p>ineligible setting: one study (<a href="./references#CD012693-bbs2-0036" title="NCT00374634. Individual versus standard follicle stimulating hormone dose for controlled ovarian stimulation and insemination [Individual versus standard RFSH dose for controlled ovarian stimulation and intrauterine insemination. A prospective randomised multi centre study]. clinicaltrials.gov/study/NCT00374634 (first posted 11 September 2006). la Cour FreieslebenN , LosslK , BogstadJ , BredkjaerHE , ToftB , RosendahlM , et al. Individual versus standard dose of rFSH in a mild stimulation protocol for intrauterine insemination: a randomized study. Human Reproduction2009;24(10):2523-30. [DOI: 10.1093/humrep/dep239]">la Cour Freiesleben 2009</a>). </p> </li> </ul> </p> <p>A further seven studies are ongoing (<a href="./references#CD012693-bbs2-0060" title="CTRI/2016/10/007367. Phase III study to evaluate the efficacy and safety of recombinant human FSH of Cadila Healthcare Limited, India as compared to Gonal-F administered subcutaneously in female patients undergoing assisted reproductive technology [A Phase III, Randomized, Open-Label, Multiple-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of Recombinant Human FSH of Cadila Healthcare Limited, India as compared to Gonal-F TM Administered Subcutaneously in Female Patients Undergoing Assisted Reproductive Technology]. ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=16431&amp;EncHid=&amp;userName=CTRI/2016/10/007367 (first received 14 October 2016). ">CTRI/2016/10/007367</a>; <a href="./references#CD012693-bbs2-0061" title="NCT01794208. Efficacy and safety of FSH-GEX™ in comparison with 150 IU Gonal-f®. clinicaltrials.gov/ct2/show/NCT01794208 (first received 18 February 2013). ">NCT01794208</a>; <a href="./references#CD012693-bbs2-0062" title="NCT02430740. Tailored ovarian stimulation based on BMI, AMH, AFC. clinicaltrials.gov/ct2/show/NCT02430740 (first received 30 April 2015). ">NCT02430740</a>; <a href="./references#CD012693-bbs2-0063" title="NCT02739269. Antimullerian hormone versus antral follicle count for determination of gonadotropin dosing in IVF. clinicaltrials.gov/ct2/show/NCT02739269 (first received 15 April 2016). ">NCT02739269</a>; <a href="./references#CD012693-bbs2-0064" title="NCT03914651. CLBR per initial cycle with different starting dose in aged patients with poor ovarian reservation: 300IU versus 150IU. clinicaltrials.gov/ct2/show/NCT03914651 (first received 16 April 2019). ">NCT03914651</a>; <a href="./references#CD012693-bbs2-0065" title="NCT05103228. Cumulative pregnancy rate with lower and higher gonadotropin dose during IVF among poor responders. clinicaltrials.gov/ct2/show/NCT05103228 (first received 2 November 2021). ">NCT05103228</a>; <a href="./references#CD012693-bbs2-0066" title="SinghM , SinghR , JindalA , JindalPC . A prospective randomised controlled trial (RCT) on the role of AMH tailored stimulation protocols (Agonist or Antagonist), in improving IVF outcome in previous failed cycles. Human Reproduction2015;30:i419-20, P-699. ">Singh 2015</a>), and four studies are awaiting classification (<a href="./references#CD012693-bbs2-0056" title="Fernández-SánchezM , VisnovaH , YuzpeA , KleinBM , MannaertsB , ArceJC . Individualization of the starting dose of follitropin delta reduces the overall OHSS risk and/or the need for additional preventive interventions: cumulative data over three stimulation cycles. Reproductive Biomedicine Online2019;38(4):528-37. ">Fernandez 2019</a>; <a href="./references#CD012693-bbs2-0057" title="Fernandez SanchezM , LarssonP , Ferrando SerranoM , BoschE , García VelascoJA , Santamaría LópezE , et al. Live birth rates following individualized dosing algorithm of follitropin delta in a long GnRH agonist protocol. Reproductive Biology and Endocrinology2023;21:45. Fernandez SanchezM , LarssonP , Ferrando SerranoM , BoschE , García VelascoJA , Santamaría LópezE , et al. The individualised dosing algorithm of follitropin delta, developed in a GnRH antagonist protocol, shows to be highly effective in a long GnRH agonist protocol. Human Reproduction2022;37(Suppl 1):i7. ">Fernandez 2022</a>; <a href="./references#CD012693-bbs2-0058" title="JanseF , EijkemansM , FauserB . Improved safety and efficiency of individualised versus conventional gonadotropin dosing for ovarian stimulation in IVF/ICSI: an individual patient meta-analysis (IPD-MA). Human Reproduction;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab126.023]">Janse 2021</a>; <a href="./references#CD012693-bbs2-0059" title="YangR , ZhangY , LiangX , SongX , WeiZ , LiuJ , et al. Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection. Reproductive Biology and Endocrinology2022;20(1):147. [DOI: 10.1186/s12958-022-01016-y]">Yang 2022</a>). </p> </section> </section> <section id="CD012693-sec-0052"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias for each included trial (<a href="./references#CD012693-sec-0246" title="">Characteristics of included studies</a>). We present the results in the risk of bias summary and graph (<a href="#CD012693-fig-0002">Figure 2</a>; <a href="#CD012693-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012693-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012693-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012693-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012693-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012693-sec-0053"> <h4 class="title">Allocation</h4> <p>We assessed 25 studies as having a low risk of selection bias related to sequence generation, as the studies used computer‐generated random numbers. Trialists of one study described it as 'randomized' only (<a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>). It was not possible to contact the study authors for further information, therefore we rated the risk of selection bias for this study as unclear. </p> <p>Overall, we judged 24 studies to have a low risk of bias for allocation concealment, as these studies: used sequentially‐numbered, opaque, sealed envelopes (SNOSE) (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>); employed a double‐blind design with patient numbers corresponding to boxes containing medication (<a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>); concealed allocation within an electronic randomisation and case‐report system (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>); or used third‐party randomisation (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>). We graded two studies as being at unclear risk, as we could not obtain any description of allocation concealment through author correspondence (<a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>). </p> </section> <section id="CD012693-sec-0054"> <h4 class="title">Blinding</h4> <p>We considered blinding of participants and personnel to be important in this review, as knowledge of trial allocation may impact on the decisions made by staff during the participants' IVF cycle: for example, whether to increase or decrease the dose in studies permitting dose adjustment, when to trigger, whether to cancel the cycle for poor or hyper‐response, what efforts to make to obtain eggs at egg retrieval, etc. This would constitute bias if these decisions differed due to the trial context compared to clinical practice. We assessed the domain of detection bias for subjective outcomes only – namely, for OHSS. Indeed, one of the included studies in predicted low responders found that clinicians were more likely to cancel cycles in the lower‐dose arm, despite strict rules for cancellation (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). These authors hypothesised that the treating clinicians were more likely to cancel the cycle in women they knew were on a lower rather than higher dose of FSH. </p> <p>We judged 15 studies to be at high risk of bias for both domains, as there was no effort made to blind participants, personnel, or outcome assessors (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>). Two studies did not report the only subjective outcome of this study (OHSS), so we rated these as being at low risk for detection bias, as the domain does not apply (<a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). Six studies employed some level of blinding: in four studies, medications were indistinguishable, and all participants and personnel were blind, so we rated these trials as being at low risk of bias (<a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>). In five studies, only trial staff were blinded, with no participant blinding (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>). The studies did not include any description of any safeguards to prevent participants from disclosing their study dose to trial staff, so we rated these studies as being at unclear risk of bias. In <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>, authors described the study as being double‐blind. However, the methods seem to indicate that blinding was broken as early as day 4 of FSH administration, which would therefore leave the study open for the most part, warranting a rating of high risk for detection bias (<a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>). One study appeared to have some level of blinding, including for outcome assessment, but because dose adjustment was allowed in one arm only, it could not have been fully blinded (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>). We assigned a high risk rating for performance bias, and low risk for detection bias. </p> </section> <section id="CD012693-sec-0055"> <h4 class="title">Incomplete outcome data</h4> <p>We rated 23 studies as being at low risk for incomplete outcome data, as there were few withdrawals or dropouts. Many studies had a number of women who did not reach the stage of embryo transfer and therefore did not have the opportunity to conceive during the study period. We did not consider these participants to contribute to the attrition numbers but rather as not achieving pregnancy or live birth. </p> <p>We rated the remaining three studies as being at high risk for attrition bias. One study described the exclusion of 19 participants; however, it was not clear which trial arms these participants were excluded from, so it was not possible to assess if the number and reasons were balanced (<a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>). In the <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a> study, 35% of participants were excluded from analyses (37 of 57 retained). The <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a> study was published as an abstract only, and authors provided the individual participant data from the trial (<a href="./references#CD012693-bbs2-0087" title="HamodaH . Query on trial: individualised versus standard dosage of recombinant FSH. Email to: Lensen S 27 March 2017.">Hamoda 2017 [pers comm]</a>). The data provided appeared to have a large amount of missing data, and outcomes were not available for a significant number of participants (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). </p> </section> <section id="CD012693-sec-0056"> <h4 class="title">Selective reporting</h4> <p>We assessed nine studies as having a high risk of reporting bias, as they were not prospectively registered and failed to report important outcomes such as live birth and OHSS (<a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>; <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>). Although trial registration was not introduced as mandatory until 2005, the potential for selective reporting remains. </p> <p>We rated a further five studies as high risk in this domain for various reasons. One study included several categorisations of oocyte yield on the trial registration entry, and not all of these appear to have been reported in the manuscript (<a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>). The <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> study reported an outcome (live birth) not included in its protocol. We rated <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a> as high risk because it changed the definition of the primary outcome from that listed on the original trial registration (the definition of a good oocyte yield). Another study provided the outcomes of poor response and hyper‐response to stimulation only within subgroups of women, and it was not possible to extract the overall data per trial arm (<a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>). These authors declined to provide the data per trial arm without providing an adequate reason (<a href="./references#CD012693-bbs2-0091" title="HelmgaardL . n/a. Email to: Lensen S 7 July 2017.">Helmgaard 2017b [pers comm]</a>). Finally, we rated one study as high risk because the primary outcome was vaguely specified on the trial registry, and secondary outcomes were not prespecified (<a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>). </p> <p>We assessed the remaining 12 studies as having a low risk of bias in this domain. One study was assessed as high risk in the previous version of the review for not reporting total dose (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>). However, after correspondence with the authors, we changed our assessment to low risk. The authors pointed out that total dose was reported as stimulation duration, which has a one‐to‐one relationship with dose due to the fact that dose was fixed during the trial. In addition, the authors supplied the outcome as total dose on request. Nine studies were registered prospectively and reported all outcomes listed at trial registration (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). Another study listed a number of outcomes on the trial registration that they did not report in the paper; however, the authors provided the data for these outcomes (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0105" title="LefebvreJ . Query on trial: 450 vs 600 IU FSH. Lefebvre 2015. Email to: Lensen S 15 May 2017.">Lefebvre 2017 [pers comm]</a>). One study did not report a predefined secondary outcome, vital pregnancy, although the importance of this omission appears to be low, as ongoing pregnancy and live birth were reported (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>). We thus assessed this study as having a low risk of bias in this domain. </p> </section> <section id="CD012693-sec-0057"> <h4 class="title">Other potential sources of bias</h4> <p>Most studies had no additional sources of possible bias. One study stopped early on the basis of the O'Brien and Fleming 1979 rules (<a href="./references#CD012693-bbs2-0110" title="O'BrienPC , FlemingTR . A multiple testing procedure for clinical trials. Biometrics1979;35(3):549-57.">O'Brien 1979</a>), which are known to be associated with a biased estimate of effect (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). The analyses in the trial correctly adjusted for the early termination – however, from our point of view as systematic review authors, the uncorrected summary data available represent a biased estimate of the treatment effect. One study does not appear to have performed a power calculation, and the decision to complete recruitment on the basis of interim results may have induced bias (<a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>). Another study was available as an abstract only, therefore detailed information about the study methodology was not available. Although the study authors provided the individual participant data, there were a lot of missing values (<a href="./references#CD012693-bbs2-0087" title="HamodaH . Query on trial: individualised versus standard dosage of recombinant FSH. Email to: Lensen S 27 March 2017.">Hamoda 2017 [pers comm]</a>; <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>), and we consequently assessed this study as having an unclear risk of bias. However, we attempted to minimise this bias by performing multiple imputations on the data set. One trial performed an interim analysis, and used these interim results to inform a decision to increase the trial sample size; however, there does not appear to be any correction for P value spending (<a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>). It is unclear whether this would bias the data available for this review. We assessed this study as high risk for this domain. </p> </section> </section> <section id="CD012693-sec-0058"> <h3 class="title" id="CD012693-sec-0058">Effects of interventions</h3> <p>See: <a href="./full#CD012693-tbl-0001"><b>Summary of findings 1</b> ORT‐based algorithm compared to standard starting dose of FSH for women undergoing IVF/ICSI</a>; <a href="./full#CD012693-tbl-0002"><b>Summary of findings 2</b> Anticipated low responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</a>; <a href="./full#CD012693-tbl-0003"><b>Summary of findings 3</b> Anticipated normal responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</a>; <a href="./full#CD012693-tbl-0004"><b>Summary of findings 4</b> Anticipated high responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</a> </p> <p>We present the results separately for direct dose comparison and ORT‐algorithm studies. Within the direct dose comparison studies, we subdivide the results according to each predicted responder category (low, normal, high). </p> <section id="CD012693-sec-0059"> <h4 class="title">Direct dose comparison studies</h4> <section id="CD012693-sec-0060"> <h5 class="title">1. Predicted low responders</h5> <p>Six studies included women who were predicted to have a low response based on at least one ORT measure (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). We pooled the studies within this comparison where the control dose was identical: </p> <p> <ul id="CD012693-list-0017"> <li> <p>300/450 IU versus 150 IU:</p> <ul id="CD012693-list-0018"> <li> <p>300 IU versus 150 IU (<a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>) </p> </li> <li> <p>450 IU versus 150 IU (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>) </p> </li> </ul> </li> <li> <p>400/450 IU versus 300 IU:</p> <ul id="CD012693-list-0019"> <li> <p>450 IU versus 300 IU (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>) </p> </li> <li> <p>400 IU versus 300 IU (<a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>) </p> </li> </ul> </li> <li> <p>600 IU versus 450 IU (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>). </p> </li> </ul> </p> <p>These comparisons are displayed within subgroups on one forest plot for illustrative purposes only (no overall pooling; <a href="./full#CD012693-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD012693-sec-0061"> <h6 class="title">Primary outcomes</h6> <section id="CD012693-sec-0062"> <p><b>1.1 Live birth or ongoing pregnancy</b></p> <p>Three studies reported live birth (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), and two reported ongoing pregnancy (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>). The estimates of difference in live birth/ongoing pregnancy rate between the dose comparisons were very imprecise, and there is little information about the true treatment effect, so we graded the body of evidence as low certainty (<a href="./references#CD012693-fig-0012" title="">Analysis 1.1</a>, <a href="#CD012693-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD012693-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anticipated low responders: higher vs lower dose, outcome: 1.1 Live birth or ongoing pregnancy per woman randomised." data-id="CD012693-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anticipated low responders: higher vs lower dose, outcome: 1.1 Live birth or ongoing pregnancy per woman randomised. </p> </div> </div> </div> <p> <ul id="CD012693-list-0020"> <li> <p><b>300/450 IU versus 150 IU</b> (OR 1.20, 95% CI 0.78 to 1.86; I<sup>2</sup> = 20%; 3 studies, 538 participants). This suggests that if the chance of live birth with 150 IU is 16%, then the chance with 300/450 IU would be 13% to 26%. </p> </li> <li> <p><b>400/450 IU versus 300 IU</b> (OR 0.77, 95% CI 0.19 to 3.19; 1 study, 62 participants). This suggests that if the chance of live birth with 300 IU is 16%, then the chance with 400/450 IU would be 4% to 38%. </p> </li> <li> <p><b>600 IU versus 450 IU</b> (OR 1.33, 95% CI 0.71 to 2.52; 1 study, 356 participants). This suggests that if the chance of live birth with 450 IU is 11%, then the chance with 600 IU would be 8% to 23%. </p> </li> </ul> </p> <p>One study also reported the outcome of cumulative live birth in two ways (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). </p> <p> <ul id="CD012693-list-0021"> <li> <p><b>Cumulative live birth – following one IVF cycle (fresh and frozen transfers)</b>. The evidence for cumulative live birth when comparing 450 IU versus 150 IU was also consistent with notable effects in either direction or of no difference (OR 0.78, 95% CI 0.35 to 1.73; 234 participants; <a href="./references#CD012693-fig-0029" title="">Analysis 1.18</a>). This suggests that if the chance of cumulative live birth with 150 IU is 13%, then the chance with 450 IU would be 5.1% to 21%. </p> </li> <li> <p><b>Cumulative live birth – following 18 months of IVF (defined as an ongoing pregnancy leading to a live birth occurring within 18 months of randomisation)</b>. The evidence when comparing 450 IU with 150 IU for cumulative live birth after 18 months of IVF was also consistent with notable effects in either direction or of no difference (OR 0.78, 95% CI 0.46 to 1.32; 234 participants; <a href="./references#CD012693-fig-0030" title="">Analysis 1.19</a>). This suggests that if the chance of cumulative live birth with 150 IU is 42%, then the chance with 450 IU would be 25% to 49%. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0063"> <p><b>1.2 Severe ovarian hyperstimulation syndrome (OHSS)</b></p> <p>Four studies reported severe OHSS; however, there were no incidents of severe OHSS in any of the studies (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>; see <a href="./references#CD012693-fig-0013" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD012693-sec-0064"> <h6 class="title">Secondary outcomes</h6> <section id="CD012693-sec-0065"> <p><b>1.3 Clinical pregnancy</b></p> <p>All six studies reported this outcome, and we graded the body of evidence as low certainty (<a href="./references#CD012693-fig-0014" title="">Analysis 1.3</a>). </p> <p>In each of the three dose comparisons in predicted low responders, the results are imprecise and remain consistent with effects in either direction, or with no effect. </p> <p> <ul id="CD012693-list-0022"> <li> <p><b>300/450 IU versus 150 IU</b> (OR 0.85, 95% CI 0.57 to 1.27; I<sup>2</sup> = 46%; 3 studies, 538 participants). This suggests that if the chance of clinical pregnancy with 150 IU is 27%, then the chance with 300/450 IU would be between 17% and 32%. </p> </li> <li> <p><b>400/450 IU versus 300 IU</b> (OR 0.84, 95% CI 0.26 to 2.69; I<sup>2</sup> = 0%; 2 studies, 110 participants). This suggests that if the chance of clinical pregnancy with 300 IU is 13%, then the chance with 400/450 IU would be between 4% and 28%. </p> </li> <li> <p><b>600 IU versus 450 IU</b> (OR 1.14, 95% CI 0.66 to 1.99; 1 study, 356 participants). This suggests that if the chance of clinical pregnancy with 450 IU is 16%, then the chance with 600 IU would be 11% to 27%. This study also reported the cumulative clinical pregnancy rate; however, this was not an outcome of this review. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0066"> <p><b>1.4 Time to clinical pregnancy</b></p> <p>None of the studies in predicted low responders reported this outcome; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a> reported the time to ongoing pregnancy, but not time to clinical pregnancy. </p> </section> <section id="CD012693-sec-0067"> <p><b>1.5 Moderate or severe OHSS</b></p> <p>All four studies reported this outcome. However, there were no incidents of moderate or severe OHSS amongst women with expected low response in three studies (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>; <a href="./references#CD012693-fig-0016" title="">Analysis 1.5</a>). In the study comparing 600 IU and 450 IU, there was only one occurrence of moderate OHSS in the higher dose arm, so the effect is too imprecise to provide any useful information (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>). </p> </section> <section id="CD012693-sec-0068"> <p><b>1.6 Multiple pregnancy rate per woman randomised</b></p> <p>Five studies reported multiple pregnancy (<a href="./references#CD012693-fig-0017" title="">Analysis 1.6</a>). In two studies, there were no cases of multiple pregnancy in either of the study arms (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>). In <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>, there were two events in the 150 IU arm and one in the 450 IU arm, while in <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>, there were six events in each arm (Peto OR 0.93, 95% CI 0.33 to 2.61; 2 studies, 538 participants). As the event rates were so low, we did not interpret these results any further. In the fifth study, there were four multiple pregnancies in the 450 IU arm and eight in the 600 IU arm (Peto OR 0.49, 95% CI 0.16 to 1.55; 356 participants; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>). </p> <p>We also calculated the multiple pregnancy rates per clinical pregnancy (Peto OR 0.92, 95% CI 0.08 to 10.54; 41 participants (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), and Peto OR 0.37, 95% CI 0.11 to 0.31; 60 participants (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>); <a href="./references#CD012693-fig-0031" title="">Analysis 1.20</a>). </p> </section> <section id="CD012693-sec-0069"> <p><b>1.7 Number of oocytes retrieved per woman randomised</b></p> <p>All six studies reported this outcome (<a href="./references#CD012693-fig-0018" title="">Analysis 1.7</a>) (the standard deviations used for <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a> were borrowed from <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a> since <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a> had none). These are ratios of mean oocytes and should not be misinterpreted as numbers of oocytes. </p> <p>In comparing 300/450 IU versus 150 IU, the pooled effect suggests a higher number of oocytes are collected in the higher dose arms (ratio of mean oocytes 1.97, 95% CI 1.70 to 2.29; I<sup>2</sup> = 79%; 3 studies, 947 participants). This pooled estimate should be treated with caution owing to the high statistical heterogeneity. The 95% CI corresponds to increases of 70% and 229%. </p> <p>In the other two comparisons, we did not detect a difference in the mean oocytes collected; however, the estimates are reasonably imprecise, and there could be small effects in either direction. </p> <p> <ul id="CD012693-list-0023"> <li> <p><b>400/450 IU versus 300 IU</b> (ratio of mean oocytes 0.97, 95% CI 0.74 to 1.27; I<sup>2</sup> = 38%; 2 studies, 110 participants). </p> </li> <li> <p><b>600 IU versus 450 IU</b> (ratio of mean oocytes 1.08, 95% CI 0.96 to 1.22; 356 participants). </p> </li> </ul> </p> </section> <section id="CD012693-sec-0070"> <p><b>1.8 Poor response to stimulation</b></p> <p>Two trials within the same subgroup reported this outcome (<a href="./references#CD012693-fig-0019" title="">Analysis 1.8</a>). One study defined a poor response as the collection of fewer than four oocytes or cycle cancellation due to poor response (<a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>), and the second study defined a poor response as cycle cancellation for poor response or the retrieval of fewer than five oocytes (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). The pooled effect demonstrates that there were fewer cases of poor response amongst women with expected poor response receiving 300/450 IU than 150 IU. </p> <p> <ul id="CD012693-list-0024"> <li> <p><b>300/450 IU versus 150 IU</b> (OR 0.52, 95% CI 0.32 to 0.84; I<sup>2</sup> = 0%; 2 studies, 286 participants). This suggests that if the chance of a poor response with 150 IU is 65%, then the chance with 400/450 IU would be 37% to 61%. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0071"> <p><b>1.9 Normal response to stimulation</b></p> <p>None of the studies in predicted low responders reported this outcome specifically in their respective papers. However, we calculated it as the difference between the number of women randomised and the number with either poor or hyper‐response in one trial that reported both of these outcomes (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). Therefore, the resulting definition is women with the retrieval of 5 to 15 oocytes or cycle cancellation for any reason other than a poor or hyper‐response (<a href="./references#CD012693-fig-0020" title="">Analysis 1.9</a>). The result suggests there is a higher rate of normal response amongst women administered 450 IU compared to 150 IU. </p> <p> <ul id="CD012693-list-0025"> <li> <p><b>300/450 IU versus 150 IU</b> (OR 1.79, 95% CI 1.05 to 3.04; 234 participants). This suggests that if the chance of a normal response with 150 IU is 33%, then the chance with 450 IU would be 34% to 60%. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0072"> <p><b>1.10 Hyper‐response to stimulation</b></p> <p>One study reported this outcome, defining it as cycle cancellation owing to excessive response or more than 15 oocytes at retrieval (<a href="./references#CD012693-fig-0021" title="">Analysis 1.10</a>). The result suggests 450 IU leads to more cases of hyper‐response than 150 IU. </p> <p> <ul id="CD012693-list-0026"> <li> <p><b>300/450 IU versus 150 IU</b> (OR 4.53, 95% CI 0.94 to 21.82; 234 participants; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). This suggests that amongst women with expected low response, if the chance of a hyper‐response with 150 IU is 1.7%, then the chance with 450 IU would be 1.6% to 27%. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0073"> <p><b>1.11 Cycle cancellations for poor response</b></p> <p>All six studies reported this outcome (<a href="./references#CD012693-fig-0022" title="">Analysis 1.11</a>). In the first subgroup, the rate of cycle cancellation for poor response amongst women with expected low response was higher amongst women in the lower‐dose group; however, this result is largely influenced by one trial, and heterogeneity remains high. </p> <p> <ul id="CD012693-list-0027"> <li> <p><b>300/450 IU versus 150 IU</b> (OR 0.24, 95% CI 0.12 to 0.48; I<sup>2</sup> = 77%; 3 studies, 538 participants). This suggests that if the chance of cycle cancellation for poor response with 150 IU is 17%, then the chance with 300/450 IU would be 2% to 9%. </p> </li> </ul> </p> <p>In the other two groupings, the effects of different doses were unclear, and the confidence intervals remain wide. </p> <p> <ul id="CD012693-list-0028"> <li> <p><b>400/450 IU versus 300 IU</b> (OR 1.47, 95% CI 0.62 to 3.49; I<sup>2</sup> = 0%; 2 studies, 110 participants). This suggests that if the chance of cycle cancellation for poor response with 300 IU is 22%, then the chance with 400/450 IU would be 15% to 49%. </p> </li> <li> <p><b>600 IU versus 450 IU</b> (OR 0.86, 95% CI 0.50 to 1.50; 1 study, 356 participants). This suggests that if the chance of cycle cancellation for poor response with 450 IU is 18%, then the chance with 600 IU would be 10% to 25%. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0074"> <p><b>1.12 Cycle cancellations for hyper‐response (including freeze‐all cycles)</b></p> <p>Five studies reported this outcome. However, in four studies there were no events (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>). In one study, there was only one event of cycle cancellation for hyper‐response, so the effect estimates remain very imprecise (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). </p> <p> <ul id="CD012693-list-0029"> <li> <p><b>400/450 IU versus 150 IU</b> (Peto OR 7.93, 95% CI 0.16 to 400.62; 234 participants; <a href="./references#CD012693-fig-0023" title="">Analysis 1.12</a>). </p> </li> </ul> </p> </section> <section id="CD012693-sec-0075"> <p><b>1.13 Cycle cancellations for poor or hyper‐response</b></p> <p>This outcome refers to the cancellation of an IVF/ICSI treatment cycle due to poor response or hyper‐response, excluding cancellations for other reasons (such as uterine anomaly). In predicted low responders, there was only one case of cancellation for hyper‐response, so the outcome primarily reflects the outcome of cycle cancellation for poor response (<a href="./references#CD012693-fig-0024" title="">Analysis 1.13</a>). </p> <p>In one case, there was a clear benefit from 300/450 IU over 150 IU in reducing the number of cycle cancellations from poor or hyper‐response. </p> <p> <ul id="CD012693-list-0030"> <li> <p><b>300/450 IU versus 150 IU</b> (OR 0.25, 95% CI 0.13 to 0.50; I<sup>2</sup> = 87%; 2 studies, 286 participants). This suggests that if the chance of cycle cancellation for poor or hyper‐response with 150 IU is 28%, then the chance with 300/450 IU would be 4.8% to 16%. Readers should treat this estimate with caution owing to the high statistical heterogeneity. </p> </li> </ul> </p> <p>However, in the other two subgroups, the effect is less clear.</p> <p> <ul id="CD012693-list-0031"> <li> <p><b>400/450 IU versus 300 IU</b> (OR 1.47, 95% CI 0.62 to 3.49; I<sup>2</sup> = 0%; 2 studies, 110 participants). This suggests that if the chance of cycle cancellation for poor or hyper‐response with 300 IU is 22%, then the chance with 400/450 IU would be 15% to 49%. </p> </li> <li> <p><b>600 IU versus 450 IU</b> (OR 0.86, 95% CI 0.50 to 1.50; 1 study, 356 participants). This suggests that if the chance of cycle cancellation for poor or hyper‐response with 450 IU is 18%, then the chance with 600 IU would be 10% to 25%. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0076"> <p><b>1.14 Proportion of women with at least one transferable embryo</b></p> <p>This outcome refers to the number of women who had at least one embryo available for transfer, either for a fresh embryo transfer or for a freeze‐all strategy. In most cases, the estimate of the difference in the number of women with at least one embryo available to transfer between the two groups was very imprecise (<a href="./references#CD012693-fig-0025" title="">Analysis 1.14</a>). </p> <p> <ul id="CD012693-list-0032"> <li> <p><b>400/450 IU versus 300 IU</b> (OR 0.71, 95% CI 0.31 to 1.60; I<sup>2</sup> = 0%; 2 studies, 110 participants). This suggests that if the chance of having at least one transferable embryo with 300 IU is 73%, then the chance with 400/450 IU would be 45% to 81%. </p> </li> <li> <p><b>600 IU versus 450 IU</b> (OR 1.19, 95% CI 0.78 to 1.82; 1 study, 356 participants). This suggests that if the chance of having at least one transferable embryo with 450 IU is 57%, then the chance with 600 IU would be 51% to 71%. </p> </li> </ul> </p> <p>However, in one subgroup, more women had at least one transferable embryo amongst those administered a higher dose. </p> <p> <ul id="CD012693-list-0033"> <li> <p><b>300/450 IU versus 150 IU</b> (OR 1.54, 95% CI 1.02 to 2.32; I<sup>2</sup> = 61%; 2 studies, 538 participants). This suggests that if the chance of having at least one transferable embryo with 150 IU is 71%, then the chance with 300/450 IU would be 71% to 85%. Readers should treat this result with caution owing to the high statistical heterogeneity. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0077"> <p><b>1.15 Total dose of FSH</b></p> <p>All studies apart from <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a> reported this outcome. In all groupings, participants in the higher dosing arm received a higher total dose of FSH on average than women in the lower dosing arm (<a href="./references#CD012693-fig-0026" title="">Analysis 1.15</a>). </p> <p> <ul id="CD012693-list-0034"> <li> <p><b>300/450 IU versus 150 IU</b> (MD IU 2780, 95% CI 2570 to 3000; I<sup>2</sup> = 98%; 2 studies, 286 participants). </p> </li> <li> <p><b>400/450 IU versus 300 IU</b> (MD IU 1110, 95% CI 910 to 1310; I<sup>2</sup> = 94%; 2 studies, 110 participants). </p> </li> <li> <p><b>600 IU versus 450 IU</b> (MD IU 1200, 95% CI 1070 to 1330; 1 study, 356 participants). </p> </li> </ul> </p> <p>We would urge caution in relation to this outcome, however, as the effect of censoring due to cancelled cycles cannot be accounted for, and there is high statistical heterogeneity. </p> </section> <section id="CD012693-sec-0078"> <p><b>1.16 Duration of FSH administration</b></p> <p>Four studies reported this outcome (<a href="./references#CD012693-fig-0027" title="">Analysis 1.16</a>). In all cases, the pooled effects suggest that higher doses reduce the duration of FSH administration. </p> <p> <ul id="CD012693-list-0035"> <li> <p><b>300/450 IU versus 150 IU</b> (MD days ‐0.70, 95% CI ‐1.48 to 0.08; 1 study, 234 participants). </p> </li> <li> <p><b>400/450 IU versus 300 IU</b> (MD days ‐0.67, 95% CI ‐1.39 to 0.06; I<sup>2</sup> = 0%; 2 studies, 110 participants). </p> </li> <li> <p><b>600 IU versus 450 IU</b> (MD days ‐1.00, 95% CI ‐1.27 to ‐0.73; 1 study, 356 participants). </p> </li> </ul> </p> <p>We would urge caution in relation to this outcome, however, as it is not possible to account for the effect of censoring due to cancelled cycles. </p> </section> <section id="CD012693-sec-0079"> <p><b>1.17 Cost per woman randomised</b></p> <p>None of the studies in predicted low responders reported this outcome. However, the outcome was available pooled across two sub‐studies in this review (one poor responder and one normal responder), which were published as one trial (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). The total cost was higher amongst women administered 450/225 IU compared to those given 150 IU (EUR 6397 versus EUR 5298; MD EUR 1099, 95% CI 562 to 1591). </p> </section> </section> </section> <section id="CD012693-sec-0080"> <h5 class="title">2. Predicted normal responders</h5> <p>Twelve studies included women with predicted normal response, as determined by at least one ORT measure (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>; <a href="./full#CD012693-tbl-0003">summary of findings Table 3</a>). The studies are pooled under the following comparisons. </p> <p> <ul id="CD012693-list-0036"> <li> <p>200 IU versus 100 IU (<a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>). </p> </li> <li> <p>225/200 IU versus 150 IU:</p> <ul id="CD012693-list-0037"> <li> <p>200 IU versus 150 IU (<a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>); </p> </li> <li> <p>225 IU versus 150 IU (<a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>). </p> </li> </ul> </li> <li> <p>300 IU versus 225 IU (<a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>). </p> </li> <li> <p>300 IU versus 150 IU (<a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>). </p> </li> </ul> </p> <p>These comparisons are also presented together in one forest plot for display purposes only (no overall pooling). </p> <p> <ul id="CD012693-list-0038"> <li> <p><b>Dose‐response effects (no pooling)</b>. <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> reported doses as 5.2 µg, 6.9 µg, 8.6 µg. 10.3 µg, and 12.1 µg, and <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> reported doses as 12 µg, 9 µg, and 6 µg rather than as international units (IU). As these doses cannot be translated into the doses described in the other studies, we present information on the dose response between increasing dose groups in separate forest plots and in descriptions in the text. </p> </li> </ul> </p> <section id="CD012693-sec-0081"> <h6 class="title">Primary outcomes</h6> <section id="CD012693-sec-0082"> <p><b>2.1 Live birth or ongoing pregnancy</b></p> <p>Eight studies reported this outcome amongst women with expected normal response: six reported live birth (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0013" title="LiuX , WenW , TaoW , LiT , NaL , TingS , et al. Individualized versus standard FSH dosing in predicted poor responders: an RCT. Human Reproduction2021;36(Suppl 1):[no pagination]. [PMID: https://doi.org/10.1093/humrep/deab127.055]LiuX , WenW , WangT , TianL , LiN , SunT , et al. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial. Human Reproduction2022;37(8):1806-15. ">Liu 2022</a>; <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), and two reported ongoing pregnancy (<a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0023" title="TanSL , ChildTJ , CheungAP , FlukerMR , YuzpeA , CasperR , et al. A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon R) in women undergoing controlled ovarian hyperstimulation for IVF treatment. Journal of Assisted Reproduction and Genetics2005;22(2):81-8. ">Tan 2005</a>). We rated the evidence as low certainty. </p> <p>In two of the comparisons, there is no clear impact of different doses on the probability of live birth, and the confidence intervals encompass the possibility of effects in either direction (<a href="./references#CD012693-fig-0032" title="">Analysis 2.1</a>; <a href="#CD012693-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD012693-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Anticipated normal responders: higher vs lower dose, outcome: 2.1 Live birth or ongoing pregnancy." data-id="CD012693-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anticipated normal responders: higher vs lower dose, outcome: 2.1 Live birth or ongoing pregnancy. </p> </div> </div> </div> <p> <ul id="CD012693-list-0039"> <li> <p><b>200 IU versus 100 IU</b> (OR 0.88, 95% CI 0.57 to 1.36; I<sup>2</sup> = 0%; 2 studies, 522 participants). This suggests that if the chance of live birth or ongoing pregnancy with 100 IU is 20%, then the chance with 200 IU would be 13% to 26%. </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (OR 0.98, 95% CI 0.70 to 1.36; I<sup>2</sup> = 0%; 2 studies, 686 participants). This suggests that if the chance of live birth or ongoing pregnancy with 150 IU is 29%, then the chance with 200/225 IU would be 22% to 36%. </p> </li> <li> <p><b>300 IU versus 225 IU</b> (OR 0.65, 95% CI 0.32 to 1.32; 1 study, 135 participants). This suggests that if the chance of live birth with 225 IU is 40%, then the chance with 300 IU would be 17% to 47%. In the third comparison, the confidence interval remains wide, and it is not clear whether there is any effect from 300 IU versus 225 IU. </p> </li> <li> <p><b>300 IU versus 150 IU</b> (OR 0.80, 95% CI 0.19 to 3.42; 1 study, 37 participants). This suggests that if the chance of live birth with 150 IU is 29%, then the chance with 300 IU would be 7% to 59%. </p> </li> <li> <p>Additionally, live birth rates and associated standard errors (SEs) across the <b>five dose groups</b> in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> in order of increasing dose were 32% (11), 32% (11), 35% (11), 25% (10), and 29% (10). Live birth rates and associated standard errors in the <b>three dose groups</b> in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> in order of increasing dose were 20% (10), 7% (6), and 8% (11). These data neither confirm nor rule out dose effects on live birth (<a href="./references#CD012693-fig-0052" title="">Analysis 2.21</a>; <a href="#CD012693-fig-0006">Figure 6</a>). </p> </li> </ul> </p> <div class="figure" id="CD012693-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Anticipated normal responders: higher vs lower dose, outcome: 2.21 Dose‐response: live birth or ongoing pregnancy." data-id="CD012693-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anticipated normal responders: higher vs lower dose, outcome: 2.21 Dose‐response: live birth or ongoing pregnancy. </p> </div> </div> </div> <p>Two trials reported cumulative live birth rates, using two definitions (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). </p> <p> <ul id="CD012693-list-0040"> <li> <p><b>Cumulative live birth – following one IVF cycle (fresh and frozen transfers)</b> (<a href="./references#CD012693-fig-0049" title="">Analysis 2.18</a>). In the comparison of 200/225 IU versus 150 IU, the OR was 0.88 (95% CI 0.51 to 1.52; 1 study, 277 participants). This suggests that if the chance of cumulative live birth with 150 IU is 26%, then the chance with 225 IU would be between 15% and 35%. Cumulative live birth rates (SEs) across the five dose groups were 37% (11), 42% (11), 35% (11), 30% (10), and 38% (11) (<a href="./references#CD012693-fig-0053" title="">Analysis 2.22</a>). These data neither confirm nor rule out dose effects on cumulative live birth. </p> </li> <li> <p><b>Cumulative live birth – following 18 months of IVF (defined as an ongoing pregnancy leading to a live birth occurring within 18 months of randomisation)</b>. The evidence in relation to cumulative live birth rate after 18 months of IVF, when comparing 225 IU with 150 IU, was consistent with notable effects in either direction or of no difference (OR 1.01, 95% CI 0.63 to 1.62; 277 participants; <a href="./references#CD012693-fig-0050" title="">Analysis 2.19</a>) (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). This suggests that if the chance of cumulative live birth with 150 IU is 47%, then the chance with 225 IU would be between 36% and 59%. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0083"> <p><b>2.2 Severe OHSS</b></p> <p>Seven of the nine trials reported this outcome. However, there were no incidents of severe OHSS in five of the studies (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>). We graded the body of evidence as of very low certainty, and the effect estimates remain very imprecise. </p> <p> <ul id="CD012693-list-0041"> <li> <p><b>200 IU versus 100 IU</b> (Peto OR 0.14, 95% CI 0.00 to 6.96; I<sup>2</sup> = 0%; 2 studies, 522 participants; <a href="./references#CD012693-fig-0033" title="">Analysis 2.2</a>). </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (Peto OR 1.00, 95% CI 0.20 to 5.02; I<sup>2</sup> = 15%; 4 studies, 740 participants; <a href="./references#CD012693-fig-0033" title="">Analysis 2.2</a>). </p> </li> <li> <p><b>300 IU versus 225 IU</b> (Peto OR 0.14, 95% CI 0.00 to 6.92; 1 study, 135 participants; <a href="./references#CD012693-fig-0033" title="">Analysis 2.2</a>). </p> </li> <li> <p>In the <b>multiple‐dosing trials</b>, there were no cases of severe OHSS (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012693-sec-0084"> <h6 class="title">Secondary outcomes</h6> <section id="CD012693-sec-0085"> <p><b>2.3 Clinical pregnancy</b></p> <p>Eight studies in predicted normal responders reported this outcome (<a href="./references#CD012693-fig-0034" title="">Analysis 2.3</a>). In each case, the point estimates suggest no benefit from increased doses on the probability of pregnancy; however, the estimates are imprecise and consistent with small effects in either direction. We graded the body of evidence as low certainty. </p> <p> <ul id="CD012693-list-0042"> <li> <p><b>200 IU versus 100 IU</b> (OR 0.86, 95% CI 0.50 to 1.49; 1 study, 330 participants). This suggests that if the chance of clinical pregnancy with 100 IU is 20%, then the chance with 200 IU would be 11% to 27%. </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (OR 1.00, 95% CI 0.79 to 1.27; I<sup>2</sup> = 0%; 6 studies, 1446 participants). This suggests that if the chance of clinical pregnancy with 150 IU is 29%, then the chance with 200/225 IU would be 25% to 35%. </p> </li> <li> <p><b>300 IU versus 225 IU</b> (OR 0.91, 95% CI 0.46 to 1.80; 1 study, 135 participants). This suggests that if the chance of clinical pregnancy with 225 IU is 44%, then the chance with 300 IU would be 27% to 59%. </p> </li> <li> <p>In the first <b>multiple‐dosing study</b>, clinical pregnancy rates were essentially identical to birth rates, since only one pregnancy did not progress to live birth; rates (SEs) across the five dose groups were 31% (11), 32% (11), 35% (11), 25% (10), and 33% (10) (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>, <a href="./references#CD012693-fig-0054" title="">Analysis 2.23</a>). In the second multiple‐dosing, clinical pregnancy rates in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> were again similar to birth rates, since only two pregnancies did not progress to live births; rates (SEs) across the three dose groups were 27% (11), 7% (6), and 20% (10). These data neither confirm nor rule out dose effects on clinical pregnancy. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0086"> <p><b>2.4 Time to clinical pregnancy</b></p> <p>None of the studies in predicted normal responders reported this outcome (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a> reported the time to ongoing pregnancy, but not time to clinical pregnancy). </p> </section> <section id="CD012693-sec-0087"> <p><b>2.5 Moderate or severe OHSS</b></p> <p>The estimates for this outcome are based on a few events in eight studies, and therefore the effect estimates remain imprecise amongst women with expected normal response, and we rated the evidence as very low certainty (<a href="./references#CD012693-fig-0036" title="">Analysis 2.5</a>). </p> <p> <ul id="CD012693-list-0043"> <li> <p><b>200 IU versus 100 IU</b> (Peto OR 0.62, 95% CI 0.21 to 1.87; I<sup>2</sup> = 0%; 2 studies, 522 participants). This suggests that if the chance of moderate or severe OHSS with 100 IU is 3.1%, then the chance with 200 IU would be 0.7% to 5.6%. </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (Peto OR 1.21, 95% CI 0.51 to 2.85; I<sup>2</sup> = 49%; 4 studies, 740 participants). This suggests that if the chance of moderate or severe OHSS with 150 IU is 2.7%, then the chance with 225/200 IU would be 1.4% to 7.3%. </p> </li> <li> <p><b>300 IU versus 225 IU</b> (Peto OR 0.67, 95% CI 0.11 to 3.99; 1 study, 135 participants). With only five total events, we refrain from interpreting this result any further. </p> </li> <li> <p>There were no incidents of moderate or severe OHSS observed in one of the study arms of the first <b>multiple‐dosing study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), while for <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, the rates (SEs) across the three dose groups were 7% (6), 7% (6), and 0% (0). </p> </li> </ul> </p> </section> <section id="CD012693-sec-0088"> <p><b>2.6 Multiple pregnancy in randomised women</b></p> <p>Five trials reported the outcome of multiple pregnancy, and as there were only a few events in each comparison, the point estimates were imprecise and consistent with substantial effects in either direction (<a href="./references#CD012693-fig-0037" title="">Analysis 2.6</a>). </p> <p> <ul id="CD012693-list-0044"> <li> <p><b>200 IU versus 100 IU</b> (Peto OR 0.97, 95% CI 0.38 to 2.52; 1 study, 330 participants). This suggests that if the chance of multiple pregnancy with 100 IU is 5.5% then the chance with 200 IU would be between 2.2% and 13%. </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (Peto OR 1.05, 95% CI 0.51 to 2.16; I<sup>2</sup> = 0%; 3 studies, 809 participants). </p> </li> <li> <p><b>300 IU versus 225 IU</b> (Peto OR 7.61, 95% CI 0.47 to 123.02; 1 study, 135 participants). In this study, there were only two multiple pregnancies, both in the 300 IU arm (<a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>). </p> </li> <li> <p>There were no multiple pregnancies in the <b>multiple‐dosing study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>, <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>). </p> </li> </ul> </p> <p>We also analysed the data as multiple pregnancy in women with clinical pregnancy amongst women with expected normal response, with similar results (<a href="./references#CD012693-fig-0051" title="">Analysis 2.20</a>). </p> </section> <section id="CD012693-sec-0089"> <p><b>2.7 Number of oocytes per woman randomised</b></p> <p>These are ratios of mean oocytes, and should not be misinterpreted as numbers of oocytes.</p> <p>All studies in normal responders reported this outcome (<a href="./references#CD012693-fig-0038" title="">Analysis 2.7</a>). The first two comparisons suggest a higher mean number of oocytes from higher doses of FSH. </p> <p> <ul id="CD012693-list-0045"> <li> <p><b>200 IU versus 100 IU</b> (ratio of mean oocytes 1.58, 95% CI 1.43 to 1.77; I<sup>2</sup> = 98%; 2 studies, 330 participants). Readers should interpret this pooled estimate with caution owing to the high observed statistical heterogeneity. </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (ratio of mean oocytes 1.16, 95% CI 1.08 to 1.25; I<sup>2</sup> = 33%; 6 studies, 872 participants). </p> </li> <li> <p><b>300 IU versus 225 IU</b> (ratio of mean oocytes 1.03, 95% CI 0.84 to 1.26; 1 study, 135 participants). In the third comparison, the evidence did not rule out differences in either direction in the number of oocytes retrieved depending on FSH dose. </p> </li> <li> <p><b>300 IU versus 150 IU</b> (ratio of mean oocytes 1.23, 95% CI 0.89 to 1.72; 1 study, 57 participants). </p> </li> <li> <p>In the first <b>multiple‐dosing study</b>, the mean (standard deviation; SD) of the number of oocytes collected across dose groups were 4 (2.5), 6 (5.1), 7 (4), 6.9 (3.8), and 9 (5.1) (<a href="./references#CD012693-fig-0055" title="">Analysis 2.24</a>). These have been recalculated to include cancelled cycles (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), and SDs estimated according to the method described in <a href="#CD012693-sec-0039">Data synthesis</a><i>.</i> We also note that the authors reported a dose‐response effect, although their analysis excluded a small number of cancelled cycles (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>). For <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, the mean (standard deviation; SD) of the number of oocytes collected across the three dose groups were 10 (3.0), 6 (3.5), and 5 (3.7). In <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, participants with cancelled cycles were assigned a value of 1 oocyte. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0090"> <p><b>2.8 Poor response to stimulation</b></p> <p>Three trials reported poor response to stimulation, defining it either as obtaining no more than three oocytes (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>), or cycle cancellation owing to insufficient growth/five oocytes or fewer at retrieval (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). In all the comparisons, there were fewer cases of poor response amongst women administered higher doses of FSH. </p> <p> <ul id="CD012693-list-0046"> <li> <p><b>225 IU versus 150 IU</b> (OR 0.50, 95% CI 0.30 to 0.83; 1 study, 277 participants; <a href="./references#CD012693-fig-0039" title="">Analysis 2.8</a>). This suggests that amongst women with expected normal response, if the chance of a poor response with 150 IU is 40%, then the chance with 225 IU would be between 17% and 36%. </p> </li> <li> <p>In the first <b>multiple‐dosing study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), the proportions (SE) of participants with poor response across the dose groups were 37% (11), 32% (11), 20% (9), 10% (7), and 14% (8) (<a href="./references#CD012693-fig-0056" title="">Analysis 2.25</a>). In the second (<a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>), the proportions (SE) of participants with poor response across the dose groups were 0% (0), 33% (12), and 33% (14). These data neither confirm nor rule out dose effects on poor response. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0091"> <p><b>2.9 Normal response to stimulation</b></p> <p>Four trials reported this outcome amongst women with expected normal response. <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> and <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a> defined a normal response as obtaining four to 14 oocytes. <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a> calculated the outcome as the difference between the number of women randomised and the number with either poor or hyper‐responses. Therefore, the resulting definition is women in whom five to 15 oocytes were retrieved or whose cycle was cancelled for any reason other than a poor or hyper‐response. There was no clear difference in the occurrence of normal response in different dose comparisons. </p> <p> <ul id="CD012693-list-0047"> <li> <p><b>225 IU versus 150 IU</b> (OR 1.26, 95% CI 0.78 to 2.04; 1 study, 277 participants; <a href="./references#CD012693-fig-0040" title="">Analysis 2.9</a>). This suggests that if the chance of a normal response with 150 IU is 56%, then the chance with 225 IU would be between 50% and 73%. </p> </li> <li> <p><b>300 IU versus 150 IU</b> (OR 0.46, 95% CI 0.11 to 1.94; 1 study, 47 participants). </p> </li> <li> <p>In the first <b>multiple‐dosing study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), the proportions (SE) of participants with normal response across the dose groups were 63% (11), 58% (11), 75% (10), 90% (7), and 76% (9), while in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, the proportions (SE) of participants with normal response across the three dose groups were 67% (14), 67% (12), and 93% (6) (<a href="./references#CD012693-fig-0057" title="">Analysis 2.26</a>). </p> </li> </ul> </p> </section> <section id="CD012693-sec-0092"> <p><b>2.10 Hyper‐response to stimulation</b></p> <p>The same four studies reported this outcome, with <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> and <a href="./references#CD012693-bbs2-0022" title="ShyamsunderA , HardyT , YazdaniA , PolyakovA , NormanR , HartR , et al. Higher doses of FSH used for superovulation do not adversely affect embryonic ploidy: a randomized controlled trial (STimulation Resulting in Embryonic Aneuploidy using Menopur (STREAM) trial). Fertility and Reproduction2021;3(3):108-14. ">Shyamsunder 2021</a> defining it as women with 15 or more eggs collected and <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a> as women with either more than 15 eggs collected or cancellation for hyper‐response. In one trial, there were more cases of hyper‐response amongst women in the higher dosing arm. </p> <p> <ul id="CD012693-list-0048"> <li> <p><b>225 IU versus 150 IU</b> (OR 4.08, 95% CI 1.47 to 11.34; 1 study, 277 participants; <a href="./references#CD012693-fig-0041" title="">Analysis 2.10</a>). This suggests that if the chance of a hyper‐response with 150 IU is 3.6%, then the chance with 225 IU would be between 5.2% and 30%. </p> </li> <li> <p><b>300 IU versus 150 IU</b> (OR 2.00, 95% CI 0.42 to 9.63; 1 study, 47 participants). </p> </li> <li> <p>In the first <b>multiple‐dosing study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), the proportions (SE) of participants with hyper‐response across the dose groups were 0% (0), 11% (7), 5% (5), 0% (0), and 10% (6), while in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, the proportions (SE) of participants with hyper‐response across the three dose groups were 6% (6), 0% (0), and 0% (0) (<a href="./references#CD012693-fig-0058" title="">Analysis 2.27</a>). These data neither confirm nor rule out dose effects on hyper‐response amongst women with expected normal response. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0093"> <p><b>2.11 Cycle cancellations for poor response</b></p> <p>This outcome was available for all studies. In the two‐arm studies, administration of a higher dose of FSH led to fewer cycle cancellations for poor response; however, the effect was of variable magnitude and precision. </p> <p> <ul id="CD012693-list-0049"> <li> <p><b>200 IU versus 100 IU</b> (OR 0.33, 95% CI 0.16 to 0.66; I<sup>2</sup> = 60%; 2 studies, 522 participants; <a href="./references#CD012693-fig-0042" title="">Analysis 2.11</a>). This suggests that if the chance of cancellation for poor response with 100 IU is 11%, then the chance with 200 IU would be 4.1% to 9.5%. </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (OR 0.56, 95% CI 0.36 to 0.88; I<sup>2</sup> = 13%; 6 studies, 1037 participants; <a href="./references#CD012693-fig-0042" title="">Analysis 2.11</a>). This suggests that if the chance of cancellation for poor response with 150 IU is 10%, then the chance with 225/220 IU would be 4.0% to 9.4%. </p> </li> <li> <p><b>300 IU versus 225 IU.</b> There was only one cancellation for poor response in both arms (OR 0.11, 95% CI 0.01 to 2.01; 1 study, 135 participants; <a href="./references#CD012693-fig-0042" title="">Analysis 2.11</a>). </p> </li> <li> <p>Cancellation rates for poor response (SEs) across the dose groups in the <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a><b>multiple‐dosing study</b> were 11% (7), 5% (5), 5% (5), 0% (0), and 5% (5), while in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, cancellation rates for poor response (SEs) across the three dose groups were 0% (0), 6% (6), and 25% (13) (<a href="./references#CD012693-fig-0059" title="">Analysis 2.28</a>). These data neither confirm nor rule out dose effects on cycle cancellation for poor response amongst women with expected normal response. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0094"> <p><b>2.12 Cycle cancellations for hyper‐response (including freeze‐all cycles)</b></p> <p>This outcome refers to cycle cancellations only for reasons of poor or hyper‐response (excluding cancellations for other reasons), and all studies reported it. As the occurrence of cancellation for hyper‐response amongst women with expected normal response was low, the pooled effects are associated with a large degree of imprecision (<a href="./references#CD012693-fig-0043" title="">Analysis 2.12</a>). </p> <p> <ul id="CD012693-list-0050"> <li> <p><b>200 IU versus 100 IU</b> (Peto OR 1.93, 95% CI 0.20 to 18.62; I<sup>2</sup> = 62%; 2 studies, 522 participants). </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (Peto OR 2.28, 95% CI 0.99 to 5.26; I<sup>2</sup> = 0%; 5 studies, 1037 participants). This suggests that if the chance of cancellation for hyper‐response with 150 IU is 1.4%, then the chance with 225/200 IU would be 1.3% to 6.7%. </p> </li> <li> <p>In the comparison of <b>300 IU versus 225 IU</b>, there was only one cancellation for hyper‐response in both arms (OR 1.02, 95% CI 0.06 to 16.40; 1 study, 135 participants). </p> </li> <li> <p>In the <b>multiple‐dosing studies</b>, there were no cycles cancelled for hyper‐response (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>). </p> </li> </ul> </p> </section> <section id="CD012693-sec-0095"> <p><b>2.13 Cycle cancellations for poor or hyper‐response</b></p> <p>In combining the cycle cancellations for hyper and poor response (2.11 and 2.12 above), the first comparison (200 IU versus 100 IU) suggests that a higher dose is associated with fewer cancellations overall amongst women with expected normal response, while other estimates were fairly imprecise (<a href="./references#CD012693-fig-0044" title="">Analysis 2.13</a>). </p> <p> <ul id="CD012693-list-0051"> <li> <p><b>200 IU versus 100 IU</b> (OR 0.37, 95% CI 0.19 to 0.72; I<sup>2</sup> = 10%; 2 studies, 522 participants). This suggests that if the chance of cycle cancellation with 100 IU is 13%, then the chance with 200 IU would be between 2.7% to 9.5%. </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (OR 0.76, 95% CI 0.51 to 1.13; I<sup>2</sup> = 0%; 5 studies, 1037 participants). This suggests that if the chance of cycle cancellation with 150 IU is 12%, then the chance with 225/200 IU would be between 6.5% to 13%. </p> </li> <li> <p><b>300 IU versus 225 IU</b> (OR 0.19, 95% CI 0.02 to 1.68; 1 study, 135 participants). This suggests that if the chance of cycle cancellation with 225 IU is 7.4%, then the chance with 300 IU would be between 0.2% to 15%. </p> </li> <li> <p>In the first <b>multiple‐dosing study</b>, there were only cancellations for poor response (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>). Thus, the rates (SE) for total cancellation are the same as presented above across the dose groups: 11% (7), 5% (5), 5% (5), 0% (0), and 5% (5). In <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, the rates (SE) for total cancellation are the same as for the poor response ones across the three dose groups: 25% (13), 7% (6), and 0% (0) (<a href="./references#CD012693-fig-0059" title="">Analysis 2.28</a>). These data neither confirm nor rule out dose effects on cycle cancellation for poor response. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0096"> <p><b>2.14 Women with at least one transferable embryo</b></p> <p>This outcome refers to the number of women who had at least one embryo available for transfer, either for a fresh embryo transfer or for a freeze‐all strategy. Some studies reported or calculated this outcome amongst women with expected normal response (<a href="./references#CD012693-fig-0045" title="">Analysis 2.14</a>). </p> <p> <ul id="CD012693-list-0052"> <li> <p><b>200 IU versus 100 IU</b> (OR 1.58, 95% CI 0.95 to 2.64; I<sup>2</sup> = 78%; 2 studies, 522 participants). This suggests that if the chance of having at least one transferable embryo with 100 IU is 84%, then the chance with 200 IU would be 83% to 93%. </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (OR 1.06, 95% CI 0.78 to 1.44; I<sup>2</sup> = 55%; 6 studies, 1037 participants). This suggests that if the chance of having at least one transferable embryo with 150 IU is 87%, then the chance with 225/200 IU would be 84% to 91%. </p> </li> <li> <p><b>300 IU versus 225 IU</b> (OR 1.75, 95% CI 0.60 to 5.13; 1 study, 135 participants). This similarly unclear evidence suggests that if the chance of having at least one transferable embryo with 225 IU is 85%, then the chance with 300 IU would be 78% to 97%. </p> </li> <li> <p>In the <b>dose‐response study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), the percentages (SEs) with at least one embryo available were 89% (7), 84% (8), 90% (7), 85% (8), and 90% (6) (<a href="./references#CD012693-fig-0060" title="">Analysis 2.29</a>). These data neither confirm nor rule out dose effects on women having at least one transferable embryo. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0097"> <p><b>2.15 Total dose of FSH</b></p> <p>In all comparisons, participants randomised to a higher daily dose of FSH received a higher total dose during their IVF/ICSI cycle (<a href="./references#CD012693-fig-0046" title="">Analysis 2.15</a>). </p> <p> <ul id="CD012693-list-0053"> <li> <p><b>200 IU versus 100 IU</b> (MD IU 795.79, 95% CI 656.67 to 934.91; I<sup>2</sup> = 8%; 2 studies, 522 participants). </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (MD IU 503.12, 95% CI 456.23 to 550.00; I<sup>2</sup> = 71%; 5 studies, 1037 participants). Readers should treat this pooled estimate with caution owing to the high statistical heterogeneity. </p> </li> <li> <p><b>300 IU versus 225 IU</b> (MD IU 725, 95% CI 597 to 853; 1 study, 135 participants). </p> </li> <li> <p>In the <b>multiple‐dosing study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), mean (SD) total doses were 47.9 µg (12.0), 59.2 µg (12.7), 72.7 µg (11.7), 80.9 µg (15.0), and 95.1 µg (28.7) (<a href="./references#CD012693-fig-0061" title="">Analysis 2.30</a>). It is not possible to convert these to IU to permit pooling with the other trials. </p> </li> </ul> </p> <p>However, we recommend caution when interpreting these results, as cancellations for poor response were essentially censored amongst women with expected normal response, making it impossible to impute doses; these cancellations were considerably more common in the lower dosing arms. </p> </section> <section id="CD012693-sec-0098"> <p><b>2.16 Duration of FSH administration</b></p> <p>Eight trials reported this outcome (<a href="./references#CD012693-fig-0047" title="">Analysis 2.16</a>). In most cases, a higher dose of FSH was associated with a shorter duration of FSH. However, we recommend caution when interpreting these results, as cancellations were censored, making it impossible to impute days of stimulation. These cancellations were considerably more common in the lower dosing arms amongst women with expected normal response. </p> <p> <ul id="CD012693-list-0054"> <li> <p><b>200 IU versus 100 IU</b> (MD days −1.80, 95% CI −2.21 to −1.39; 1 study, 330 participants). </p> </li> <li> <p><b>225/200 IU versus 150 IU</b> (MD days −0.25, 95% CI −0.51 to 0.01; I<sup>2</sup> = 76%; 4 studies, 961 participants). This pooled estimate should be treated with caution owing to the high statistical heterogeneity. </p> </li> <li> <p><b>300 IU versus 225 IU</b> (MD days −0.30, 95% CI −0.79 to 0.19; 1 study, 135 participants). </p> </li> <li> <p>In the first <b>multiple‐dosing study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), the mean (SD) days stimulated were 9.2 (2.3), 8.6 (1.8), 8.5 (1.4), 7.9 (1.5), and 7.9 (2.4). In the second <b>multiple dosing study</b> (<a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>), mean (SD) days stimulated were 10.9 (2.4), 9.6 (2.2), and 9.1 (1.9) (<a href="./references#CD012693-fig-0062" title="">Analysis 2.31</a>). We tentatively note that the mean duration decreases across the groups. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0099"> <p><b>2.17 Cost per woman randomised</b></p> <p>None of the studies in predicted normal responders reported this outcome. However, the outcome was available pooled across two sub‐studies in this review (one low responder and one normal responder) which were published as one trial (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). The total cost was higher amongst women administered 450/225 IU compared to those given 150 IU (EUR 6397 versus EUR 5298; MD EUR 1099, 95% CI 562 to 1591). </p> </section> </section> </section> <section id="CD012693-sec-0100"> <h5 class="title">3. Predicted high responders</h5> <p>There are three studies included in this comparison (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> and <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> were dose‐response studies of a novel gonadotropin (follitropin delta) that included predicted high responder participants. <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> reported outcomes in groups given five doses (5.2 µg, 6.9 µg, 8.6 µg, 10.3 µg, and 12.1 µg), and <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> reported outcomes in groups given three doses (12 µg, 9 µg, and 6 µg). Translation to IU was not possible (<a href="./full#CD012693-tbl-0004">summary of findings Table 4</a>). The third trial compared doses of 150 IU versus 100 IU in women with AFC over 15 (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). Data from the three studies are presented in two separate forest plots, as follows: </p> <p> <ul id="CD012693-list-0055"> <li> <p><b>150 IU versus 100 IU</b> (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>); </p> </li> <li> <p><b>Dose‐response effects (no pooling)</b>: 5.2 µg, 6.9 µg, 8.6 µg, 10.3 µg, and 12.1 µg (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>); 12 µg, 9 µg, and 6 µg (<a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>). These doses cannot be translated into the doses described in the other studies, so we present information on the dose response between increasing dose groups in separate forest plots and describe them in the text. </p> </li> </ul> </p> <section id="CD012693-sec-0101"> <h6 class="title">Primary outcomes</h6> <section id="CD012693-sec-0102"> <p><b>3.1 Live birth or ongoing pregnancy</b></p> <p>Three trials reported live birth amongst women with expected high response, and in all cases there was insufficient evidence to determine whether there was any difference in live birth rate between the doses investigated; we cannot rule out moderate effects in either direction. We graded the body of evidence as low certainty. </p> <p> <ul id="CD012693-list-0056"> <li> <p><b>150 IU versus 100 IU</b> (OR 0.98, 95% CI 0.66 to 1.46; 1 study, 521 participants; <a href="./references#CD012693-fig-0063" title="">Analysis 3.1</a>; <a href="#CD012693-fig-0007">Figure 7</a>). This suggests that if the chance of live birth with 100 IU is 26%, then the chance with 150 IU would be 18% to 33%. </p> </li> <li> <p>Birth rates (SEs) across the <b>five dose groups</b> were 39% (10), 42% (10), 38% (10), 25% (9), and 46% (10) (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), while in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, birth rates (SEs) across the <b>three dose groups</b> were 24% (9), 24%(9), and 16% (7) (<a href="./references#CD012693-fig-0083" title="">Analysis 3.21</a>; <a href="#CD012693-fig-0008">Figure 8</a>). These data neither confirm nor rule out dose effects on live birth. </p> </li> </ul> </p> <div class="figure" id="CD012693-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Anticipated high‐responders: higher vs lower dose, outcome: 3.1 Live birth or ongoing pregnancy." data-id="CD012693-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Anticipated high‐responders: higher vs lower dose, outcome: 3.1 Live birth or ongoing pregnancy. </p> </div> </div> </div> <div class="figure" id="CD012693-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Anticipated high‐responders: higher vs lower dose, outcome: 3.21 Dose‐response: live birth or ongoing pregnancy." data-id="CD012693-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Anticipated high‐responders: higher vs lower dose, outcome: 3.21 Dose‐response: live birth or ongoing pregnancy. </p> </div> </div> </div> <p>Additionally, two trials reported the cumulative live birth rate, one using two definitions (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). </p> <p> <ul id="CD012693-list-0057"> <li> <p><b>Cumulative live birth rate – following one IVF cycle (fresh and frozen transfers)</b><i>.</i> </p> <ul id="CD012693-list-0058"> <li> <p><b>150 IU versus 100 IU</b> (OR 1.16, 95% CI 0.81 to 1.65; 1 study, 521 participants; <a href="./references#CD012693-fig-0080" title="">Analysis 3.18</a>). This suggests that if the chance of cumulative live birth with 100 IU is 36%, then the chance with 150 IU would be between 31% and 48%. </p> </li> <li> <p>Cumulative birth rates (SEs) across the <b>five dose groups</b> in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> were 43% (10), 54% (10), 46% (10), 38% (10), and 50% (10) (<a href="./references#CD012693-fig-0085" title="">Analysis 3.23</a>). These data neither confirm nor rule out dose effects on live birth. </p> </li> </ul> </li> <li> <p><b>Cumulative live birth – following 18 months of IVF (defined as an ongoing pregnancy leading to a live birth occurring within 18 months of randomisation)</b> (<a href="./references#CD012693-fig-0081" title="">Analysis 3.19</a>)<i>.</i> </p> <ul id="CD012693-list-0059"> <li> <p><b>150 IU versus 100 IU</b> (OR 1.16, 95% CI 0.80 to 1.68; 1 study, 521 participants). This suggests that if the chance of cumulative live birth with 100 IU is 66%, then the chance with 150 IU would be between 61% and 77%. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD012693-sec-0103"> <p><b>3.2 Severe OHSS</b></p> <p>Two trials reported severe OHSS amongst women with expected high response, and in both cases, there were too few events to make any assessment regarding the effect of the different doses on the probability of this outcome. We graded the body of evidence as very low certainty. </p> <p> <ul id="CD012693-list-0060"> <li> <p><b>150 IU versus 100 IU</b> (Peto OR 0.72, 95% CI 0.16 to 3.19; 1 study, 521 participants; <a href="./references#CD012693-fig-0064" title="">Analysis 3.2</a>). </p> </li> <li> <p>Severe OHSS rates (SEs) were 0% (0), 0% (0), 4% (4), 0% (0), and 8% (5) (<a href="./references#CD012693-fig-0086" title="">Analysis 3.24</a>). The event rates were too low to make a reasonable inference regarding a treatment effect. </p> </li> </ul> </p> </section> </section> <section id="CD012693-sec-0104"> <h6 class="title">Secondary outcomes</h6> <section id="CD012693-sec-0105"> <p><b>3.3 Clinical pregnancy</b></p> <p>Three trials reported clinical pregnancy rate amongst women with expected high response, and in all cases, there was no obvious benefit of higher or lower dose on the probability of pregnancy; however, the evidence is consistent with moderate effects in either direction. We graded the body of evidence as low certainty. </p> <p> <ul id="CD012693-list-0061"> <li> <p><b>150 IU versus 100 IU</b> (OR 1.14, 95% CI 0.78 to 1.66; 1 study, 521 participants; <a href="./references#CD012693-fig-0065" title="">Analysis 3.3</a>). This suggests that if the chance of clinical pregnancy with 100 IU is 28%, then the chance with 150 IU would be 23% to 39%. </p> </li> <li> <p>Clinical pregnancy rates (SEs) across the <b>five dose groups</b> were 39% (10), 46% (10), 38% (10), 25% (9), and 46% (10) (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), while clinical pregnancy rates (SEs) across the <b>three dose groups</b> were 36% (10), 28% (9), and 24% (9) (<a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>) (<a href="./references#CD012693-fig-0084" title="">Analysis 3.22</a>). These data neither confirm nor rule out dose effects on clinical pregnancy. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0106"> <p><b>3.4 Time to clinical pregnancy</b></p> <p>None of the studies in predicted high responders reported this outcome (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a> reported the time to ongoing pregnancy, but not time to clinical pregnancy). </p> </section> <section id="CD012693-sec-0107"> <p><b>3.5 Moderate or severe OHSS</b></p> <p>Three trials reported moderate/severe OHSS amongst women with expected high response, and in all cases, there was a trend towards increased risk of moderate/severe OHSS with increasing dose; however, even a small reduction in risk is possible. </p> <p> <ul id="CD012693-list-0062"> <li> <p><b>150 IU versus 100 IU</b> (Peto OR 2.31, 95% CI 0.80 to 6.67; 1 study, 521 participants; <a href="./references#CD012693-fig-0067" title="">Analysis 3.5</a>). This suggests that if the chance of moderate or severe OHSS with 100 IU is 1.6%, then the chance with 150 IU would be 1.3% to 9.6%. </p> </li> <li> <p>Rates (SE) of moderate or severe OHSS across the <b>five dose groups</b> were 0% (0), 0% (0), 4% (4), 4% (4), and 12% (6) (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), while rates (SE) of moderate or severe OHSS across the <b>three dose groups</b> were 16% (7), 8% (5), and 16% (7) (<a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>) (<a href="./references#CD012693-fig-0087" title="">Analysis 3.25</a>). Event rates were too low to make any reasonable inference here. We rated the body of evidence for this outcome as very low certainty. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0108"> <p><b>3.6 Multiple pregnancy in randomised women</b></p> <p>Three trials reported this outcome amongst women with expected high response. However, the number of multiple pregnancies was very small, so we do not interpret the results further. </p> <p> <ul id="CD012693-list-0063"> <li> <p><b>150 IU versus 100 IU</b> (Peto OR 1.87, 95% CI 0.19 to 18.09; 1 study, 521 participants; <a href="./references#CD012693-fig-0068" title="">Analysis 3.6</a>). The multiple pregnancy rates were also calculated per clinical pregnancy, with similar results (<a href="./references#CD012693-fig-0082" title="">Analysis 3.20</a>). </p> </li> <li> <p>There were no multiple pregnancies in the <b>multiple‐dosing arm</b> studies (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>). </p> </li> </ul> </p> </section> <section id="CD012693-sec-0109"> <p><b>3.7 Number of oocytes per woman randomised</b></p> <p>Three trials reported this outcome and indicated higher oocyte yield with higher doses of FSH, amongst women with expected high response. These are ratios of mean oocytes and should not be misinterpreted as numbers of oocytes. </p> <p> <ul id="CD012693-list-0064"> <li> <p><b>150 IU versus 100 IU</b> (ratio of mean oocytes 1.95, 95% CI 1.73 to 2.20; 1 study, 521 participants; <a href="./references#CD012693-fig-0069" title="">Analysis 3.7</a>). </p> </li> <li> <p>In the <b>multiple‐dosing studies</b>, the mean (standard deviation; SD) of the number of oocytes collected across dose groups were 5.9 (3.9), 9.1 (6.4), 10.2 (5), 13.6 (7.8), and 14.4 (5.8) in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>, and 8 (4.1), 11 (5.6), and 13 (6.4) in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> (<a href="./references#CD012693-fig-0088" title="">Analysis 3.26</a>). In <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>, these have been recalculated to include cancelled cycles, and SDs estimated according to the method described in <a href="#CD012693-sec-0039">Data synthesis</a><i>.</i> In <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, participants with cancelled cycles were assigned a value of 1 oocyte. We tentatively note that the means increase with increasing dose in both studies. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0110"> <p><b>3.8 Poor response to stimulation</b></p> <p>One study defined a poor response as cycle cancellation for poor response or the retrieval of fewer than five oocytes (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). Two other studies defined poor response as the retrieval of fewer than four oocytes (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>). </p> <p> <ul id="CD012693-list-0065"> <li> <p><b>150 IU versus 100 IU</b> (OR 0.15, 95% CI 0.09 to 0.25; 1 study, 521 participants; <a href="./references#CD012693-fig-0070" title="">Analysis 3.8</a>). This suggests that if the chance of a poor response with 100 IU is 36%, then the chance with 150 IU would be 4.8% to 12%. </p> </li> <li> <p>Rates (SE) of poor response across the <b>five dose groups</b> were 35% (10), 15% (7), 8% (6), 8% (6), and 0% (0) (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), while rates (SE) of poor response across the <b>three dose groups</b> were 4% (1), 4% (1), and 13% (7) (<a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>) (<a href="./references#CD012693-fig-0089" title="">Analysis 3.27</a>). These data neither confirm nor rule out dose effects on poor response amongst women with expected high response, although we note that the rate decreases across the dose groups. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0111"> <p><b>3.9 Normal response to stimulation</b></p> <p>Three trials reported this outcome amongst women with expected high response. One study reported poor and hyper‐response and calculated normal events as the difference between them, the resulting definition being the number of women with five to 15 oocytes collected or with cycle cancellation for any reason other than poor or hyper‐response (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> and <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> defined a normal response as the retrieval of four to 14 oocytes. The results suggest a similar number of women achieving a normal response amongst those administered different doses. </p> <p> <ul id="CD012693-list-0066"> <li> <p><b>150 IU versus 100 IU</b> (OR 1.07, 95% CI 0.76 to 1.50; 1 study, 521 participants; <a href="./references#CD012693-fig-0071" title="">Analysis 3.9</a>). This suggests that if the chance of a normal response with 100 IU is 53%, then the chance with 150 IU would be 46% to 62%. </p> </li> <li> <p>The proportion of participants (SE) with normal response across the <b>five dose groups</b> in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> were 57% (10), 58% (10), 79% (8), 54% (10), and 50% (10), while the proportions of participants (SE) with normal response across the three dose groups in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> were 56% (10), 72% (9), and 79% (8) (<a href="./references#CD012693-fig-0090" title="">Analysis 3.28</a>). These data neither confirm nor rule out dose effects on normal response. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0112"> <p><b>3.10 Hyper‐response to stimulation</b></p> <p>The <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a> study defined a hyper‐response as cycle cancellation for excessive response or the retrieval of more than 15 oocytes. <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> and <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> defined it as the collection of more than 14 oocytes. There were significantly more women with a hyper‐response amongst those administered 150 IU compared to those given 100 IU, amongst women with expected high response. </p> <p> <ul id="CD012693-list-0067"> <li> <p><b>150 IU versus 100 IU</b> (OR 5.04, 95% CI 3.17 to 8.02; 1 study, 521 participants; <a href="./references#CD012693-fig-0072" title="">Analysis 3.10</a>). This suggests that if the chance of a hyper‐response with 100 IU is 11%, then the chance with 150 IU would be 28% to 50%. </p> </li> <li> <p>The proportion of participants (SE) with hyper‐response across the <b>five dose groups</b> in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> were 9% (6), 19% (8), 21% (8), 38% (10), and 50% (10), while the proportion of participants (SE) with hyper‐response across the <b>three dose groups</b> in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> were 8% (6), 24% (9), and 40% (10) (<a href="./references#CD012693-fig-0091" title="">Analysis 3.29</a>). These data neither confirm nor rule out dose effects on hyper‐response, although we note that the rate increases across the dose groups. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0113"> <p><b>3.11 Cycle cancellations for poor response</b></p> <p>In one trial, the pooled results suggest that cycle cancellation for poor response occurs more in women administered 100 IU than those given 150 IU, amongst women with expected high response. </p> <p> <ul id="CD012693-list-0068"> <li> <p><b>150 IU versus 100 IU</b> (OR 0.13, 95% CI 0.06 to 0.28; 1 study, 521 participants; <a href="./references#CD012693-fig-0073" title="">Analysis 3.11</a>). This suggests that if the chance of a cycle cancellation for poor response with 100 IU is 21%, then the chance with 150 IU would be 1.5% to 6.8%. </p> </li> <li> <p>Cancellation rates for poor response (SEs) across the <b>five dose groups in</b><a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> were 0% (0), 0% (0), 4% (5), 0% (0), and 0% (0), while cancellation rates for poor response (SEs) across the <b>three dose groups</b> in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> were 0% (0), 4% (1), and 8% (2) (<a href="./references#CD012693-fig-0092" title="">Analysis 3.30</a>). The event rates were too low to allow any meaningful inference. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0114"> <p><b>3.12 Cycle cancellations for hyper‐response (including freeze‐all cycles)</b></p> <p>The pooled results suggest that cancellation for hyper‐response occurs more in women administered 150 IU compared to 100 IU, amongst women with expected high response. </p> <p> <ul id="CD012693-list-0069"> <li> <p><b>150 IU versus 100 IU</b> (OR 5.28, 95% CI 2.16 to 12.90; 1 study, 521 participants; <a href="./references#CD012693-fig-0074" title="">Analysis 3.12</a>). This suggests that if the chance of a cycle cancellation for hyper‐response with 100 IU is 2.4%, then the chance with 150 IU would be 4.9% to 24%. </p> </li> <li> <p>Cancellation rates (SEs) for hyper‐response across the <b>five dose groups</b> in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> were 0% (0), 4% (4), 0% (0), 4% (4), and 0% (0), while cancellation rates for poor response (SEs) across the <b>three dose groups</b> in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> were 0% (0), 0% (0), and 0% (0) (<a href="./references#CD012693-fig-0093" title="">Analysis 3.31</a>). </p> </li> </ul> </p> </section> <section id="CD012693-sec-0115"> <p><b>3.13 Cycle cancellations for poor or hyper‐response</b></p> <p>The rate of cycle cancellation for either a poor or hyper‐response (combining 3.11 and 3.12 above) was higher amongst women given 100 IU than in women given 150 IU, as this outcome was denominated by higher overall rates of cancellation for poor response than for hyper‐response. </p> <p> <ul id="CD012693-list-0070"> <li> <p><b>150 IU versus 100 IU</b> (OR 0.57, 95% CI 0.36 to 0.89; 1 study, 521 participants; <a href="./references#CD012693-fig-0075" title="">Analysis 3.13</a>). This suggests that if the chance of a cycle cancellation for poor or hyper‐response with 100 IU is 23%, then the chance with 150 IU would be 9.8% to 21%. </p> </li> <li> <p>Cancellation rates (SEs) across the <b>five dose groups</b> in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> were 0% (0), 4% (4), 4% (4), 4% (4), and 0% (0), while cancellation rates for poor or hyper‐response (SEs) across the <b>three dose groups</b> in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a> were 0% (0), 4% (1), and 8% (2) (<a href="./references#CD012693-fig-0094" title="">Analysis 3.32</a>). Event rates were too low to permit inference. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0116"> <p><b>3.14 Women with at least one transferable embryo</b></p> <p>Two studies reported this outcome (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). This outcome refers to the number of women who had at least one embryo available for transfer, either for a fresh embryo transfer or for a freeze‐all strategy, amongst women with expected high response. </p> <p> <ul id="CD012693-list-0071"> <li> <p><b>150 IU versus 100 IU</b> (OR 2.33, 95% CI 1.53 to 3.55; 1 study, 521 participants; <a href="./references#CD012693-fig-0076" title="">Analysis 3.14</a>). This suggests that if the chance of having at least one embryo for transfer with 100 IU is 69%, then the chance with 150 IU would be significantly higher: 77% to 89%. </p> </li> <li> <p>The rate (SEs) of women with at least one transferable embryo across the <b>five dose groups</b> in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> were 91% (6), 88% (6), 92% (6), 79% (8), and 96% (4) (<a href="./references#CD012693-fig-0095" title="">Analysis 3.33</a>). No dose‐response is evident, and the second‐highest dose group appears to have fewer women with transferable embryos. </p> </li> </ul> </p> </section> <section id="CD012693-sec-0117"> <p><b>3.15 Total dose of FSH</b></p> <p> <ul id="CD012693-list-0072"> <li> <p><b>150 IU versus 100 IU</b>. The total dose of FSH administered was higher amongst women administered a higher daily dose of FSH (MD IU 345.00, 95% CI 280.34 to 409.66; 1 study, 521 participants; <a href="./references#CD012693-fig-0077" title="">Analysis 3.15</a>). </p> </li> <li> <p>In the <b>multiple‐dosing study</b> (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>), mean total doses (SDs) were 51.8 (11.2), 64.0 (14.3), 71.3 (16.1), 81.1 (13.7), and 100.0 (14.7) (<a href="./references#CD012693-fig-0096" title="">Analysis 3.34</a>). It is not possible to carry out any robust analysis using these summary measures, although we tentatively note that the mean total dose decreases across the groups. </p> </li> </ul> </p> <p>We would urge caution in relation to this outcome, however, as it is not possible to account for the effect of censoring due to cancelled cycles. </p> </section> <section id="CD012693-sec-0118"> <p><b>3.16 Duration of FSH administration</b></p> <p> <ul id="CD012693-list-0073"> <li> <p><b>150 IU versus 100 IU</b>. The pooled results demonstrate that the duration of FSH administration was shorter in women administered the higher dose (MD days −1.40, 95% CI −1.91 to −0.89; 1 study, 521 participants; <a href="./references#CD012693-fig-0078" title="">Analysis 3.16</a>). </p> </li> <li> <p>In the <b>five dose groups</b> in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>, mean days stimulated (SDs) were 10 (2.2), 9.3 (2.1), 8.3 (1.9), 7.9 (1.3), and 8.3 (1.2). In the <b>three dose groups</b> in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>, mean days stimulated (SDs) were 9.3 (2.0), 8.4 (1.3), and 8.4 (1.0) (<a href="./references#CD012693-fig-0097" title="">Analysis 3.35</a>). We tentatively note that the mean duration decreases across the first four groups in <a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a> and across the first two groups in <a href="./references#CD012693-bbs2-0007" title="IshiharaO , KleinBM , Arce J-C, for the Japanese Follitropin Delta Phase 2 Trial Group*. Randomized, assessor-blind, antimullerian hormone–stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertility and Sterility2021;115(6):1478-86. [DOI: 10.1016/j.fertnstert.2020.10.059]">Ishihara 2021a</a>. </p> </li> </ul> </p> <p>We would urge caution in relation to this outcome, however, as it is not possible to account for the effect of censoring due to cancelled cycles. </p> </section> <section id="CD012693-sec-0119"> <p><b>3.17 Cost per woman randomised</b></p> <p>None of the studies in predicted high responders reported this outcome as prespecified for this review. However, <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a> reported that the total cost was similar in women administered 150 IU compared to those given 100 IU (EUR 4714 versus EUR 4622; MD EUR −92, 95% CI −479 to 325). </p> </section> </section> </section> </section> <section id="CD012693-sec-0120"> <h4 class="title">ORT‐algorithm studies</h4> <section id="CD012693-sec-0121"> <h5 class="title">4. ORT‐based algorithm compared to standard starting dose or non‐ORT algorithm</h5> <p>Eight studies were included in this comparison: seven comparing an ORT‐based algorithm to a standard starting dose of 150 IU (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>), and one comparing an ORT‐based algorithm to an algorithm that did not use any ORT (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./full#CD012693-tbl-0001">summary of findings Table 1</a>). We created one of these trials by merging results from two other trials (three dose comparisons) reported in comparisons one and three (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), and we reference it here as <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>. </p> <p>As the trials in this comparison display considerable protocol heterogeneity, with different algorithms tested in each, we would advise the reader to interpret pooled estimates loosely as summaries of the existing studies, rather than as unified estimates of underlying treatment effects. </p> <section id="CD012693-sec-0122"> <h6 class="title">Primary outcomes</h6> <section id="CD012693-sec-0123"> <p><b>4.1 Live birth or ongoing pregnancy</b></p> <p>Data on live births were available for six studies (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>), and one study reported ongoing pregnancy (<a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>). There was a suggestion, but not clear evidence, of an overall difference in live birth rate (OR 1.12, 95% CI 0.98 to 1.29; I<sup>2</sup> = 30%; 7 studies, 4400 participants; <a href="./references#CD012693-fig-0098" title="">Analysis 4.1</a>; <a href="#CD012693-fig-0009">Figure 9</a>). This suggests that if the chance of live birth with a standard starting dose is 25%, the chance with dosing based on an ORT‐algorithm would be between 25% and 31%. We graded the body of evidence as low certainty. This result should be interpreted in light of heterogeneity between the studies (different algorithms were used). </p> <div class="figure" id="CD012693-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 ORT‐based algorithm vs standard dose or non‐ORT based algorithm, outcome: 4.1 Live birth or ongoing pregnancy per woman randomised." data-id="CD012693-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 ORT‐based algorithm vs standard dose or non‐ORT based algorithm, outcome: 4.1 Live birth or ongoing pregnancy per woman randomised. </p> </div> </div> </div> </section> <section id="CD012693-sec-0124"> <p><b>4.2 Severe OHSS</b></p> <p>The occurrence of severe OHSS was reported or confirmed following author correspondence for six studies (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>). A seventh study only provided OHSS for the combined outcome of moderate/severe OHSS, and it was not possible to obtain the number of severe events (<a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>). We are unable to comment on the effects on severe OHSS, since there was a total of 52 events across four studies (two studies had zero outcomes), and we graded the body of evidence as low certainty; therefore, we refrain from interpreting these results further (<a href="./references#CD012693-fig-0099" title="">Analysis 4.2</a>). </p> <p> <ul id="CD012693-list-0074"> <li> <p><b>ORT‐based algorithm versus 150 IU</b> (Peto OR 0.74, 95% CI 0.42 to 1.28; I<sup>2</sup> = 0%; 5 studies, 2724 participants). </p> </li> <li> <p><b>ORT‐based algorithm versus non‐ORT‐based algorithm</b>: no events (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). </p> </li> </ul> </p> </section> </section> <section id="CD012693-sec-0125"> <h6 class="title">Secondary outcomes</h6> <section id="CD012693-sec-0126"> <p><b>4.3 Clinical pregnancy</b></p> <p>There did not appear to be any substantial difference in the rate of clinical pregnancy when comparing an ORT‐based algorithm to a standard starting dose of 150 IU (OR 1.04, 95% CI 0.91 to 1.18; I<sup>2</sup> = 18%; 7 studies, 4400 participants), but there was greater uncertainty when comparing to a non‐ORT‐based algorithm (OR 0.88, 95% CI 0.48 to 1.61; 194 participants; <a href="./references#CD012693-fig-0100" title="">Analysis 4.3</a>). This suggests that if the chance of clinical pregnancy with a standard starting dose of 150 IU is 32%, the chance with dosing based on an ORT‐algorithm would be between 30% and 36%, and if the chance with a non‐ORT based algorithm is 31%, then the chance with an ORT‐based algorithm would be between 29% and 35%. We graded the body of evidence as low certainty. </p> </section> <section id="CD012693-sec-0127"> <p><b>4.4 Time to clinical pregnancy</b></p> <p>None of the studies reported this outcome (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a> reported the time to ongoing pregnancy, but not time to clinical pregnancy). </p> </section> <section id="CD012693-sec-0128"> <p><b>4.5 Moderate or severe OHSS</b></p> <p>The pooled evidence suggested that the use of an ORT‐based algorithm reduced the incidence of moderate or severe OHSS when compared to a standard starting dose of 150 IU (Peto OR 0.60, 95% CI 0.42 to 0.84; I<sup>2</sup> = 0%; 7 studies, 4400 participants; <a href="./references#CD012693-fig-0102" title="">Analysis 4.5</a>). There were no events observed when comparing an ORT‐based algorithm to a non‐ORT algorithm (not estimable, 0 events in each arm, 1 study; <a href="./references#CD012693-fig-0102" title="">Analysis 4.5</a>; <a href="#CD012693-fig-0010">Figure 10</a>). This suggests that if the chance of moderate or severe OHSS with a standard starting dose is assumed to be 5%, the chance with dosing based on an ORT‐algorithm would be between 2% and 5%. We graded the body of evidence as low certainty. </p> <div class="figure" id="CD012693-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 ORT‐based algorithm vs standard dose or non‐ORT based algorithm, outcome: 4.5 Moderate or severe OHSS." data-id="CD012693-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-10.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 ORT‐based algorithm vs standard dose or non‐ORT based algorithm, outcome: 4.5 Moderate or severe OHSS. </p> </div> </div> </div> </section> <section id="CD012693-sec-0129"> <p><b>4.6 Multiple pregnancy in randomised women</b></p> <p>There was insufficient evidence to determine whether there was a difference in the rate of multiple pregnancies when comparing a standard starting dose of 150 IU to an ORT‐based algorithm, although the confidence interval was consistent with small effects in either direction (Peto OR 0.77, 95% CI 0.43 to 1.36; I<sup>2</sup> = 0%; 4 studies, 2823 participants; <a href="./references#CD012693-fig-0103" title="">Analysis 4.6</a>). This suggests that if the chance of multiple pregnancy with a standard starting dose is 2.0%, the chance with dosing based on an ORT‐algorithm would be between 0.9% and 2.7%. We also calculated the data as multiple pregnancy in women with clinical pregnancy, with similar results (<a href="./references#CD012693-fig-0117" title="">Analysis 4.20</a>). The trial comparing an ORT‐based algorithm to a non‐ORT‐based algorithm did not report this outcome (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). </p> </section> <section id="CD012693-sec-0130"> <p><b>4.7 Number of oocytes retrieved per woman randomised</b></p> <p>These are ratios of mean oocytes and should not be misinterpreted as numbers of oocytes.</p> <p>Seven trials reported this outcome (<a href="./references#CD012693-fig-0104" title="">Analysis 4.7</a>). There is no evidence of a higher number of oocytes retrieved in women using an ORT‐based algorithm compared to a standard starting dose of 150 IU (ratio of mean oocytes 1.01, 95% CI 0.98 to 1.04; I<sup>2</sup> = 98%; 6 studies, 3126 participants). However, the heterogeneity is very high, with different studies reporting effects in different directions, indicating that there is scope for substantial variation according to the particular algorithm used and/or the characteristics of the treated population. </p> <p>The estimate of the effect of ORT‐based versus non‐ORT‐based algorithm suggests that there may be a higher mean number of oocytes for the former compared to the latter (ratio of mean oocytes 1.13, 95% CI 0.98 to 1.30; 194 participants), although the magnitude of the difference is unclear, given the width of the CI. </p> </section> <section id="CD012693-sec-0131"> <p><b>4.8 Poor response to stimulation</b></p> <p>This outcome was available for five studies, which defined a poor response as the retrieval of fewer than five oocytes (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>), fewer than nine oocytes (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>), and either cycle cancellation for poor response or the retrieval of fewer than five oocytes (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>). The pooled effect would be consistent with a small decrease or anything up to a substantial increase in the probability of poor response under an ORT‐algorithm compared to standard dosing; however, the heterogeneity is very high (OR 1.17, 95% CI 0.93 to 1.47; I<sup>2</sup> = 68%; 4 studies, 1858 participants; <a href="./references#CD012693-fig-0105" title="">Analysis 4.8</a>). By contrast, the probability of poor response was reduced under an ORT‐algorithm compared to a non‐ORT algorithm; however, the magnitude of the reduction is unclear (OR 0.50, 95% CI 0.27 to 0.92; 194 participants; <a href="./references#CD012693-fig-0105" title="">Analysis 4.8</a>; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). </p> <p>This suggests that if the chance of a poor response with a standard starting dose is 16%, then the chance with ORT‐algorithm dosing would be between 15% and 22%. Further, if the chance of retrieving eight or fewer oocytes with a non‐ORT algorithm was 40%, then the chance with ORT‐algorithm dosing would be between 16% and 38%. </p> <p>Another study reported the total number of women experiencing either a poor or hyper‐response as an aggregate outcome and declined to provide the number of women experiencing a poor response and hyper‐response separately (<a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>). </p> </section> <section id="CD012693-sec-0132"> <p><b>4.9 Normal response to stimulation</b></p> <p>Seven studies reported this outcome and defined a normal response as retrieval of: five to 14 oocytes (<a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>), five to 15 oocytes (or cycle cancellation for any reason other than a poor or hyper‐response) (<a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>); four to 14 oocytes retrieved (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>), and eight to 14 oocytes (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>). </p> <p>The pooled effect suggested an increase in the probability of a normal response to stimulation when using an ORT‐algorithm compared to standard dosing (OR 1.16, 95% CI 1.02 to 1.31; I<sup>2</sup> = 9%; 6 studies, 4196 participants; <a href="./references#CD012693-fig-0106" title="">Analysis 4.9</a>) or non‐ORT algorithm dosing (OR 2.13, 95% CI 1.20 to 3.78; 194 participants; <a href="./references#CD012693-fig-0106" title="">Analysis 4.9</a>; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). This suggests that if the chance of having a normal response with a standard starting dose is 58%, then the chance with ORT‐algorithm dosing would be between 58% and 64%, and further, if the chance with a non‐ORT algorithm was 42%, then the chance with ORT‐algorithm dosing would be between 47% and 74%. </p> </section> <section id="CD012693-sec-0133"> <p><b>4.10 Hyper‐response to stimulation</b></p> <p>This outcome was available for five studies. All defined a hyper‐response as 15 or more oocytes retrieved (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-fig-0107" title="">Analysis 4.10</a>). </p> <p>The use of an ORT‐algorithm appeared to reduce the number of women with a hyper‐response compared to a standard starting dose of 150 IU; however, heterogeneity was high (OR 0.79, 95% CI 0.61 to 1.02; I<sup>2</sup> = 88%; 4 studies, 1858 participants). There was insufficient evidence to determine whether there was any difference between the groups when comparing an ORT‐based algorithm to a non‐ORT‐based algorithm (OR 0.57, 95% CI 0.25 to 1.31; 194 participants; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). This suggests that if the chance of having a hyper‐response with a standard starting dose is 14%, then the chance with ORT‐algorithm dosing would be between 9% and 14%, and further, if the chance with a non‐ORT algorithm was 17%, then the chance with ORT‐algorithm dosing would be between 4.9% and 21%. </p> <p>As described above, we were unable to fully assess this outcome, which appears to have been recorded but not reported for one study (<a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>). </p> </section> <section id="CD012693-sec-0134"> <p><b>4.11 Cycle cancellations for poor response</b></p> <p>Cycle cancellation due to poor response was an uncommon event, so the effect estimates are imprecise when comparing an ORT‐based algorithm to a standard starting dose of 150 IU (OR 1.20, 95% CI 0.89 to 1.60; I<sup>2</sup> = 0%; 6 studies, 3391 participants; <a href="./references#CD012693-fig-0108" title="">Analysis 4.11</a>), or a non‐ORT based algorithm (OR 0.14, 95% CI 0.01 to 2.83; 194 participants; <a href="./references#CD012693-fig-0108" title="">Analysis 4.11</a>; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). This suggests that if the chance of having a cycle cancellation for poor response with a standard starting dose is 2%, then the chance with ORT‐algorithm dosing would be between 2% and 3%. </p> </section> <section id="CD012693-sec-0135"> <p><b>4.12 Cycle cancellations for hyper‐response (including freeze‐all cycles)</b></p> <p>An ORT‐based algorithm resulted in fewer cancellations for hyper‐response than a standard starting dose of 150 IU (OR 0.36, 95% CI 0.23 to 0.56; I<sup>2</sup> = 0%; 5 studies, 3170 participants; <a href="./references#CD012693-fig-0109" title="">Analysis 4.12</a>). This suggests that if the chance of having a cycle cancellation for hyper‐response with a standard starting dose is 4.2%, then the chance with ORT‐algorithm dosing would be between 0.9% and 2.3%. However, there was insufficient evidence to determine whether there was any difference in cancellation rates for hyper‐response in the study comparing an ORT‐based algorithm with a non‐ORT‐based algorithm (OR 0.95, 95% CI 0.40 to 2.27; 194 participants; <a href="./references#CD012693-fig-0109" title="">Analysis 4.12</a>; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). This suggests that if the chance of having cycle cancellation for hyper‐response with a non‐ORT algorithm is 12%, then the chance with ORT‐algorithm dosing would be between 5.2% and 24%. </p> </section> <section id="CD012693-sec-0136"> <p><b>4.13 Cycle cancellations for poor or hyper‐response</b></p> <p>Cycle cancellation or freeze‐all due to hyper‐response occurred less often than cancellation for poor response, so the occurrence of cancellation for a poor response contributed more to this analysis. Overall, the pooled evidence suggested a reduced probability of cycle cancellations for either poor or hyper‐response using an ORT‐based algorithm compared to a standard starting dose of 150 IU (OR 0.78, 95% CI 0.61 to 1.00; I<sup>2</sup> = 0%; 4 studies, 2823 participants); however, there was no effect when comparing an ORT‐based algorithm with a non‐ORT algorithm (OR 0.73, 95% CI 0.32 to 1.69; 194 participants; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-fig-0110" title="">Analysis 4.13</a>). This suggests that if the chance of having a cycle cancellation for poor or hyper‐response with a standard starting dose is 12%, then the chance with ORT‐algorithm dosing would be between 7.5% and 12%, and further, if the chance with a non‐ORT algorithm was 15%, then the chance with ORT‐algorithm dosing would be between 5.4% and 23%. </p> </section> <section id="CD012693-sec-0137"> <p><b>4.14 Women with at least one transferable embryo</b></p> <p>Eight studies reported this outcome, which refers to the number of women with at least one embryo available to transfer (i.e. either undergoing a fresh transfer, or having a freeze‐all) (<a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>; <a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>; <a href="./references#CD012693-bbs2-0019" title="PetersenJF , LokkegaardE , AndersenLF , TorpK , EgebergA , HedegaardL , et al. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF. Human Reproduction Open2019;1:1-11. ">Petersen 2019</a>; <a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>; <a href="./references#CD012693-fig-0111" title="">Analysis 4.14</a>). The estimate of the difference in the number of women with embryos available to transfer was precise and appeared to rule out notable effects when comparing an ORT‐based algorithm with a standard starting dose of 150 IU (OR 0.98, 95% CI 0.84 to 1.15; I<sup>2</sup> = 0%; 7 studies, 4397 participants) and was imprecise and consistent with non‐trivial effects in either direction when comparing an ORT‐based algorithm with a non‐ORT algorithm (OR 1.15, 95% CI 0.57 to 2.33; 194 participants; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). This suggests that if the chance of having at least one transferable embryo with a standard starting dose is 83%, then the chance with ORT‐algorithm dosing would be between 80% and 85%, and further, if the chance with a non‐ORT algorithm was 79%, then the chance with ORT‐algorithm dosing would be between 68% and 90%. </p> </section> <section id="CD012693-sec-0138"> <p><b>4.15 Total dose of FSH</b></p> <p>When comparing an ORT‐based algorithm to a standard starting dose of 150 IU, the pooled mean total dose of FSH administered was lower in the ORT‐based algorithm group (MD IU −377.62, 95% CI −412.01 to −343.24; I<sup>2</sup> = 97%; 5 studies, 2850 participants; <a href="./references#CD012693-fig-0112" title="">Analysis 4.15</a>). However, the five studies included in this estimate report very different results for this outcome, and the large effect reported here is largely due to three trials that reported a much lower total dose in the ORT‐algorithm arm (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>). All five trials comparing an ORT‐based algorithm to 150 IU reported this outcome; however, the doses used by one study were in a drug‐specific unit (µg) that we could not pool with the other studies (which used international units (IU)). This study reported a significantly higher average total dose in women in the standard dosing arm (mean (SD) 90.0 µg (25.3) versus 103.7 µg (33.6) P &lt; 0.001; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>). </p> <p>In the study comparing an ORT‐based algorithm to a non‐ORT algorithm, there was no clear evidence of a difference in total dose between the two arms (MD IU −11.00, 95% CI −210.30 to 188.30; 194 participants; <a href="./references#CD012693-fig-0112" title="">Analysis 4.15</a>; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). </p> <p>Readers should treat these results with caution due to handling of censored cycle cancellations. </p> </section> <section id="CD012693-sec-0139"> <p><b>4.16 Duration of FSH administration</b></p> <p>When comparing an ORT‐based algorithm to a standard starting dose of 150 IU, the average duration of stimulation in days was slightly longer in the ORT‐based algorithm group (MD days 0.32, 95% CI 0.21 to 0.43; I<sup>2</sup> = 46%; 7 studies, 4400 participants; <a href="./references#CD012693-fig-0113" title="">Analysis 4.16</a>); however, there was no difference in days of FSH exposure when comparing an ORT‐algorithm to a non‐ORT algorithm (MD days −0.40, 95% CI −0.84 to 0.04; 194 participants; <a href="./references#CD012693-fig-0113" title="">Analysis 4.16</a>; <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>). </p> <p>These results should be treated with caution due to handling of censored cycle cancellations.</p> </section> <section id="CD012693-sec-0140"> <p><b>4.17 Cost per woman randomised</b></p> <p>None of the studies included in this comparison reported this outcome.</p> </section> </section> </section> <section id="CD012693-sec-0141"> <h5 class="title">5. ORT‐based algorithm versus different ORT‐based algorithm</h5> <p>Three trials compared different ORT algorithms against each other: anti‐Müllerian hormone (AMH) versus antral follicular count (AFC) (<a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>), AFC plus AMH versus AFC alone (<a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>), and AMH plus AFC plus basal FSH (bFSH) versus bFSH alone (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). </p> </section> <section id="CD012693-sec-0142"> <h5 class="title">5.1 AMH‐based algorithm versus AFC‐based algorithm</h5> <p>One trial (348 participants) made this comparison (<a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>). </p> <section id="CD012693-sec-0143"> <h6 class="title">Primary outcomes</h6> <section id="CD012693-sec-0144"> <p><b>5.1.1 Live birth or ongoing pregnancy</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0145"> <p><b>5.1.2 Severe OHSS</b></p> <p>There were no events in either study arm (<a href="./references#CD012693-fig-0119" title="">Analysis 5.2</a>). </p> </section> </section> <section id="CD012693-sec-0146"> <h6 class="title">Secondary outcomes</h6> <section id="CD012693-sec-0147"> <p><b>5.1.3 Clinical pregnancy</b></p> <p>The confidence interval is wide and encompasses the possibility of an effect in either direction (OR 0.82, 95% CI 0.53 to 1.27; 348 participants, low‐certainty evidence; <a href="./references#CD012693-fig-0120" title="">Analysis 5.3</a>). This suggests that if the chance of clinical pregnancy with an AFC algorithm is 39%, then the chance with an AMH algorithm would be between 25% and 45%. </p> </section> <section id="CD012693-sec-0148"> <p><b>5.1.4 Time to clinical pregnancy</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0149"> <p><b>5.1.5 Moderate or severe OHSS</b></p> <p>Findings were inconclusive as to whether moderate or severe OHSS was increased in those with an AMH‐based dose compared to those with an AFC‐based dose (Peto OR 4.28, 95% CI 0.96 to 19.07; 348 participants; very low‐certainty evidence; <a href="./references#CD012693-fig-0122" title="">Analysis 5.5</a>). This suggests that if the chance of moderate or severe OHSS with dosing based on AFC is 0.6%, then the chance with dosing using AMH would be between 0.6% and 9.9%. </p> </section> <section id="CD012693-sec-0150"> <p><b>5.1.6 Multiple pregnancy in randomised women</b></p> <p>The confidence interval is consistent with substantial effects in multiple pregnancy rates in either direction (Peto OR 1.21, 95% CI 0.66 to 2.23; 348 participants; <a href="./references#CD012693-fig-0123" title="">Analysis 5.6</a>). This suggests that if the chance of multiple pregnancy with dosing based on AFC is 13%, then the chance with dosing using AMH would be between 8.7% and 24%. We also calculated the multiple pregnancy rates per clinical pregnancy, with similar results (<a href="./references#CD012693-fig-0136" title="">Analysis 5.19</a>). </p> </section> <section id="CD012693-sec-0151"> <p><b>5.1.7 Number of oocytes retrieved per woman randomised</b></p> <p>This is a ratio of mean oocytes and should not be misinterpreted as numbers of oocytes.</p> <p>There were more oocytes retrieved in women with dose‐selection using an AFC algorithm compared to an algorithm using AMH (ratio of mean oocytes 0.78, 95% CI 0.69 to 0.88; 348 participants; <a href="./references#CD012693-fig-0124" title="">Analysis 5.7</a>). </p> </section> <section id="CD012693-sec-0152"> <p><b>5.1.8 Poor response to stimulation</b></p> <p>Findings were suggestive of a higher rate of poor response in the arm using the AMH algorithm than in the arm using an AFC algorithm, although the confidence interval crossed the line of no effect (OR 2.25, 95% CI 0.94 to 5.35; 348 participants; <a href="./references#CD012693-fig-0125" title="">Analysis 5.8</a>). </p> </section> <section id="CD012693-sec-0153"> <p><b>5.1.9 Normal response to stimulation</b></p> <p>This outcome was defined as the retrieval of eight to 12 oocytes. There was no clear difference between the groups in the number of participants experiencing a normal response, but the confidence interval was wide (OR 1.38, 95% CI 0.87 to 2.17; 348 participants; <a href="./references#CD012693-fig-0126" title="">Analysis 5.9</a>). </p> </section> <section id="CD012693-sec-0154"> <p><b>5.1.10 Hyper‐response to stimulation</b></p> <p>This outcome was defined as more than 12 oocytes. There were fewer women with more than 12 oocytes collected amongst those allocated to an AMH‐based algorithm, compared to an AFC‐based algorithm (OR 0.45, 95% CI 0.23 to 0.88; 348 participants; <a href="./references#CD012693-fig-0127" title="">Analysis 5.10</a>). </p> </section> <section id="CD012693-sec-0155"> <p><b>5.1.11 Cycle cancellations for poor response</b></p> <p>We could not draw any conclusions, as the rate of cycle cancellation for poor response was low and therefore the confidence interval for the effect estimate is imprecise (OR 1.51, 95% CI 0.25 to 9.14; 348 participants; <a href="./references#CD012693-fig-0128" title="">Analysis 5.11</a>). </p> </section> <section id="CD012693-sec-0156"> <p><b>5.1.12 Cycle cancellations for hyper‐response (including freeze‐all cycles)</b></p> <p>We could not draw any conclusions, as the rate of cycle cancellation for hyper‐response was low, so the confidence interval for the effect estimate is imprecise (OR 0.54, 95% CI 0.23 to 1.25; 348 participants; <a href="./references#CD012693-fig-0129" title="">Analysis 5.12</a>). This suggests that if the chance of cycle cancellation for hyper‐response with an AFC algorithm is 9.2%, then the chance with an AMH algorithm would be between 2.3% and 11%. </p> </section> <section id="CD012693-sec-0157"> <p><b>5.1.13 Cycle cancellations for poor or hyper‐response</b></p> <p>We could not draw any conclusions, as the rate of cycle cancellation for poor or hyper‐response was low, so the confidence interval for the effect estimate is imprecise (OR 0.64, 95% CI 0.30 to 1.38; 348 participants; <a href="./references#CD012693-fig-0130" title="">Analysis 5.13</a>). This suggests that if the chance of cycle cancellation for either poor or hyper‐response with an AFC algorithm is 10%, then the chance with an AMH algorithm would be between 3.3% and 14%. </p> </section> <section id="CD012693-sec-0158"> <p><b>5.1.14 Women with at least one transferable embryo</b></p> <p>This outcome refers to the number of women who had at least one embryo available for transfer, either for a fresh embryo transfer or for a freeze‐all strategy. We could not draw any conclusions, as the confidence interval is imprecise and consistent with large effects in either direction (OR 1.21, 95% CI 0.36 to 4.03; 348 participants; <a href="./references#CD012693-fig-0131" title="">Analysis 5.14</a>). This suggests that if the chance of having at least one transferable embryo with an AFC algorithm is 97%, then the chance with an AMH algorithm would be between 91% and 99%. </p> </section> <section id="CD012693-sec-0159"> <p><b>5.1.15 Total dose of FSH</b></p> <p>We could not draw any conclusions, as the confidence interval is imprecise and could be consistent with small effects in either direction (MD IU −178.00, 95% CI −413.88 to 57.88, 348 participants; <a href="./references#CD012693-fig-0132" title="">Analysis 5.15</a>). We would urge caution when interpreting this result, as it was not possible to account for censored data arising from cancelled cycles. </p> </section> <section id="CD012693-sec-0160"> <p><b>5.1.16 Duration of FSH administration</b></p> <p>There was no clear evidence of a difference between the two dosing algorithms in the duration of FSH administration (MD 0.20 days, 95% CI −0.11 to 0.51; 348 participants; <a href="./references#CD012693-fig-0133" title="">Analysis 5.16</a>). We would urge caution when interpreting this result as it was not possible to account for censored data arising from cancelled cycles. </p> </section> <section id="CD012693-sec-0161"> <p><b>5.1.17 Cost per woman randomised</b></p> <p>The <a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a> study did not report this outcome.​ </p> </section> </section> </section> <section id="CD012693-sec-0162"> <h5 class="title">5.2 AMH plus AFC‐based algorithm versus AFC‐based algorithm</h5> <p>One study (308 participants) made this comparison (<a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>). </p> <section id="CD012693-sec-0163"> <h6 class="title">Primary outcomes</h6> <section id="CD012693-sec-0164"> <p><b>5.2.1 Live birth or ongoing pregnancy</b></p> <p>The confidence interval is wide and encompasses the possibility of an effect in either direction (OR 1.18, 95% CI 0.72 to 1.93; 308 participants; low‐certainty evidence; <a href="./references#CD012693-fig-0137" title="">Analysis 6.1</a>; <a href="#CD012693-fig-0011">Figure 11</a>). This suggests that if the chance of live birth with ORT dosing using AFC only is 27%, then the chance with dosing based on AFC and AMH would be between 21% and 42%. </p> <div class="figure" id="CD012693-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 6 AMH + AFC‐based algorithm vs AFC‐based algorithm, outcome: 6.1 Live birth or ongoing pregnancy." data-id="CD012693-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-11.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 6 AMH + AFC‐based algorithm vs AFC‐based algorithm, outcome: 6.1 Live birth or ongoing pregnancy. </p> </div> </div> </div> </section> <section id="CD012693-sec-0165"> <p><b>5.2.2 Severe OHSS</b></p> <p>Findings were inconclusive, as there were only five events in total (Peto OR 0.68, 95% CI 0.12 to 4.00; 308 participants; low‐certainty evidence; <a href="./references#CD012693-fig-0138" title="">Analysis 6.2</a>). </p> </section> </section> <section id="CD012693-sec-0166"> <h6 class="title">Secondary outcomes</h6> <section id="CD012693-sec-0167"> <p><b>5.2.3 Clinical pregnancy</b></p> <p>The confidence interval is wide and encompasses the possibility of an effect in either direction (OR 1.37, 95% CI 0.84 to 2.23; 308 participants; moderate‐certainty evidence; <a href="./references#CD012693-fig-0139" title="">Analysis 6.3</a>). This suggests that if the chance of clinical pregnancy with ORT dosing using AFC only is 27%, then the chance with dosing based on AFC and AMH would be between 24% and 45%. </p> </section> <section id="CD012693-sec-0168"> <p><b>5.2.4 Time to clinical pregnancy</b></p> <p>This outcome was not reported.</p> </section> <section id="CD012693-sec-0169"> <p><b>5.2.5 Moderate or severe OHSS</b></p> <p>The confidence interval is wide and encompasses the possibility of an effect in either direction (Peto OR 0.85, 95% CI 0.26 to 2.83; 308 participants; very low‐certainty evidence; <a href="./references#CD012693-fig-0141" title="">Analysis 6.5</a>). This suggests that if the chance of moderate or severe OHSS with ORT dosing using AFC only is 3.8%, then the chance with dosing based on AFC and AMH would be between 1.0% and 10.0%. </p> </section> <section id="CD012693-sec-0170"> <p><b>5.2.6 Multiple pregnancy in randomised women</b></p> <p>There were no multiple pregnancies in either study arm (<a href="./references#CD012693-fig-0142" title="">Analysis 6.6</a>; <a href="./references#CD012693-fig-0155" title="">Analysis 6.19</a>). </p> </section> <section id="CD012693-sec-0171"> <p><b>5.2.7 Number of oocytes retrieved per woman randomised</b></p> <p>This is a ratio of mean oocytes and should not be misinterpreted as difference in mean numbers of oocytes. </p> <p>There were fewer oocytes retrieved in women with dose‐selection using an AFC plus AMH algorithm compared to an algorithm using AFC only (ratio of mean oocytes 0.83, 95% CI 0.73 to 0.93; 308 participants; <a href="./references#CD012693-fig-0143" title="">Analysis 6.7</a>). </p> </section> <section id="CD012693-sec-0172"> <p><b>5.2.8 Poor response to stimulation</b></p> <p>This outcome was defined as the retrieval of fewer than five oocytes. There were substantially more women with a poor response amongst those in the group with an algorithm using AMH and AFC, compared to those with an algorithm using AFC only (OR 2.82, 95% CI 1.52 to 5.25; 308 participants; <a href="./references#CD012693-fig-0144" title="">Analysis 6.8</a>). </p> </section> <section id="CD012693-sec-0173"> <p><b>5.2.9 Normal response to stimulation</b></p> <p>This outcome was defined as the retrieval of five to 12 oocytes. There was no clear evidence of a difference between the groups in the number of participants experiencing a normal response (OR 0.71, 95% CI 0.45 to 1.12; 308 participants; <a href="./references#CD012693-fig-0145" title="">Analysis 6.9</a>). </p> </section> <section id="CD012693-sec-0174"> <p><b>5.2.10 Hyper‐response to stimulation</b></p> <p>This outcome was defined as more than 12 oocytes. Findings were consistent with effects in either direction (OR 0.72, 95% CI 0.43 to 1.23; 308 participants; <a href="./references#CD012693-fig-0146" title="">Analysis 6.10</a>). </p> </section> <section id="CD012693-sec-0175"> <p><b>5.2.11 Cycle cancellations for poor response</b></p> <p>We could not draw any conclusions, as the rate of cycle cancellation for poor response was low, so the confidence interval for the effect estimate is imprecise (OR 1.83, 95% CI 0.53 to 6.40; 308 participants; <a href="./references#CD012693-fig-0147" title="">Analysis 6.11</a>). This suggests that if the chance of cycle cancellation for poor response with ORT dosing using AFC only is 2.6%, then the chance with dosing based on AFC and AMH would be between 1.4% and 14%. </p> </section> <section id="CD012693-sec-0176"> <p><b>5.2.12 Cycle cancellations for hyper‐response (including freeze‐all cycles)</b></p> <p>We could not draw any conclusions, as the rate of cycle cancellation for hyper‐response was low, so the confidence interval for the effect estimate is imprecise (OR 0.50, 95% CI 0.12 to 2.05; 308 participants; <a href="./references#CD012693-fig-0148" title="">Analysis 6.12</a>). This suggests that if the chance of cycle cancellation for hyper‐response with ORT dosing using AFC only is 3.8%, then the chance with dosing based on AFC and AMH would be between 0.5% and 7.6%. </p> </section> <section id="CD012693-sec-0177"> <p><b>5.2.13 Cycle cancellations for poor or hyper‐response</b></p> <p>We could not draw any conclusions, as the rate of cycle cancellation for poor or hyper‐response was low, so the confidence interval for the effect estimate is imprecise (OR 1.03, 95% CI 0.42 to 2.55; 308 participants; <a href="./references#CD012693-fig-0149" title="">Analysis 6.13</a>). This suggests that if the chance of cycle cancellation for poor or hyper‐response with ORT dosing using AFC only is 6.4%, then the chance with dosing based on AFC and AMH would be between 2.8% and 15%. </p> </section> <section id="CD012693-sec-0178"> <p><b>5.2.14 Women with at least one transferable embryo</b></p> <p>This outcome refers to the number of women who had at least one embryo available for transfer, either for a fresh embryo transfer or for a freeze‐all strategy. We could not draw any conclusions, as the confidence interval is wide and imprecise and consistent with large effects in either direction (OR 1.04, 95% CI 0.50 to 2.19; 308 participants; <a href="./references#CD012693-fig-0150" title="">Analysis 6.14</a>). This suggests that if the chance of having at least one transferable embryo with ORT dosing using AFC only is 90%, then the chance with dosing based on AFC and AMH could be between 81% and 95%. </p> </section> <section id="CD012693-sec-0179"> <p><b>5.2.15 Total dose of FSH</b></p> <p>We could not draw any conclusions, as the confidence interval is wide and imprecise and consistent with small effects in either direction (MD IU 81.00, 95% CI −111.93 to 273.93; 308 participants; <a href="./references#CD012693-fig-0151" title="">Analysis 6.15</a>). </p> <p>We would urge caution when interpreting this result, as it was not possible to account for censored data arising from cancelled cycles. </p> </section> <section id="CD012693-sec-0180"> <p><b>5.2.16 Duration of FSH administration</b></p> <p>Participants in the AMH plus AFC‐dosing algorithm had a longer duration of stimulation than those in the group using the AFC‐dosing algorithm (MD days 0.50 days, 95% CI 0.10 to 0.90; 308 participants; <a href="./references#CD012693-fig-0152" title="">Analysis 6.16</a>). </p> <p>We would urge caution when interpreting this result, as it was not possible to account for censored data arising from cancelled cycles. </p> </section> <section id="CD012693-sec-0181"> <p><b>5.2.17 Cost per woman randomised</b></p> <p>The <a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a> study did not report this outcome.​ </p> </section> </section> </section> <section id="CD012693-sec-0182"> <h5 class="title">5.3 AMH plus AFC plus bFSH‐based algorithm versus bFSH‐based algorithm</h5> <p>One study (286 participants randomised; individual patient data available for 215 participants) made this comparison (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). </p> <section id="CD012693-sec-0183"> <h6 class="title">Primary outcomes</h6> <section id="CD012693-sec-0184"> <p><b>5.3.1 Live birth or ongoing pregnancy</b></p> <p>Findings were inconclusive but were suggestive of a lower event rate in the AMH plus AFC plus bFSH group (OR 0.54, 95% CI 0.28 to 1.04; 215 participants; very low‐certainty evidence; <a href="./references#CD012693-fig-0156" title="">Analysis 7.1</a>). This suggests that if the chance of live birth with dosing based on bFSH is 28%, then the chance with dosing using AMH, AFC, and bFSH would be between 10% and 29%. However, readers should treat this result with caution, as the review team extracted the data from individual participant data, which were incomplete. </p> </section> <section id="CD012693-sec-0185"> <p><b>5.3.2 Severe OHSS</b></p> <p>The trial did not report this outcome.</p> </section> </section> <section id="CD012693-sec-0186"> <h6 class="title">Secondary outcomes</h6> <section id="CD012693-sec-0187"> <p><b>5.3.3 Clinical pregnancy</b></p> <p>The clinical pregnancy rate appeared to be lower in the participants having dose‐selection based on an algorithm using AMH, AFC, and bFSH (OR 0.51, 95% CI 0.28 to 0.93; 215 participants; very low‐certainty evidence; <a href="./references#CD012693-fig-0158" title="">Analysis 7.3</a>). This suggests that if the chance of clinical pregnancy with dosing based on bFSH alone is 36%, then the chance with dosing using AMH, AFC, and bFSH would be between 14% and 35%. </p> </section> <section id="CD012693-sec-0188"> <p><b>5.3.4 Time to clinical pregnancy</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0189"> <p><b>5.3.5 Moderate or severe OHSS</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0190"> <p><b>5.3.6 Multiple pregnancy in randomised women</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0191"> <p><b>5.3.7 Number of oocytes retrieved per woman randomised</b></p> <p>There was no clear difference between the groups in the average number of oocytes retrieved (ratio of mean oocytes 0.82, 95% CI 0.44 to 1.51; 215 participants; <a href="./references#CD012693-fig-0162" title="">Analysis 7.7</a>). </p> </section> <section id="CD012693-sec-0192"> <p><b>5.3.8 Poor response to stimulation</b></p> <p>This outcome was defined as the retrieval of fewer than five oocytes. We could not draw any conclusions, as the confidence interval is wide and imprecise (OR 1.46, 95% CI 0.77 to 2.79; 215 participants; <a href="./references#CD012693-fig-0163" title="">Analysis 7.8</a>). </p> </section> <section id="CD012693-sec-0193"> <p><b>5.3.9 Normal response to stimulation</b></p> <p>This outcome was defined as the retrieval of five to 14 oocytes. There was no clear evidence of a difference between the groups (OR 0.75, 95% CI 0.42 to 1.35; 215 participants; <a href="./references#CD012693-fig-0164" title="">Analysis 7.9</a>). </p> </section> <section id="CD012693-sec-0194"> <p><b>5.3.10 Hyper‐response to stimulation</b></p> <p>This outcome was defined as the retrieval of more than 14 oocytes. We could not draw any conclusions, as the confidence interval is wide and imprecise (OR 0.93, 95% CI 0.45 to 1.93; 215 participants; <a href="./references#CD012693-fig-0165" title="">Analysis 7.10</a>). </p> </section> <section id="CD012693-sec-0195"> <p><b>5.3.11 Cycle cancellations for poor response</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0196"> <p><b>5.3.12 Cycle cancellations for hyper‐response</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0197"> <p><b>5.3.13 Cycle cancellations for poor or hyper‐response</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0198"> <p><b>5.3.14 Women with at least one transferable embryo</b></p> <p>The trial did not report this outcome.</p> </section> <section id="CD012693-sec-0199"> <p><b>5.3.15 Total dose of FSH</b></p> <p>We could not draw any conclusions, as the confidence interval is wide and consistent with small effects in either direction (MD IU −148.00, 95% CI −433.61 to 137.61; 215 participants; <a href="./references#CD012693-fig-0170" title="">Analysis 7.15</a>). We would urge caution when interpreting this result, as it was not possible to account for censored data arising from cancelled cycles. </p> </section> <section id="CD012693-sec-0200"> <p><b>5.3.16 Duration of FSH administration</b></p> <p>There was no clear evidence of a difference between the groups in the duration of FSH administration (MD 0.00 days, 95% CI −0.60 to 0.60; 215 participants; <a href="./references#CD012693-fig-0171" title="">Analysis 7.16</a>). We would urge caution when interpreting this result, as it was not possible to account for censored data arising from cancelled cycles. </p> </section> <section id="CD012693-sec-0201"> <p><b>5.3.17 Cost per woman randomised</b></p> <p>The trial did not report this outcome.​</p> </section> </section> </section> </section> <section id="CD012693-sec-0202"> <h4 class="title">Sensitivity analyses</h4> <p>We stated in the Methods that we would conduct sensitivity or subgroup analyses by excluding studies with various characteristics. As the evidence was limited for most outcomes and associated with significant imprecision, most of the planned sensitivity analyses are moot. We also stated that we would perform a sensitivity analysis where we relaxed the requirement for trials to have low or unclear risk of bias for the first two domains, but all studies satisfied this requirement. If we switch to a random‐effects analysis, we do not reach a different conclusion for any comparison. In addition, we have presented pooled estimates for our ORT‐algorithm studies. However, these are not intended to represent estimates of underlying treatment effects, but rather summaries of the results of individual studies. The considerable protocol variation between ORT‐algorithm studies precludes effect estimation. Random‐effects meta‐analysis does not overcome this fact. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012693-sec-0203" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012693-sec-0203"></div> <section id="CD012693-sec-0204"> <h3 class="title" id="CD012693-sec-0204">Summary of main results</h3> <section id="CD012693-sec-0205"> <h4 class="title">Direct dose comparison studies</h4> <section id="CD012693-sec-0206"> <h5 class="title">Predicted low responders</h5> <p>This review included six studies in predicted low responders, testing five different combinations of FSH doses against each other. Five trials reported the primary outcome 'live birth or ongoing pregnancy', and there was insufficient evidence to determine whether there was any difference in the probability of this outcome between women randomised to different doses. For example, if we assume a birth rate of 16% in women treated with 150 IU, then the results of one analysis would be consistent with live birth rates as low as 13% or as high as 26% in the higher dose (300/450 IU) arm. The effect on cumulative live birth remains unknown, as it was only available for one trial (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). </p> <p>All six studies reported clinical pregnancy, and the pooled results of one comparison suggest that women administered 150 IU had a higher chance of achieving pregnancy than women administered 300 or 450 IU (albeit with imprecision). This did not translate into an increase in live birth rate, however, since in one of the trials, 10 of 24 pregnancies in the lower dosing arm were subsequently lost (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). This may or may not be attributable to chance. In the other two comparisons, sample sizes were too small to draw a conclusion. </p> <p>There were no events of severe OHSS, the primary safety outcome of this review. Moreover, only one case of moderate OHSS occurred in studies reporting this outcome. Therefore, we are unable to make any inferences about dose effects on this outcome. However, OHSS is expected to occur only very rarely in a population of women with predicted low ovarian response. Our best available surrogates are cancellation for hyper‐response (or freeze‐all) and excessive response to stimulation. Although the event rates for the former are too low to be useful, it seems reasonably clear that using 150 IU instead of higher doses reduces hyper‐response in this subgroup, as <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a> reported. However, this must be balanced against the probability of cancellation for poor response, which was higher in the lower dose arms of this trial. The rate of normal response favoured the use of a higher dose of 450 IU. </p> </section> <section id="CD012693-sec-0207"> <h5 class="title">Predicted normal responders</h5> <p>There were 12 studies included in this comparison, 10 of which were available for pooling in meta‐analysis. Two could not be compared to the rest, as the type of FSH used was expressed in a different unit. In a similar trend to that seen for the low responder group, there was no observed influence from higher or lower doses on the probability of live birth, OHSS, or clinical pregnancy. However, the estimates were imprecise and remain consistent with small effects in either direction. An exception is the effect on clinical pregnancy for 225/200 IU versus 150 IU, which constituted a reasonably precise null result. </p> <p>It was difficult to assess the five‐arm and three‐arm trials for dose‐response effects on clinical outcomes, as the numbers of participants and event rates were low. </p> <p>As with predicted low responders, there is evidence of effects of increasing dose on preclinical outcomes such as oocyte yield and cycle cancellation, but the evidence reported in this review does not demonstrate that these effects translate into differences in clinical outcomes such as live birth or clinical pregnancy. </p> </section> <section id="CD012693-sec-0208"> <h5 class="title">Predicted high responders</h5> <p>There were only three studies in this comparison: one trial comparing 150 IU versus 100 IU in women with AFC of more than 15; a five‐arm study in women with AMH between 15 pmol/L and 55 pmol/L comparing five different doses of FSH; and a three‐arm study in women with AMH between 15 pmol/L and 44.9 pmol/L comparing three different doses of FSH. However, the three‐arm study did not report the primary outcomes of this review separately for the high‐AMH stratum. There was no observed effect of dose reduction below 150 IU on the probability of live birth or clinical pregnancy. However, 100 IU did seem to reduce the occurrence of moderate or severe OHSS compared to 150 IU. This observed benefit from lower doses may be weighed against the disadvantages, as a reduced dose also led to the retrieval of fewer oocytes, an increased chance of cancellation for poor response, more overall cancellations, and fewer women with at least one embryo for transfer. However, these effects did not translate into a reduced probability of clinical outcomes, which could be due to a number of reasons, including lack of power, as discussed further below. The event rates in the five‐arm trial are consistent with the treatment effects found in the other studies. </p> </section> </section> <section id="CD012693-sec-0209"> <h4 class="title">ORT‐algorithm studies</h4> <p>These studies were divided into two comparisons: those comparing an ORT‐based algorithm to a standard starting dose of 150 IU or another algorithm which did not use ORT, and those comparing two different ORT‐based algorithms. </p> <section id="CD012693-sec-0210"> <h5 class="title">ORT‐based algorithm versus standard starting dose or non‐ORT‐based algorithm</h5> <p>There were eight trials comparing ORT‐based algorithms to a standard starting dose of 150 IU or an algorithm not using ORT, and these studies were subgrouped according to whether the control arm was a standard starting dose of 150 IU or a non‐ORT‐based algorithm. Pooling within subgroups was conducted with the caveat that the pooled effects should be interpreted as summaries of the effects estimated in the included studies, rather than an estimate of a distinct underlying treatment effect, as the studies included several different ORT algorithms and heterogeneity was very high. One AMH‐based algorithm for selecting the dose of follitropin delta was investigated in three studies (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>). </p> <p>When comparing ORT algorithms with 150 IU, the confidence interval for the pooled estimate ruled out notable disadvantages of ORT‐based algorithms on live birth, while a benefit of indeterminate magnitude would be possible. However, as noted above, the pooled estimate is difficult to interpret due to differences in algorithms. Point estimates for four of seven studies were close to the line of null effect. Two trials were somewhat discordant, if not completely inconsistent, with the others, suggesting a benefit of indeterminate magnitude when using an ORT algorithm (<a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>). A third study had a positive estimate, but had results which were also compatible with a lack of effect (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>). It is not possible to identify the reasons for this heterogeneity, which could be the result of the differential effectiveness of the various algorithms considered, differences in studied populations, biases, or chance. Two of these three studies investigated the same algorithm for follitropin delta (<a href="./references#CD012693-bbs2-0008" title="IshiharaO , Arce J-C, for the Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reproductive BioMedicine Online2021;42(5):909-18. ">Ishihara 2021b</a>; <a href="./references#CD012693-bbs2-0021" title="QiaoJ , ZhangY , LiangX , HoT , Huang H-Y, Kim S-H, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction2021;39(9):2452-62. [DOI: 10.1093/humrep/deab155]">Qiao 2021</a>), although another study of the same algorithm did not give any indication of effectiveness (<a href="./references#CD012693-bbs2-0015" title="Nyboe AndersenA , NelsonSM , FauserBC , García-VelascoJA , KleinBM , ArceJC , ESTHER-1 study group. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility2017;107(2):387-96. ">Nyboe Andersen 2017</a>). One possible explanation would be that tailoring based on ORT may be more effective in East Asian populations. One positive trial was conducted over a decade earlier than the other trials in this comparison (<a href="./references#CD012693-bbs2-0020" title="Popovic-TodorovicB , LoftA , BredkjñerHE , BangsbùllS , NielsenIK , Nyboe AndersenA . A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human Reproduction2003;18(11):2275-82. ">Popovic‐Todorovic 2003</a>), and the difference may be a consequence of changes in the general IVF population and in IVF techniques over time. To the extent that we consider the pooled estimate to represent a meaningful summary of this heterogeneous assortment of trials, birth rates under ORT algorithms do not appear to be adversely affected compared to those resulting from a uniform fixed 150 IU dose, and there may be benefits for specific algorithms. There were too few cases of severe OHSS to discuss effects on this outcome. If we extended our definition to include both moderate and severe cases, however, then ORT algorithms were consistently associated with reduced OHSS. This subjective outcome might be particularly prone to performance and detection biases arising from a lack of blinding. </p> <p>Only one study compared an ORT‐based algorithm with a non‐ORT‐based algorithm, which used only age. The authors found that the ORT algorithm increased the number of oocytes retrieved, reduced the probability of a poor response, and increased the probability of a normal response (with the caveat that the definition of 'normal response' was not prespecified, which probably would have changed the inference of the trial). However, there were insufficient events to determine effects on either pregnancy or OHSS, with no moderate or severe cases in either arm. </p> </section> <section id="CD012693-sec-0211"> <h5 class="title">ORT‐based algorithm versus different ORT‐based algorithm</h5> <p>Three studies were included in the comparison of different approaches to ORT‐based dosing (e.g. AMH versus AFC). </p> <p>There was insufficient evidence of differences in live birth rate between an AFC‐only algorithm and another using both AMH and AFC (<a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>), although the results are consistent with advantages of either. Any possible disadvantage of adding AMH to the algorithm would be small (and counterintuitive), however. The clinical pregnancy results supported these observations. There were too few moderate or severe OHSS events to assess which algorithm was safer in this regard. </p> <p>Another study suggested a disadvantage of adding AMH and AFC to basal FSH to select dose for the outcomes of clinical pregnancy and live birth (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). However, these results constitute very weak evidence, as we pieced the results together from an incomplete data set with a high proportion of missing data. Thus, we do not interpret them further. </p> <p>A third study compared AMH‐based to AFC‐based dose selection. Live birth was not reported, and the clinical pregnancy estimate was imprecise (<a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>). However, the upper confidence limit suggested at most a small advantage of AMH compared to AFC in this regard, and potentially a large disadvantage. Investigators did not observe any severe OHSS, although there may have been an advantage of indeterminate magnitude of AFC in relation to moderate OHSS; however, this was based on only a few events. </p> <p>Across all comparisons, we found no impact of dosing on the probability of multiple pregnancy, although estimates were too imprecise to rule anything out. </p> </section> </section> </section> <section id="CD012693-sec-0212"> <h3 class="title" id="CD012693-sec-0212">Overall completeness and applicability of evidence</h3> <section id="CD012693-sec-0213"> <h4 class="title">Applicability of the evidence</h4> <p>The included studies varied in their design, restricting meta‐analysis to subgroups within comparisons, with the caveat that these pooled estimates are unlikely to represent unified underlying treatment effects due to clinically heterogeneous trials. For example, in Comparison 1, six included studies in anticipated poor responders compared five distinct combinations of FSH doses. </p> <p>Across the first three comparisons investigated (direct dose comparison studies investigating effects of different doses in different populations), there were apparent effects of increasing dose on the 'upstream' outcomes of IVF, including: </p> <p> <ul id="CD012693-list-0075"> <li> <p>oocyte yield, in terms of the average number of oocytes retrieved (although effect sizes were variable and often reasonably modest); </p> </li> <li> <p>the number of women categorised as having either a poor (e.g. fewer than five oocytes), normal, or hyper‐response (e.g. more than 15 oocytes); </p> </li> <li> <p>the chance of cycle cancellation for either a poor or hyper‐response; and</p> </li> <li> <p>the probability of women having at least one embryo available for transfer (or freezing).</p> </li> </ul> </p> <p>Importantly, demonstrable effects on these outcomes fall short of demonstrating effects on clinical outcomes. </p> <p>Notably, most included studies only assessed the outcome of pregnancy (and/or birth) following a fresh embryo transfer, and few trials reported cumulative rates (following the transfer of fresh and all frozen embryos). This is important because it could be that an increased dose of FSH leads to higher freeze‐all rates for excessive response, as was observed in a number of comparisons amongst predicted normal and high responders. In most of the included studies, women with freeze‐all cycles were not given an opportunity to conceive in the study because the result of the first frozen transfer was not captured. Further, a higher dose of FSH may yield more oocytes and therefore more embryos for frozen transfer (in addition to any fresh transfer). However, the utility of having extra candidate embryos for transfer remains uncertain, since the included studies did not test the probability of these leading to a live birth in a frozen cycle. It was for this reason that this review captured the outcome 'women with at least one transferable embryo' which was a count of the women who either underwent fresh embryo transfer or who had a freeze‐all cycle (for any reason). However, the limitations remain that this outcome does not consider the <i>number</i> of transferable embryos each women had, and further, that an outcome related to the number of embryos remains a surrogate, rather than a clinically important, outcome. This review did not capture the outcome 'number of transferable embryos', which may have provided an indication of whether higher observed rates of hyper‐response and freeze‐all in the higher dosing arms resulted in a higher number of embryos available for transfer. However, ultimately, availability of more embryos (for transfer or freezing) does not definitively lead to a higher chance of pregnancy and live birth (as discussed below). It is worth emphasising that there may not be a strong association between effects on upstream outcomes (e.g. increased number of oocytes or cycle cancellation) and the effects on pregnancy or live birth. Previous observational research has suggested that the optimum number of oocytes retrieved during an IVF cycle is between five and 15, and the retrieval of 20 or more oocytes reduces the probability of pregnancy from a fresh IVF cycle (<a href="./references#CD012693-bbs2-0118" title="SunkaraSK , RittenbergV , Raine-FenningN , BhattacharyaS , ZamoraJ , CoomarasamyA . Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Human Reproduction2011;26(7):1768-74.">Sunkara 2011</a>). However, it does not necessarily follow that, for example, if a women has four oocytes collected in her first cycle, that she will benefit from targeting an increased number of oocytes in her second cycle (which may or may not be achieved by increasing her FSH dose). This correlation is only an observation that women who do obtain between five and 15 oocytes at retrieval have a higher probability of pregnancy and live birth. </p> <p>Another reason why effects on upstream outcomes may not translate into effects on clinical outcomes is that the increased FSH dose, possibly in combination with excess oestrogen production in the ovaries, can have a detrimental effect on the quality of the endometrium, reducing its receptivity and therefore the probability of implantation (<a href="./references#CD012693-bbs2-0074" title="BourgainC , DevroeyP . The endometrium in stimulated cycles for IVF. Human Reproduction Update2003;9:515-22.">Bourgain 2003</a>; <a href="./references#CD012693-bbs2-0097" title="KolibianakisE , BourgainC , AlbanoC , OsmanagaogluK , SmitzJ , Van SteirteghemA , et al. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertility and Sterility2002;78:1025-9.">Kolibianakis 2002</a>). Such suggestions have led to the increasing implementation of the freeze‐all strategy as routine, whereby all embryos are frozen for transfer in a subsequent non‐stimulated cycle (<a href="./references#CD012693-bbs2-0130" title="WongKM , vanWelyM , MolF , ReppingS , MastenbroekS . Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database of Systematic Reviews2017, Issue 3. Art. No: CD011184. [DOI: 10.1002/14651858.CD011184.pub2]">Wong 2017</a>). Indeed, the aforementioned observational study excluded cycles in which a freeze‐all strategy was employed (<a href="./references#CD012693-bbs2-0118" title="SunkaraSK , RittenbergV , Raine-FenningN , BhattacharyaS , ZamoraJ , CoomarasamyA . Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Human Reproduction2011;26(7):1768-74.">Sunkara 2011</a>). </p> <p>Moreover, there may be an additional effect of increased FSH dosing on the oocytes themselves, and subsequently on the number and quality of embryos available for transfer (or freezing). In one study included in this review, increasing doses of FSH led to increased oocyte yield but simultaneously reduced the fertilisation rate, resulting in fewer blastocysts per oocyte (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>). Similar trends were apparent in other included studies (<a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>). Several studies have demonstrated an effect of increasing FSH dose on the oocyte quality and aneuploidy rate in animal models (<a href="./references#CD012693-bbs2-0109" title="McGowanMR , BraithwaiteM , JochleW , MaplecoftRJ . Superovulation of beef heifers with Pergonal (HMG): a dose response trial. Theriogenology1985;24(2):173-84.">McGowan 1985</a>; <a href="./references#CD012693-bbs2-0112" title="RobertsR , IatropoulouA , CiantarD , StarkJ , BeckerDL , FranksS , et al. Follicle-stimulating hormone affects metaphase I chromosome alignment and increases aneuploidy in mouse oocytes matured in vitro. Biology of Reproduction2005;72(1):107-18.">Roberts 2005</a>; <a href="./references#CD012693-bbs2-0117" title="SuganoM , WatanabeS . Use of highly purified porcine FSH preparation for superovulation in Japanese black cattle. Journal of Veterinary Medical Science1997;59(3):223-5.">Sugano 1997</a>). However, research has not consistently detected the same effect in humans (<a href="./references#CD012693-bbs2-0101" title="La MarcaA , MinasiMG , SighinolfiG , GrecoP , ArgentoC , GrisendiV , et al. Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertility and Sterility2017;108(5):777-83.">La Marca 2017</a>; <a href="./references#CD012693-bbs2-0103" title="LabartaE , BoschE , MercaderA , AlamáP , MateuE , PellicerA . A higher ovarian response after stimulation for IVF is related to a higher number of euploid embryos. BioMed Research International2017;2017:5637923.">Labarta 2017</a>; <a href="./references#CD012693-bbs2-0122" title="TingPY , WenXY . The influence of FSH on the aneuploidy rate of human in vitro matured oocytes. Fertility and Sterility2009;92(3):S14.">Ting 2009</a>). This reinforces the need for caution regarding the use of surrogate outcomes, such as the number of oocytes retrieved or the number of women achieving a 'normal response', which are commonly used as primary outcomes in IVF trials (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>; <a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0009" title="JayaprakasanK , HopkissonJ , CampbellB , JohnsonI , ThorntonJ , Raine-FenningN . A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count. British Journal of Obstetrics and Gynaecology2010;117:853-62. ">Jayaprakasan 2010</a>; <a href="./references#CD012693-bbs2-0010" title="KlinkertER , BroekmansFJM , LoomanCWN , HabbemaJDF , te VeldeER . Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial. Human Reproduction2005;20(3):611-5. ">Klinkert 2005</a>; <a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>; <a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>; <a href="./references#CD012693-bbs2-0014" title="Magnusson Å, NilssonL , OlerödG , Thurin-Kjellberg1A , BerghC . The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response—a randomized, controlled trial. Human Reproduction2017;32(4):811-9. ">Magnusson 2017</a>). </p> <p>Variation in the choice of control group for the ORT studies was another source of concern in relation to the applicability of the evidence, and was reflected in the GRADE assessment. In particular, total doses of gonadotropin were high for control groups in some studies, which may have compromised the control group success rates (giving a more positive impression of the ORT algorithm in these studies). This could plausibly represent a source of heterogeneity in results, while also compounding doubts about the interpretability of the pooled estimate(s) for Comparison 4 and applicability to real‐world practice (noting that real‐world practice is itself variable). </p> <p>We did not include birth of a second child in the review. Some preliminary results have been presented from follow‐up of participants in <a href="./references#CD012693-bbs2-0017" title="OudshoornSC , Van TilborgTC , EijkemansMJ , OosterhuisGJ , FriederichJ , Van HooffHA , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: the predicted hyper responder. Human Reproduction2017;32(12):2506-14. ">Oudshoorn 2017</a>, suggesting a reduction in births of second children for women allocated to the individualised dose arm, which could be a relevant consideration. </p> </section> <section id="CD012693-sec-0214"> <h4 class="title">Applicability of different trial designs</h4> <p>We included two different trial designs in this review:</p> <p> <ul id="CD012693-list-0076"> <li> <p>Direct dose comparison studies: recruiting a subgroup of women based on an ORT measure (e.g. AFC of 0 to 7) and randomising them to two or more doses of FSH (e.g. 450 IU versus 150 IU); </p> </li> <li> <p>ORT‐algorithm studies: recruiting a more general group of women, and randomising them to dose selection based on their individual ORT measure compared to either a standard starting dose, an algorithm not using an ORT, or a different ORT‐based algorithm (e.g. AMH‐based algorithm versus 150 IU). </p> </li> </ul> </p> <p>Direct dose comparison studies answer the following question: in women within a given ORT range, do different doses result in better outcomes? The interpretation of these studies is simple and directly applicable to practice. ORT‐algorithm studies instead answer the question of whether an algorithm that assigns women to doses of FSH according to their ORT is better than giving everyone the same dose (or alternatively, than using a different algorithm). The general applicability of ORT‐algorithm trial results to practice is less clear. Many of the ORT‐algorithm studies compared an ORT‐based algorithm to the consistent administration of 150 IU. In practice, clinicians often tailor the FSH dose to some extent, based on characteristics such as age, presence of PCOS, and response to stimulation in previous cycles. Only one study, <a href="./references#CD012693-bbs2-0001" title="AllegraA , MarinoA , VolpesA , CoffaroF , ScaglioneP , GulloA , et al. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles. Reproductive Biomedicine Online2017;34(4):429-38. ">Allegra 2017</a>, considered the value of using ORT to tailor the dose, compared to tailoring the dose without ORT (specifically on the basis of age). The review therefore provides limited information about the comparative effectiveness of ORT dosing compared to routine practice. Moreover, all the ORT‐algorithm studies excluded women with PCOS, who are known to be at higher risk of hyper‐response (<a href="./references#CD012693-bbs2-0068" title="AljawoanFY , HuntLP , GordonUD . Prediction of ovarian hyperstimulation syndrome in coasted patients in an IVF/ICSI program. Journal of Human Reproductive Sciences2012;5(1):32-6.">Aljawoan 2012</a>), and one study specifically excluded women who had previous poor or hyper‐response to ovarian stimulation (<a href="./references#CD012693-bbs2-0016" title="OlivennesF , TrewG , BoriniA , BroekmansF , ArriagadaP , WarneDW , HowlesCM . Randomized, controlled, open-label, noninferiority study of the CONSORT algorithm for individualized dosing of follitropin alfa. Reproductive BioMedicine Online2015;30:248-57. ">Olivennes 2015</a>). Many of the study cohorts are therefore unlikely to be representative of typical subfertile populations. However, the exclusion of women with PCOS from these trials is sensible, as they are known to respond variably and usually excessively to ovarian stimulation. This matters in the context of this review, since there are reasons to expect individualisation to be more or less effective depending on a woman's ovarian reserve (<a href="./references#CD012693-bbs2-0002" title="ArceJC , AndersenAN , Fernandez-SanchezM , VisnovaH , BoschE , Garcia-VelascoJA , et al. Ovarian response to recombinant human follicle-stimulating hormone: a randomized, antimullerian hormone-stratified, dose response trial in women undergoing in vitro fertilization/ intracytoplasmic sperm injection. Fertility and Sterility2014;102(6):1633-40. ">Arce 2014</a>). On balance, however, we decided not to downgrade the assessed certainty of the evidence due to this apparent indirectness, as the extent of the indirectness varies depending on the clinical practice within different fertility clinics. </p> </section> <section id="CD012693-sec-0215"> <h4 class="title">Heterogeneity in studied populations</h4> <p>We also note that ORT values of women classified as predicted low, normal, or high responders varied between the studies. For example, in the low‐responder population, the median AFC in two substudies was 3 (<a href="./references#CD012693-bbs2-0003" title="BastuE , BuyruF , OzsurmeliM , DemiralI , DoganM , YehJ . A randomized, single-blind, prospective trial comparing three different gonadotropin doses with or without addition of letrozole during ovulation stimulation in patients with poor ovarian response. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology2016;203:30-4. ">Bastu 2016</a>; <a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>), while in another two studies it was 9 (<a href="./references#CD012693-bbs2-0012" title="LefebvreJ , AntakiR , KadochIJ , DeanNL , SylvestreC , BissonnetteF , et al. 450 IU versus 600 IU gonadotropin for controlled ovarian stimulation in poor responders: a randomized controlled trial. Fertility and Sterility2015;104(6):1419-25. ">Lefebrve 2015</a>). Further, we permitted the definition of a population subgroup (low, normal, or high responders) on the basis of one or more ORT measures, specifically: AMH, AFC, or bFSH. Extensive literature indicates that these measures are not equally useful for predicting response to stimulation: AMH appears be superior to AFC, and both appear to be superior to bFSH (<a href="./references#CD012693-bbs2-0075" title="BroekmansFJ , KweeJ , HendriksDJ , MolBW , LambalkCB . A systematic review of tests predicting ovarian reserve and IVF outcome. Human Reproduction Update2006;12:685-718.">Broekmans 2006</a>; <a href="./references#CD012693-bbs2-0078" title="BroerSL , DóllemanM , vanDisseldorpJ , BroezeKA , OpmeerBC , BossuytPM , et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertility and Sterility2013;100(2):420-9.">Broer 2013a</a>; <a href="./references#CD012693-bbs2-0079" title="BroerSL , vanDisseldorpJ , BroezeKA , DollemanM , OpmeerBC , BossuytP , et al, on behalf of the IMPORT study group. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Human Reproduction Update2013;19(1):26-36.">Broer 2013b</a>; <a href="./references#CD012693-bbs2-0080" title="BroerSL , BroekmansFJM , LavenJSE , FauserBCJM . Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Human Reproduction Update2014;20(5):688-701.">Broer 2014</a>). Additionally, and as mentioned below, we included any trials comparing different FSH doses, so long as the trial population could be categorised as predicted low, normal, or high responders based on available ORT data. This may have led to the inclusion of studies with more clinically heterogeneous populations. For example, a study that we included in the 'predicted low responders' comparison because all participants had a bFSH of more than 8.5 IU/L (for example, <a href="./references#CD012693-bbs2-0005" title="HarrisonRF , JacobS , SpillaneH , MallonE , HennellyB . A prospective randomized clinical trial of differing starter doses of recombinant follicle-stimulating hormone (follitropin-β) for first time in vitro fertilization and intracytoplasmic sperm injection treatment cycles. Fertility and Sterility2001;75(1):23-31. ">Harrison 2001</a>) would include more clinically diverse women than a study defining their trial population as women with an AFC of 0 to 7 (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). Indeed, most of the trials in the normal responder category defined their trial population on the basis of bFSH alone, so these trials are likely to contain a mixture of normal and high responders according to their AFC and AMH levels (however, we do not have this information). Further, the different ORT measures have other strengths and weaknesses other than their predictive capacities. The strength of AMH is the investigator‐independence and stability, and limitations include the use of different assays and difficulty in translating values between assays (<a href="./references#CD012693-bbs2-0080" title="BroerSL , BroekmansFJM , LavenJSE , FauserBCJM . Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Human Reproduction Update2014;20(5):688-701.">Broer 2014</a>). The strength of AFC is that it is easily measured during other routine ultrasound assessments and thus has limited additional cost; however, the weakness is the potential for inter‐observer variation. </p> <p>Often, this clinical and design heterogeneity between trials might be expected to strengthen the external validity of the review. In this case, however, since we usually observed small numbers of trials comparing any particular pair of interventions, differences between populations serve as an unwelcome source of between‐study confounding. Despite this, we made a post hoc decision to pool a number of these trials, and this may contribute to the observed statistical heterogeneity in several of the review outcomes, especially average number of oocytes retrieved and total dose and duration of FSH administration. Moreover, this is a research question where the ORT values used to classify women are crucial, since it is the utility of these thresholds for the purpose of matching people to doses that is under investigation. This heterogeneity is a clear barrier to making a unified judgement regarding the effectiveness and safety of ORT dosing. </p> </section> <section id="CD012693-sec-0216"> <h4 class="title">Uncertainty regarding safety</h4> <p>There is an expectation that ORT‐based dosing might reduce incidence of OHSS. Because event rates were so low, this review provides little information about this outcome, especially for the case of severe OHSS. However, it appears that using ORT algorithms may, in general, reduce the incidence of moderate or severe OHSS. </p> </section> </section> <section id="CD012693-sec-0217"> <h3 class="title" id="CD012693-sec-0217">Certainty of the evidence</h3> <p>Evidence certainty ranged from very low to low. The main limitations were imprecision and risk of bias associated with lack of blinding. For the ORT algorithm studies, we also identified possible indirectness arising from variation in control groups, as described under <a href="#CD012693-sec-0212">Overall completeness and applicability of evidence</a>, above. </p> <p>We conducted GRADE assessments for the main review comparisons: for effects of increasing dose in predicted low, normal, and high responders; and for ORT‐based algorithm dosing versus dosing without ORT. We did this separately for the outcomes live birth, moderate and severe OHSS, and clinical pregnancy. Our assessments were generally consistent across the comparisons: we considered the certainty of the evidence to be low for live birth for all comparisons. We downgraded live birth in all comparisons for high risk of bias in the individual studies. We were particularly concerned about performance bias due to a lack of blinding in many of the studies. Patients are monitored during ovarian stimulation, and clinicians make judgements about dose adjustments and about whether to cancel IVF cycles that are not going well. There is clearly scope for knowledge of treatment assignment to influence these decisions. There was some evidence of this in one included trial, where a greater proportion of underperforming cycles were cancelled in the 150 IU arm compared to the individualised (higher dose) arm (<a href="./references#CD012693-bbs2-0025" title="Van TilborgTC , TorranceHL , OudshoornSC , EijkemansMJ , KoksCA , VerhoeveHR , et al. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: the predicted poor responder. Human Reproduction2017;32(12):2496-2505. ">Van Tilborg 2017</a>). The trial authors hypothesised that the treating clinicians were more likely to cancel the cycle of women on a lower dose of FSH than in women with a higher FSH dose. In most comparisons, we further downgraded for imprecision; confidence intervals were so wide as to be consistent with a plurality of plausible scenarios. For the ORT algorithm studies, we downgraded for indirectness arising from variation in control group treatments, as described in <a href="#CD012693-sec-0212">Overall completeness and applicability of evidence</a>. </p> <p>We considered the evidence to be of very low certainty for the outcome of OHSS (moderate and severe) for several comparisons, since there were very few cases, so the effects of individualised dosing on this outcome were often unclear. However, using an ORT‐based algorithm does appear to reduce the probability of moderate or severe OHSS compared to a standard starting dose of 150 IU, and we classified this as representing moderate‐certainty evidence. </p> <p>We considered the evidence relating to clinical pregnancy to be of low certainty for all dose comparisons, and moderate certainty for comparisons of ORT algorithms versus dosing without ORT; limitations were risk of bias and imprecision (as for live birth). </p> </section> <section id="CD012693-sec-0218"> <h3 class="title" id="CD012693-sec-0218">Potential biases in the review process</h3> <p>We conducted a comprehensive search with the help of an experienced Information Specialist, as well as extensive manual searching in an effort to retrieve all eligible studies; however, it remains possible that we may not have identified unpublished studies. We did identify one study that was published only as a conference abstract (<a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a>). We were unable to construct a funnel plot to investigate the possible extent of publication bias because fewer than 10 studies were available for all comparisons. </p> <p>Although we contacted authors for additional information, we could not obtain all the requested information, either because some trial authors did not provide this, or because we did not receive any reply to our queries. This may have introduced bias due to the inclusion of trials with insufficient information. Furthermore, there remains the potential for study authors to provide inaccurate information and overly positive answers. </p> <p>It was difficult to decide on the structure of this review at the protocol stage (without knowing the types of studies or comparisons that would be included), so we planned to analyse each combination of protocols separately (e.g. for direct dose comparison studies: 150 IU versus 300 IU separate from 150 IU versus 450 IU, and for ORT‐algorithm studies: AMH‐based individualisation versus bFSH‐based individualisation, and AMH‐based individualisation versus AFC‐based individualisation, etc.). It would not be meaningful to pool trials investigating different combinations of biomarkers in their study arms (for example, pooling a study of AMH‐based individualisation versus bFSH‐based individualisation with a study of AFC‐based individualisation versus bFSH‐based individualisation). At the outset of the review, we planned to pool only direct dose comparison trials that compared the same doses against one another. However, while conducting the review, we found that most of the included studies had compared different dose combinations, which made pooling impossible and limited the utility of the data. Therefore, we made a post hoc decision to pool studies in which the comparator dose (lower dose for predicted low and normal responders, and higher dose for predicted high responders) was the same (only within the same predicted response group). For example, in poor responders, we pooled a trial comparing 150 IU versus 300 IU with a trial comparing 150 IU versus 450 IU. This is a major deviation from the protocol. Further, and of minor consequence, we decided to display all outcome data within a predicted response category on the same forest plots to streamline the review and improve visibility of trial results. As a consequence, review comparisons appear as 'subgroup' results (corresponding to different dose combinations) and are reported in the summary of findings tables. This is not normally recommended. However, after considering many possible configurations, we settled on the scheme presented here as the clearest way to present this complex review. </p> <p>We also made other more minor post hoc decisions during the review process. For example, we decided to use the Peto OR for analysing multiple pregnancy data, as this outcome occurred at lower rates than anticipated. Another post hoc and arbitrary decision was to avoid the interpretation of treatment effects when there were five or fewer events in both trial arms. </p> <p>As described previously, this review included two types of studies (direct dose comparison and ORT‐algorithm studies) that answer different questions regarding the utility of individualised FSH dosing, and some may view the inclusion of direct dose comparison studies as only indirectly addressing the review aims. </p> </section> <section id="CD012693-sec-0219"> <h3 class="title" id="CD012693-sec-0219">Agreements and disagreements with other studies or reviews</h3> <p>Although there is a lot of literature regarding the predictive ability of ORT measures and the association between increased dose and outcomes, we are aware of only one similar review of randomised controlled trials (<a href="./references#CD012693-bbs2-0128" title="Van TilborgTC , BroekmansFJM , DollemanM , EijkemansMJC , MolBW , LavenJSE . Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review. Acta Obstetricia et Gynecologica Scandinavica2016;95:1333-44.">Van Tilborg 2016</a>). This review was also a systematic review on the same topic and included seven studies. The discrepancy between the number of included studies in <a href="./references#CD012693-bbs2-0128" title="Van TilborgTC , BroekmansFJM , DollemanM , EijkemansMJC , MolBW , LavenJSE . Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review. Acta Obstetricia et Gynecologica Scandinavica2016;95:1333-44.">Van Tilborg 2016</a> and our review appears largely due to differences in trial eligibility: the <a href="./references#CD012693-bbs2-0128" title="Van TilborgTC , BroekmansFJM , DollemanM , EijkemansMJC , MolBW , LavenJSE . Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review. Acta Obstetricia et Gynecologica Scandinavica2016;95:1333-44.">Van Tilborg 2016</a> review included randomised trials "in which ORTs were used to determine the gonadotrophin starting dose", which resulted in the exclusion of some trials that we considered eligible. For example, we included studies that measured at least one ORT for all participants and provided descriptions of these measures (e.g. mean and SD), as long as the study population could be reasonably categorised into predicted low, normal, or high responders. In contrast, <a href="./references#CD012693-bbs2-0128" title="Van TilborgTC , BroekmansFJM , DollemanM , EijkemansMJC , MolBW , LavenJSE . Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review. Acta Obstetricia et Gynecologica Scandinavica2016;95:1333-44.">Van Tilborg 2016</a> excluded these trials (e.g. <a href="./references#CD012693-bbs2-0004" title="CavagnaM , DzikA , FreitasGC , SoaresJB , De PawnK , SalesALM , et al. Comparison of 150 IU and 225 IU of follitropin-beta in a fixed-dose regimen for ovarian stimulation using a depot formulation of GnRH agonist: a prospective randomized clinical trial. Jornal Brasileiro de Reproducao Assistida2006;10(2):21-4. ">Cavagna 2006</a>; <a href="./references#CD012693-bbs2-0006" title="HoomansEHM , MulderBB , on behalf of the Asian Puregon Study Group. A group-comparative, randomized, double-blind comparison of the efficacy and efficiency of two fixed daily dose regimens (100- and 200-IU) of recombinant follicle stimulating hormone (rFSH, Puregon) in Asian women undergoing ovarian stimulation for IVF/ICSI. Journal of Assisted Reproduction and Genetics2002;19(10):470-6. ">Hoomans 2002</a>; <a href="./references#CD012693-bbs2-0018" title="OutHJ , RutherfordA , FlemingR , TayCCK , TrewG , LedgerW , et al. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Human Reproduction2004;19(1):90-5. ">Out 2004</a>; <a href="./references#CD012693-bbs2-0026" title="YongPYK , BrettS , BairdDT , ThongKJ . A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone(Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertility and Sterility2003;79(2):308-15. ">Yong 2003</a>). Additionally, this earlier review performed the literature search across only three databases, which may be the reason that review authors did not identify <a href="./references#CD012693-bbs2-0024" title="TaskerF , HamodaH , WilnerH , GraceJ , KhalafY . A randomised controlled trial comparing cycle outcome of individualised versus standard dosage of recombinant FSH with IVF/ICSI treatment. Human Reproduction2010;25(Suppl 1):i170-210. ">Tasker 2010</a> (a conference abstract) or <a href="./references#CD012693-bbs2-0011" title="LanVTN , LinhNK , TuongHM , WongPC , HowlesCM . Anti-Mullerian hormone versus antral follicle count for defining the starting dose of FSH. Reproductive BioMedicine Online2013;27(4):390-9. ">​Lan 2013</a>. Further, although the <a href="./references#CD012693-bbs2-0128" title="Van TilborgTC , BroekmansFJM , DollemanM , EijkemansMJC , MolBW , LavenJSE . Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review. Acta Obstetricia et Gynecologica Scandinavica2016;95:1333-44.">Van Tilborg 2016</a> review aimed to include only randomised studies, it did include one quasi‐randomised study that we excluded based on author correspondence explaining that participants were allocated to trial arms based on their patient number rather than a truly random sequence (<a href="./references#CD012693-bbs2-0028" title="BerkkanogluM , OzgurK . What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?Fertility and Sterility2010;94(2):662-5. ">Berkkanoglu 2010</a>). </p> <p>The <a href="./references#CD012693-bbs2-0128" title="Van TilborgTC , BroekmansFJM , DollemanM , EijkemansMJC , MolBW , LavenJSE . Individualized follicle-stimulating hormone dosing and in vitro fertilization outcome in agonist downregulated cycles: a systematic review. Acta Obstetricia et Gynecologica Scandinavica2016;95:1333-44.">Van Tilborg 2016</a> review authors elected not to pool any of the studies due to the clinical and methodological heterogeneity of the studies, which we also encountered and was the reason that we only pooled some subgroups of studies in this review. Lack of author correspondence also led to different risk of bias judgements between the reviews, as we were able to obtain further clarification. Additionally, some of the outcomes for included studies differed, as we made adjustments to outcomes that were not reported appropriately according to the intention‐to‐treat principle. For example, we adjusted for censoring of the number of oocytes collected, which was commonly reported with the denominator of number of women reaching oocyte retrieval rather than the denominator of number of women randomised. Despite these differences and the additional trials included in our more recent review, the conclusions are similar. Both reviews state that there appears to be some benefit from individualising on upstream outcomes, such as rates of hyper‐response and the number of oocytes retrieved, but that information on the most important clinical outcomes is limited. In light of recently published studies, we go slightly further than this by pointing out that differences in birth rates according to use of ORT are probably no more than a few percentage points, but OHSS risk may be reduced by ORT algorithms. Both reviews stated that most of the evidence is of low certainty. </p> <p>A similar author team has also conducted another review focusing on different doses in women under the age of 39 (<a href="./references#CD012693-bbs2-0115" title="SterrenburgMD , Veltman-VerhulstSM , EijkemansMJC , HughesEG , MacklonNS , BroekmansFJ , et al. Clinical outcomes in relation to the daily dose of recombinant follicle stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. Human Reproduction Update2011;17(2):184-96.">Sterrenburg 2011</a>). This review did not consider any ORT‐based algorithms. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012693-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012693-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012693-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012693-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anticipated low responders: higher vs lower dose, outcome: 1.1 Live birth or ongoing pregnancy per woman randomised." data-id="CD012693-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anticipated low responders: higher vs lower dose, outcome: 1.1 Live birth or ongoing pregnancy per woman randomised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Anticipated normal responders: higher vs lower dose, outcome: 2.1 Live birth or ongoing pregnancy." data-id="CD012693-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anticipated normal responders: higher vs lower dose, outcome: 2.1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Anticipated normal responders: higher vs lower dose, outcome: 2.21 Dose‐response: live birth or ongoing pregnancy." data-id="CD012693-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Anticipated normal responders: higher vs lower dose, outcome: 2.21 Dose‐response: live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Anticipated high‐responders: higher vs lower dose, outcome: 3.1 Live birth or ongoing pregnancy." data-id="CD012693-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Anticipated high‐responders: higher vs lower dose, outcome: 3.1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Anticipated high‐responders: higher vs lower dose, outcome: 3.21 Dose‐response: live birth or ongoing pregnancy." data-id="CD012693-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Anticipated high‐responders: higher vs lower dose, outcome: 3.21 Dose‐response: live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 ORT‐based algorithm vs standard dose or non‐ORT based algorithm, outcome: 4.1 Live birth or ongoing pregnancy per woman randomised." data-id="CD012693-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 ORT‐based algorithm vs standard dose or non‐ORT based algorithm, outcome: 4.1 Live birth or ongoing pregnancy per woman randomised. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 ORT‐based algorithm vs standard dose or non‐ORT based algorithm, outcome: 4.5 Moderate or severe OHSS." data-id="CD012693-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 ORT‐based algorithm vs standard dose or non‐ORT based algorithm, outcome: 4.5 Moderate or severe OHSS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 6 AMH + AFC‐based algorithm vs AFC‐based algorithm, outcome: 6.1 Live birth or ongoing pregnancy." data-id="CD012693-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Forest plot of comparison: 6 AMH + AFC‐based algorithm vs AFC‐based algorithm, outcome: 6.1 Live birth or ongoing pregnancy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-FIG-11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 1: Live birth or ongoing pregnancy" data-id="CD012693-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 2: Severe OHSS" data-id="CD012693-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 2: Severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 3: Clinical pregnancy" data-id="CD012693-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 3: Clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 4: Time to clinical pregnancy" data-id="CD012693-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 4: Time to clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 5: Moderate or severe OHSS" data-id="CD012693-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 5: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 6: Multiple pregnancy in randomised women" data-id="CD012693-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 6: Multiple pregnancy in randomised women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 8: Poor response to stimulation" data-id="CD012693-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 8: Poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 9: Normal response to stimulation" data-id="CD012693-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 9: Normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 10: Hyper‐response to stimulation" data-id="CD012693-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 10: Hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 11: Cycle cancellations for poor response" data-id="CD012693-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 11: Cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 12: Cycle cancellations for hyper‐response" data-id="CD012693-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 12: Cycle cancellations for hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 13: Cycle cancellations for poor or hyper‐response" data-id="CD012693-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 13: Cycle cancellations for poor or hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 14: Women with at least one transferable embryo" data-id="CD012693-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 14: Women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 15: Total dose of FSH" data-id="CD012693-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 15: Total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 16: Duration of FSH administration" data-id="CD012693-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 16: Duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 17: Cost per woman randomised" data-id="CD012693-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 17: Cost per woman randomised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 18: Cumulative live birth: 1 cycle (fresh + frozen)" data-id="CD012693-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 18: Cumulative live birth: 1 cycle (fresh + frozen) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 19: Cumulative live birth: 18 months" data-id="CD012693-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 19: Cumulative live birth: 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-001.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 20: Multiple pregnancy in women with clinical pregnancy" data-id="CD012693-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-001.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1: Anticipated low responders: higher versus lower dose, Outcome 20: Multiple pregnancy in women with clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-001.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 1: Live birth or ongoing pregnancy" data-id="CD012693-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 2: Severe OHSS" data-id="CD012693-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 2: Severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 3: Clinical pregnancy" data-id="CD012693-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 3: Clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 4: Time to clinical pregnancy" data-id="CD012693-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 4: Time to clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 5: Moderate or severe OHSS" data-id="CD012693-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 5: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 6: Multiple pregnancy in randomised women" data-id="CD012693-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 6: Multiple pregnancy in randomised women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 8: Poor response to stimulation" data-id="CD012693-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 8: Poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 9: Normal response to stimulation" data-id="CD012693-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 9: Normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 10: Hyper‐response to stimulation" data-id="CD012693-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 10: Hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 11: Cycle cancellations for poor response" data-id="CD012693-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 11: Cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 12: Cycle cancellations for hyper‐response" data-id="CD012693-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 12: Cycle cancellations for hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 13: Cycle cancellations for poor or hyper‐response" data-id="CD012693-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 13: Cycle cancellations for poor or hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 14: Women with at least one transferable embryo" data-id="CD012693-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 14: Women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 15: Total dose of FSH" data-id="CD012693-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 15: Total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 16: Duration of FSH administration" data-id="CD012693-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 16: Duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 17: Cost per woman randomised" data-id="CD012693-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 17: Cost per woman randomised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 18: Cumulative live birth: 1 cycle (fresh + frozen)" data-id="CD012693-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 18: Cumulative live birth: 1 cycle (fresh + frozen) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 19: Cumulative live birth: 18 months" data-id="CD012693-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 19: Cumulative live birth: 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 20: Multiple pregnancy in women with clinical pregnancy" data-id="CD012693-fig-0051" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 20: Multiple pregnancy in women with clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 21: Dose‐response: live birth or ongoing pregnancy" data-id="CD012693-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 21: Dose‐response: live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 22: Dose‐response: cumulative live birth: 1 cycle (fresh + frozen)" data-id="CD012693-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 22: Dose‐response: cumulative live birth: 1 cycle (fresh + frozen) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 23: Dose‐response: clinical pregnancy" data-id="CD012693-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 23: Dose‐response: clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 24: Dose‐response: log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0055" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 24: Dose‐response: log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 25: Dose‐response: poor response to stimulation" data-id="CD012693-fig-0056" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 25: Dose‐response: poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 26: Dose‐response: normal response to stimulation" data-id="CD012693-fig-0057" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 26: Dose‐response: normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 27: Dose‐response: hyper‐response to stimulation" data-id="CD012693-fig-0058" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 27: Dose‐response: hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 28: Dose‐response: cycle cancellations for poor response" data-id="CD012693-fig-0059" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 28: Dose‐response: cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 29: Dose‐response: women with at least one transferable embryo" data-id="CD012693-fig-0060" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.29</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 29: Dose‐response: women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 30: Dose‐response: total dose of FSH" data-id="CD012693-fig-0061" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.30</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 30: Dose‐response: total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-002.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 31: Dose‐response: duration of FSH administration" data-id="CD012693-fig-0062" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-002.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.31</div> <div class="figure-caption"> <p>Comparison 2: Anticipated normal responders: higher versus lower dose, Outcome 31: Dose‐response: duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-002.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 1: Live birth or ongoing pregnancy" data-id="CD012693-fig-0063" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 2: Severe OHSS" data-id="CD012693-fig-0064" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 2: Severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 3: Clinical pregnancy" data-id="CD012693-fig-0065" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 3: Clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 4: Time to clinical pregnancy" data-id="CD012693-fig-0066" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 4: Time to clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 5: Moderate or severe OHSS" data-id="CD012693-fig-0067" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 5: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 6: Multiple pregnancy in randomised women" data-id="CD012693-fig-0068" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 6: Multiple pregnancy in randomised women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0069" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 8: Poor response to stimulation" data-id="CD012693-fig-0070" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 8: Poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 9: Normal response to stimulation" data-id="CD012693-fig-0071" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 9: Normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 10: Hyper‐response to stimulation" data-id="CD012693-fig-0072" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 10: Hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 11: Cycle cancellations for poor response" data-id="CD012693-fig-0073" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 11: Cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 12: Cycle cancellations for hyper‐response" data-id="CD012693-fig-0074" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 12: Cycle cancellations for hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 13: Cycle cancellations for poor or hyper‐response" data-id="CD012693-fig-0075" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 13: Cycle cancellations for poor or hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 14: Women with at least one transferable embryo" data-id="CD012693-fig-0076" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 14: Women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 15: Total dose of FSH" data-id="CD012693-fig-0077" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 15: Total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 16: Duration of FSH administration" data-id="CD012693-fig-0078" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 16: Duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 17: Cost per woman randomised" data-id="CD012693-fig-0079" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 17: Cost per woman randomised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 18: Cumulative live birth: 1 cycle (fresh + frozen)" data-id="CD012693-fig-0080" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 18: Cumulative live birth: 1 cycle (fresh + frozen) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 19: Cumulative live birth: 18 months" data-id="CD012693-fig-0081" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 19: Cumulative live birth: 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 20: Multiple pregnancy in women with clinical pregnancy" data-id="CD012693-fig-0082" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 20: Multiple pregnancy in women with clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 21: Dose‐response: live birth or ongoing pregnancy" data-id="CD012693-fig-0083" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 21: Dose‐response: live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 22: Dose‐response: clinical pregnancy" data-id="CD012693-fig-0084" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 22: Dose‐response: clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 23: Dose‐response: cumulative live birth: 1 cycle (fresh + frozen)" data-id="CD012693-fig-0085" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.23</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 23: Dose‐response: cumulative live birth: 1 cycle (fresh + frozen) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 24: Dose‐response: severe OHSS" data-id="CD012693-fig-0086" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.24</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 24: Dose‐response: severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.25" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 25: Dose‐response: moderate or severe OHSS" data-id="CD012693-fig-0087" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.25</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 25: Dose‐response: moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.26" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 26: Dose‐response: log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0088" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.26</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 26: Dose‐response: log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 27: Dose‐response: poor response to stimulation" data-id="CD012693-fig-0089" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.27</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 27: Dose‐response: poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 28: Dose‐response: normal response to stimulation" data-id="CD012693-fig-0090" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.28</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 28: Dose‐response: normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 29: Dose‐response: hyper‐response to stimulation" data-id="CD012693-fig-0091" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.29</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 29: Dose‐response: hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 30: Dose‐response: cycle cancellations for poor response" data-id="CD012693-fig-0092" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.30</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 30: Dose‐response: cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 31: Dose‐response: cycle cancellations for hyper‐response" data-id="CD012693-fig-0093" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.31</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 31: Dose‐response: cycle cancellations for hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 32: Dose‐response: cycle cancellations for poor or hyper‐response" data-id="CD012693-fig-0094" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.32</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 32: Dose‐response: cycle cancellations for poor or hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.33" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 33: Dose‐response: women with at least one transferable embryo" data-id="CD012693-fig-0095" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.33.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.33.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.33</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 33: Dose‐response: women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.33.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.34" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 34: Dose‐response: total dose of FSH" data-id="CD012693-fig-0096" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.34.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.34.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.34</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 34: Dose‐response: total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.34.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-003.35" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 35: Dose‐response: duration of FSH administration" data-id="CD012693-fig-0097" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.35.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-003.35.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.35</div> <div class="figure-caption"> <p>Comparison 3: Anticipated high‐responders: higher versus lower dose, Outcome 35: Dose‐response: duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-003.35.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 1: Live birth or ongoing pregnancy" data-id="CD012693-fig-0098" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 2: Severe OHSS" data-id="CD012693-fig-0099" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 2: Severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 3: Clinical pregnancy" data-id="CD012693-fig-0100" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 3: Clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 4: Time to clinical pregnancy" data-id="CD012693-fig-0101" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 4: Time to clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 5: Moderate or severe OHSS" data-id="CD012693-fig-0102" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 5: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 6: Multiple pregnancy in randomised women" data-id="CD012693-fig-0103" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 6: Multiple pregnancy in randomised women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0104" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 8: Poor response to stimulation" data-id="CD012693-fig-0105" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 8: Poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 9: Normal response to stimulation" data-id="CD012693-fig-0106" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 9: Normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 10: Hyper‐response to stimulation" data-id="CD012693-fig-0107" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 10: Hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 11: Cycle cancellations for poor response" data-id="CD012693-fig-0108" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 11: Cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 12: Cycle cancellations for hyper‐response" data-id="CD012693-fig-0109" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 12: Cycle cancellations for hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 13: Cycle cancellations for poor or hyper‐response" data-id="CD012693-fig-0110" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 13: Cycle cancellations for poor or hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 14: Women with at least one transferable embryo" data-id="CD012693-fig-0111" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 14: Women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 15: Total dose of FSH" data-id="CD012693-fig-0112" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 15: Total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 16: Duration of FSH administration" data-id="CD012693-fig-0113" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 16: Duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 17: Cost per woman randomised" data-id="CD012693-fig-0114" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 17: Cost per woman randomised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 18: Cumulative live birth: 1 cycle (fresh + frozen)" data-id="CD012693-fig-0115" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 18: Cumulative live birth: 1 cycle (fresh + frozen) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 19: Cumulative live birth: 18 months" data-id="CD012693-fig-0116" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 19: Cumulative live birth: 18 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-004.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 20: Multiple pregnancy in women with clinical pregnancy" data-id="CD012693-fig-0117" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-004.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4: ORT‐based algorithm versus standard dose or non‐ORT based algorithm, Outcome 20: Multiple pregnancy in women with clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-004.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 1: Live birth or ongoing pregnancy" data-id="CD012693-fig-0118" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 2: Severe OHSS" data-id="CD012693-fig-0119" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 2: Severe OHSS</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 3: Clinical pregnancy" data-id="CD012693-fig-0120" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 3: Clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 4: Time to clinical pregnancy" data-id="CD012693-fig-0121" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 4: Time to clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 5: Moderate or severe OHSS" data-id="CD012693-fig-0122" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 5: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 6: Multiple pregnancy in randomised women" data-id="CD012693-fig-0123" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 6: Multiple pregnancy in randomised women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0124" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 8: Poor response to stimulation" data-id="CD012693-fig-0125" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 8: Poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 9: Normal response to stimulation" data-id="CD012693-fig-0126" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 9: Normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 10: Hyper‐response to stimulation" data-id="CD012693-fig-0127" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 10: Hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 11: Cycle cancellations for poor response" data-id="CD012693-fig-0128" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 11: Cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 12: Cycle cancellations for hyper‐response" data-id="CD012693-fig-0129" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 12: Cycle cancellations for hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 13: Cycle cancellations for poor or hyper‐response" data-id="CD012693-fig-0130" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 13: Cycle cancellations for poor or hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 14: Women with at least one transferable embryo" data-id="CD012693-fig-0131" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 14: Women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 15: Total dose of FSH" data-id="CD012693-fig-0132" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 15: Total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 16: Duration of FSH administration" data-id="CD012693-fig-0133" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 16: Duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 17: Live birth or ongoing pregnancy (including FET for freeze‐all)" data-id="CD012693-fig-0134" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 17: Live birth or ongoing pregnancy (including FET for freeze‐all) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 18: Cost per woman randomised" data-id="CD012693-fig-0135" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 18: Cost per woman randomised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-005.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 19: Multiple pregnancy in women with clinical pregnancy" data-id="CD012693-fig-0136" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-005.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5: AMH‐based algorithm versus AFC‐based algorithm, Outcome 19: Multiple pregnancy in women with clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-005.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 1: Live birth or ongoing pregnancy" data-id="CD012693-fig-0137" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 2: Severe OHSS" data-id="CD012693-fig-0138" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 2: Severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 3: Clinical pregnancy" data-id="CD012693-fig-0139" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 3: Clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 4: Time to clinical pregnancy" data-id="CD012693-fig-0140" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 4: Time to clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 5: Moderate or severe OHSS" data-id="CD012693-fig-0141" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 5: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 6: Multiple pregnancy in randomised women" data-id="CD012693-fig-0142" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 6: Multiple pregnancy in randomised women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0143" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 8: Poor response to stimulation" data-id="CD012693-fig-0144" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 8: Poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 9: Normal response to stimulation" data-id="CD012693-fig-0145" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 9: Normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 10: Hyper‐response to stimulation" data-id="CD012693-fig-0146" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 10: Hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 11: Cycle cancellations for poor response" data-id="CD012693-fig-0147" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 11: Cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 12: Cycle cancellations for hyper‐response" data-id="CD012693-fig-0148" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 12: Cycle cancellations for hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 13: Cycle cancellations for poor or hyper‐response" data-id="CD012693-fig-0149" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 13: Cycle cancellations for poor or hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 14: Women with at least one transferable embryo" data-id="CD012693-fig-0150" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 14: Women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 15: Total dose of FSH" data-id="CD012693-fig-0151" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 15: Total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 16: Duration of FSH administration" data-id="CD012693-fig-0152" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 16: Duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 17: Cost per woman randomised" data-id="CD012693-fig-0153" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 17: Cost per woman randomised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 18: Live birth or ongoing pregnancy (including FET for freeze‐all)" data-id="CD012693-fig-0154" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 18: Live birth or ongoing pregnancy (including FET for freeze‐all) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-006.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 19: Multiple pregnancy in women with clinical pregnancy" data-id="CD012693-fig-0155" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-006.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.19</div> <div class="figure-caption"> <p>Comparison 6: AMH + AFC‐based algorithm versus AFC‐based algorithm, Outcome 19: Multiple pregnancy in women with clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-006.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 1: Live birth or ongoing pregnancy" data-id="CD012693-fig-0156" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 1: Live birth or ongoing pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 2: Severe OHSS" data-id="CD012693-fig-0157" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 2: Severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 3: Clinical pregnancy" data-id="CD012693-fig-0158" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 3: Clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 4: Time to clinical pregnancy" data-id="CD012693-fig-0159" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 4: Time to clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 5: Moderate or severe OHSS" data-id="CD012693-fig-0160" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 5: Moderate or severe OHSS </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 6: Multiple pregnancy in randomised women" data-id="CD012693-fig-0161" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 6: Multiple pregnancy in randomised women </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes" data-id="CD012693-fig-0162" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 7: Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 8: Poor response to stimulation" data-id="CD012693-fig-0163" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 8: Poor response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 9: Normal response to stimulation" data-id="CD012693-fig-0164" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 9: Normal response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 10: Hyper‐response to stimulation" data-id="CD012693-fig-0165" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.10</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 10: Hyper‐response to stimulation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 11: Cycle cancellations for poor response" data-id="CD012693-fig-0166" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.11</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 11: Cycle cancellations for poor response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 12: Cycle cancellations for hyper‐response" data-id="CD012693-fig-0167" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.12</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 12: Cycle cancellations for hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 13: Cycle cancellations for poor or hyper‐response" data-id="CD012693-fig-0168" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.13</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 13: Cycle cancellations for poor or hyper‐response </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 14: Women with at least one transferable embryo" data-id="CD012693-fig-0169" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.14</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 14: Women with at least one transferable embryo </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 15: Total dose of FSH" data-id="CD012693-fig-0170" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.15</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 15: Total dose of FSH </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 16: Duration of FSH administration" data-id="CD012693-fig-0171" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.16</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 16: Duration of FSH administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 17: Cost per woman randomised" data-id="CD012693-fig-0172" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.17</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 17: Cost per woman randomised </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 18: Live birth or ongoing pregnancy (including FET for freeze‐all)" data-id="CD012693-fig-0173" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.18</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 18: Live birth or ongoing pregnancy (including FET for freeze‐all) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012693-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/urn:x-wiley:14651858:media:CD012693:CD012693-CMP-007.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 19: Multiple pregnancy in women with clinical pregnancy" data-id="CD012693-fig-0174" src="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_t/tCD012693-CMP-007.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.19</div> <div class="figure-caption"> <p>Comparison 7: AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm, Outcome 19: Multiple pregnancy in women with clinical pregnancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/media/CDSR/CD012693/image_n/nCD012693-CMP-007.19.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012693-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">ORT‐based algorithm compared to standard starting dose of FSH for women undergoing IVF/ICSI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>ORT‐based algorithm compared to standard starting dose of FSH for women undergoing IVF/ICSI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : women undergoing IVF/ICSI<br/><b>Setting</b> : hospital or fertility clinic<br/><b>Intervention</b> : ORT‐based algorithm<br/><b>Comparison</b>: standard starting dose FSH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Evidence summary</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with 150 IU FSH</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ORT‐based algorithm</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Live birth or ongoing pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000 (250 to 310)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>280 per 1000 (270 to 330)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.12<br/>(0.98 to 1.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4400<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a suggestion, but not clear evidence, of an overall increase in live birth rate. However, this estimate is difficult to interpret due to differences in interventions, which may differ in their effectiveness. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OHSS</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>13 per 1000 (6 to 17)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/>(4 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/>(0.42 to 1.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2724<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Although the effect estimate remains imprecise, the pooled evidence suggests that ORT‐based algorithms reduce the incidence of moderate or severe OHSS by an unspecified amount. Effects on severe OHSS are unclear. There were zero events in one study. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>5 per 1000 (2 to 5)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>16 per 1000<br/>(8 to 24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.6<br/>(0.42 to 0.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4400<br/>(7 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical pregnancy</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>310 per 1000 (290 to 350)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>320 per 1000<br/>(300 to 360) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.04<br/>(0.91 to 1.18) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4400<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Although the effect estimate remains imprecise, the pooled evidence suggests it is unlikely that ORT‐based algorithms impacted on rates of clinical pregnancy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FSH</b> : follicle‐stimulating hormone; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IVF</b> : in vitro fertilisation; <b>OHSS</b> : ovarian hyperstimulation syndrome; <b>OR</b> : odds ratio; <b>ORT</b> : ovarian reserve test; <b>RCT</b>: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias, associated mainly with performance bias due to lack of blinding and/or selective reporting.<br/><sup>b</sup>Downgraded one level for serious imprecision associated with a small number of events.<br/><sup>c</sup>Downgraded one level for indirectness arising from the choice of control group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">ORT‐based algorithm compared to standard starting dose of FSH for women undergoing IVF/ICSI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012693-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anticipated low responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anticipated low responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : women undergoing IVF/ICSI who are anticipated to have a low response to stimulation based on one or more ORT measure<br/><b>Setting</b> : hospital or fertility clinic<br/><b>Intervention</b> : higher dose of FSH<br/><b>Comparison</b>: lower dose of FSH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Evidence summary</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher dose</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome: live birth or ongoing pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300/450 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (130 to 260)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>190 per 1000 (140 to 280)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.20 (0.78 to 1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>538<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>It was difficult to determine whether the different doses impacted on rates of live birth or ongoing pregnancy; therefore, there is no evidence to suggest increased dosing in low responders is beneficial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400/450 IU vs 300 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (40 to 380)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000 (30 to 320)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.77 (0.19 to 3.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 IU vs 450 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000 (80 to 230)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000<br/>(100 to 290) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.33<br/>(0.71 to 2.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome: ovarian hyperstimulation syndrome (OHSS)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300/450 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>It was not possible to determine whether the different doses impacted on rates of OHSS, as the event rates were too low (there were no incidents of severe OHSS in any of the studies). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286<br/>(2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>400/450 IU vs 300 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>600 IU vs 450 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/>(0 to 0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356<br/>(1 study) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome: clinical pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300/450 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>270 per 1000 (170 to 320)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>227 per 1000(140 to 260)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.85<br/>(0.57 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>538<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of clinical pregnancy. Therefore, there is no evidence to suggest increased dosing in low responders is beneficial, and it may even be detrimental compared to a dose of 150 IU. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>400/450 IU vs 300 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>130 per 1000 (40 to 280)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>105 per 1000 (30 to 250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.84<br/>(0.26 to 2.69) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110<br/>(2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>600 IU vs 450 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (110 to 270)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/>(111 to 274) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.14<br/>(0.66 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>356<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FSH</b> : follicle‐stimulating hormone; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IU</b> : international units; <b>IVF</b> : in vitro fertilisation; <b>OHSS</b> : ovarian hyperstimulation syndrome; <b>OR</b> : odds ratio; <b>ORT</b> : ovarian reserve test; <b>RCT</b>: randomised controlled trial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated mainly with performance bias due to lack of blinding and/or selective reporting.<br/><sup>b</sup>Downgraded one level for serious imprecision associated with a small number of events.<br/><sup>c</sup>Downgraded two levels for very serious imprecision associated with a very small number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anticipated low responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012693-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anticipated normal responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anticipated normal responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : women undergoing IVF/ICSI who are anticipated to have a normal response to stimulation based on at least one ORT measure<br/><b>Setting</b> : hospital or fertility clinic<br/><b>Intervention</b> : higher dose of FSH<br/><b>Comparison</b>: lower dose of FSH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Evidence summary</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher dose</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> : <b>live birth or ongoing pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000 (130 to 260)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000 (120 to 250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.88<br/>(0.57 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of live birth or ongoing pregnancy. Therefore, there is no evidence to suggest increased dosing in normal responders is beneficial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225/200 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000 (220 to 360)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000 (220 to 360)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.98<br/>(0.70 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>686<br/>(2 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 IU vs 225 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>400 per 1000 (170 to 470)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000<br/>(120 to 360) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.65<br/>(0.32 to 1.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000 (70 to 590)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000 (60 to 530)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.80 (0.19 to 3.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> : <b>ovarian hyperstimulation syndrome (OHSS)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>200 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>5 per 1000</p> <p>(0 to 34)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.14 (0.00 to 6.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>It was impossible to determine whether the dose differences impacted on rates of OHSS.</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>31 per 1000</p> <p>(7 to 60)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> <p>(4 to 37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.62 (0.21 to 1.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>522<br/>(2 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>225/200 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>12 per 1000</p> <p>(6 to 29)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000 (6 to 29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/>(0.20 to 5.20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>740<br/>(4 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>27 per 1000 (14 to 73)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>110 per 1000</p> <p>(60 to 260)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.21<br/>(0.51 to 2.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>740<br/>(4 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300 IU vs 225 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>15 per 1000</p> <p>(0 to 100)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.14 (0.00 to 6.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135 (1 RCT)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>44 per 1000</p> <p>(5 to 155)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000 (3 to 110)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.67<br/>(0.11 to 3.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/>(1 study) </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> : <b>clinical pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000 (110 to 270)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000 (100 to 250)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.86 (0.50 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of clinical pregnancy. Therefore, there is no evidence to suggest increased dosing in normal responders is beneficial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225/200 IU vs 150 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>290 per 1000 (250 to 350)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>300 per 1000 (250 to 350)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/>(0.79 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1446<br/>(6 RCTs) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>300 IU vs 225 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>440 per 1000 (270 to 590)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>420 per 1000 (250 to 570)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.91<br/>(0.46 to 1.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/>(1 RCT) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FSH</b> : follicle‐stimulating hormone; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IU</b> : international units; <b>IVF</b> : in vitro fertilisation; <b>OHSS</b> : ovarian hyperstimulation syndrome; <b>OR</b> : odds ratio; <b>ORT</b> : ovarian reserve test; <b>RCT</b>: randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated mainly with performance bias due to lack of blinding and/or selective reporting and/or selection bias due to unclear methods of randomisation.<br/><sup>b</sup>Downgraded one level for serious imprecision associated with a small number of events.<br/><sup>c</sup>Downgraded two levels for very serious imprecision associated with a very small number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Anticipated normal responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012693-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anticipated high responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Anticipated high responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b> : women undergoing IVF/ICSI who are anticipated to have a hyper‐response to stimulation based on at least one ORT measure<br/><b>Setting</b> : hospital or fertility clinic<br/><b>Intervention</b> : higher dose of FSH<br/><b>Comparison</b>: lower dose of FSH </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comparison</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Evidence summary</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with lower dose</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with higher dose</b> </p> </th> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign=""> <p><b>Outcome</b> : <b>live birth or ongoing pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>260 per 1000 (180 to 330)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>251 per 1000<br/>(184 to 333) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.98<br/>(0.66 to 1.46) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of live birth or ongoing pregnancy. Therefore, there is no evidence to suggest increased dosing in high responders is beneficial. </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> : <b>ovarian hyperstimulation syndrome (OHSS)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>150 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Severe</i> </b> </p> <p>16 per 1000</p> <p>(3 to 60)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000<br/>(3 to 48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.72<br/>(0.16 to 3.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It was not possible to definitively say whether dose differences impacted on rates of OHSS, but there could be a reduction with lower doses. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b><i>Moderate or severe</i> </b> </p> <p>16 per 1000</p> <p>(13 to 96)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 1000<br/>(13 to 96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 2.31<br/>(0.80 to 6.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (1 RCT)</p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Outcome</b> : <b>clinical pregnancy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 IU vs 100 IU</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000 (230 to 390)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>301 per 1000<br/>(228 to 386) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.14<br/>(0.78 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>521 (1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>Low<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>It was difficult to determine whether the dose differences impacted on rates of clinical pregnancy. Therefore, there is no evidence to suggest increased dosing in high responders is beneficial. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI</b> : confidence interval; <b>FSH</b> : follicle‐stimulating hormone; <b>ICSI</b> : intracytoplasmic sperm injection; <b>IU</b> : international units; <b>IVF</b> : in vitro fertilisation; <b>OHSS</b> : ovarian hyperstimulation syndrome; <b>OR</b> : odds ratio; <b>ORT</b> : ovarian reserve test; <b>RCT</b>: randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias associated mainly with performance bias due to lack of blinding and/or selective reporting.<br/><sup>b</sup>Downgraded one level for serious imprecision associated with a small number of events.<br/><sup>c</sup>Downgraded two levels for very serious imprecision associated with a very small number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Anticipated high responders: higher compared to lower dose of FSH for women undergoing IVF/ICSI</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/full#CD012693-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012693-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticipated low responders: higher versus lower dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.78, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.19, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.71, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.26, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.66, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Time to clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.23 [0.14, 364.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Multiple pregnancy in randomised women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.33, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.16, 1.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.53, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.03 [‐0.30, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.04, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.32, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.05, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.53 [0.94, 21.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.12, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.62, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.50, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11.4 225 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Cycle cancellations for hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.93 [0.16, 400.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Cycle cancellations for poor or hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.13, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.62, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.50, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [1.02, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.31, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.78, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.15 Total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [2.57, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.91, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.15.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [1.07, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.16 Duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.48, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.39, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.16.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐1.27, ‐0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.17 Cost per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.18 Cumulative live birth: 1 cycle (fresh + frozen) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.18.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>486</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.83, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.19 Cumulative live birth: 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.19.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.46, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.20 Multiple pregnancy in women with clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.1 300/450 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.08, 10.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.2 400/450 IU vs 300 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.20.3 600 IU vs 450 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.11, 1.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticipated low responders: higher versus lower dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012693-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anticipated normal responders: higher versus lower dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.57, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.32, 1.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 300 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.19, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.00, 6.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.20, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.00, 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.50, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.46, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Time to clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.21, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.51, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.11, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Multiple pregnancy in randomised women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.38, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.51, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.61 [0.47, 123.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.36, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.08, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.17, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.4 300 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.12, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.30, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.2 300 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.00 [2.63, 218.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.78, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 300 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.11, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.08 [1.47, 11.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.2 300 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.42, 9.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.16, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.36, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.12 Cycle cancellations for hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.20, 18.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [0.99, 5.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.06, 16.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.13 Cycle cancellations for poor or hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.19, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.51, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.02, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.14 Women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.95, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1446</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.78, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [0.60, 5.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.15 Total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>795.79 [656.67, 934.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>503.12 [456.23, 550.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>725.00 [597.44, 852.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.16 Duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐2.21, ‐1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>961</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.51, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.79, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.17 Cost per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.18 Cumulative live birth: 1 cycle (fresh + frozen) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.1 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.79, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18.2 300 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.24, 4.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.19 Cumulative live birth: 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19.1 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.63, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.20 Multiple pregnancy in women with clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.1 200 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.39, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.2 225/200 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.28, 9.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.3 300 IU vs 225 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.24 [0.50, 135.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20.4 300 IU vs 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.31, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.21 Dose‐response: live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.39, 5.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.25, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.16, 2.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.25, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [0.32, 38.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21.6 9 μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.03, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.22 Dose‐response: cumulative live birth: 1 cycle (fresh + frozen) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.32, 4.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.22, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.19, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.42, 5.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.23 Dose‐response: clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.30, 4.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.19, 3.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.25, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.25, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.09 [0.50, 52.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.02, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.24 Dose‐response: log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [‐0.05, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.31, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐0.13, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [‐0.12, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.5 12 μg vs 9 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.32, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24.6 9 μg vs 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.36, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.25 Dose‐response: poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.12, 7.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.09, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.10, 2.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.19, 3.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25.6 9 μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.20, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.26 Dose‐response: normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.08, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [1.08, 33.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [0.55, 9.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.21, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [0.71, 69.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.20, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.27 Dose‐response: hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.26 [0.24, 116.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.04, 5.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.57 [0.25, 124.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.21 [0.12, 85.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.28 Dose‐response: cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.12, 78.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.06, 16.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.04, 5.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 8.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.02, 2.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.29 Dose‐response: women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.29.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.25, 11.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.29.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.09, 4.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.29.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [0.25, 11.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.29.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.09, 4.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.30 Dose‐response: total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.20 [0.28, 28.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.20 [‐0.14, 16.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.50 [5.83, 21.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.30 [3.44, 19.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.31 Dose‐response: duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.31.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐1.08, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.31.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.50, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.31.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.12, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.31.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.91, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.31.5 12 μg/d vs 9 μg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.97, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.31.6 9 μg/d vs 6 μg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.30 [‐3.06, 0.46]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Anticipated normal responders: higher versus lower dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012693-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anticipated high‐responders: higher versus lower dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.66, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.16, 3.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.78, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Time to clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [0.80, 6.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Multiple pregnancy in randomised women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.19, 18.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.7 Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.55, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.8 Poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.09, 0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.9 Normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.76, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.10 Hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.04 [3.17, 8.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.11 Cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.06, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.12 Cycle cancellations for hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.28 [2.16, 12.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.13 Cycle cancellations for poor or hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.36, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.14 Women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [1.53, 3.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.15 Total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>345.00 [280.34, 409.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.16 Duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐1.91, ‐0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.17 Cost per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐92.00 [‐325.24, 141.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.18 Cumulative live birth: 1 cycle (fresh + frozen) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.18.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.81, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.19 Cumulative live birth: 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.19.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.80, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.20 Multiple pregnancy in women with clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.20.1 150 IU vs 100 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.18, 16.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.21 Dose‐response: live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.77, 8.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.16, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.26, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.36, 3.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.27, 3.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.21.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.41, 6.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.22 Dose‐response: clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [0.77, 8.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.16, 1.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.23, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.43, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.44, 4.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.22.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.35, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.23 Dose‐response: cumulative live birth: 1 cycle (fresh + frozen) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.54, 5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.22, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.24, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.23.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [0.49, 4.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.24 Dose‐response: severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.12 [0.43, 117.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.00, 6.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.03 [0.16, 406.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.24.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.25 Dose‐response: moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.35, 20.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.03 [0.16, 406.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.25.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.26 Dose‐response: log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.13, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [‐0.02, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.10, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.06, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.5 9μg vs 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.09, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.26.6 12 μg vs 9 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [‐0.11, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.27 Dose‐response: poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.01, 3.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.18, 24.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [0.02, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.07, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.27.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.43 [0.33, 35.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.28 Dose‐response: normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.33, 3.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.10, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.47, 5.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [0.55, 5.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.15, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.28.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.18, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.29 Dose‐response: hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.46, 4.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.71 [0.76, 9.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.28, 4.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.50 [0.44, 14.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.62, 7.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.29.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.47 [0.63, 19.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.30 Dose‐response: cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.38 [0.13, 87.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.30.7 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.31 Dose‐response: cycle cancellations for hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [0.12, 80.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.01, 8.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.11, 71.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.31.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.32 Dose‐response: cycle cancellations for poor or hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 7.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 16.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.06, 18.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.01, 7.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32.5 12μg vs 9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.01, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.32.6 9μg vs 6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.04, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.33 Dose‐response: women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.58 [0.71, 61.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.06, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.22, 9.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.33.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.11, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.34 Dose‐response: total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.90 [11.03, 26.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.80 [1.34, 18.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.30 [‐1.17, 15.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.34.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.20 [5.05, 19.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.35 Dose‐response: duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35.1 12.1μg vs 10.3μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.30, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35.2 10.3μg vs 8.6μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.32, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35.3 8.6μg vs 6.9μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐2.11, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35.4 6.9μg vs 5.2μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.91, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35.5 12 μg vs 9 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.64, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.35.6 9 μg vs 6 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.84, 0.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Anticipated high‐responders: higher versus lower dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012693-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">ORT‐based algorithm versus standard dose or non‐ORT based algorithm</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.42, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.91, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.48, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Time to clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.42, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Multiple pregnancy in randomised women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.43, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.02, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.02, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.93, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.27, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [1.02, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.20, 3.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.10 Hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1858</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.61, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.25, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.11 Cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.89, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.12 Cycle cancellations for hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.23, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.40, 2.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.13 Cycle cancellations for poor or hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.61, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.32, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.14 Women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4397</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.84, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.57, 2.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.15 Total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2850</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐377.62 [‐412.01, ‐343.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.15.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.00 [‐210.30, 188.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.16 Duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.21, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.16.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.84, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.17 Cost per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.18 Cumulative live birth: 1 cycle (fresh + frozen) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.18.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.68, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.18.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.19 Cumulative live birth: 18 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.19.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1032</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.19.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.20 Multiple pregnancy in women with clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.20.1 Control group: standard dose 150 IU</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>898</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.39, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.20.2 Control group: non‐ORT algorithm</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">ORT‐based algorithm versus standard dose or non‐ORT based algorithm</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012693-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">AMH‐based algorithm versus AFC‐based algorithm</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.53, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Time to clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.28 [0.96, 19.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Multiple pregnancy in randomised women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.66, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐0.37, ‐0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.94, 5.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.87, 2.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.23, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 Cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.25, 9.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 Cycle cancellations for hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.23, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.13 Cycle cancellations for poor or hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.30, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.14 Women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.36, 4.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.15 Total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐178.00 [‐413.88, 57.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.16 Duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.11, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.17 Live birth or ongoing pregnancy (including FET for freeze‐all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.18 Cost per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.19 Multiple pregnancy in women with clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.78, 3.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">AMH‐based algorithm versus AFC‐based algorithm</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012693-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">AMH + AFC‐based algorithm versus AFC‐based algorithm</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.72, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.12, 4.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.84, 2.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Time to clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.26, 2.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Multiple pregnancy in randomised women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.31, ‐0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [1.52, 5.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.45, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 Hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.43, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.11 Cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [0.53, 6.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.12 Cycle cancellations for hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.12, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.13 Cycle cancellations for poor or hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.42, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.14 Women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.50, 2.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.15 Total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>81.00 [‐111.93, 273.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.16 Duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.10, 0.90]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.17 Cost per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.18 Live birth or ongoing pregnancy (including FET for freeze‐all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.77, 2.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.19 Multiple pregnancy in women with clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">AMH + AFC‐based algorithm versus AFC‐based algorithm</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012693-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Live birth or ongoing pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.28, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.28, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.4 Time to clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.5 Moderate or severe OHSS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.6 Multiple pregnancy in randomised women <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.7 Log(N oocytes retrieved); data presented on the log scale ‐ cannot interpret pooled estimates as N of oocytes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.81, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.8 Poor response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.77, 2.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.9 Normal response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.42, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.10 Hyper‐response to stimulation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.45, 1.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.11 Cycle cancellations for poor response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.12 Cycle cancellations for hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.13 Cycle cancellations for poor or hyper‐response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.14 Women with at least one transferable embryo <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.15 Total dose of FSH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐148.00 [‐433.61, 137.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.16 Duration of FSH administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>215</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.60, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.17 Cost per woman randomised <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.18 Live birth or ongoing pregnancy (including FET for freeze‐all) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.19 Multiple pregnancy in women with clinical pregnancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">AMH + AFC + bFSH‐based algorithm versus bFSH‐based algorithm</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012693.pub3/references#CD012693-tbl-0011">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012693.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012693-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012693-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012693-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012693-note-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD012693-note-0012">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012693-note-0011">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012693-note-0010">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012693-note-0009">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012693\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012693\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012693\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012693\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012693\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012693.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012693.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012693.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012693.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012693.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718080665"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012693.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718080669"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012693.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc77dbd88f49c',t:'MTc0MDcxODA4MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 